


**CUMULATIVE
SUPPLEMENT 5**
May 2025



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

**Cumulative Supplement 5
May 2025**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi

DRUG PRODUCT LISTS

Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

**CUMULATIVE SUPPLEMENT 5
May 2025**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
DR REDDYS LABORATORIES INC (DR REDDYS LABS INC)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES LTD (DR REDDYS)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES LTD (DR REDDYS LABS LTD)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
ICU MEDICAL INC (ICU MEDICAL INC)	OTSUKA ICU MEDICAL LLC (OTSUKA ICU MEDCL)
MYLAN INSTITUTIONAL LLC (MYLAN INSTITUTIONAL)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)

MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
STERISCIENCE SPECIALITIES PTE LTD (STERISCIENCE SPECLTS)	ONESOURCE SPECIALTY PTE LTE (ONESOURCE SPECIALTY)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
---------	------------------	-----------	----------	---------	-----	----

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	–	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2024</u>	<u>MAR</u> <u>2025</u>	<u>JUN</u> <u>2025</u>	<u>SEP</u> <u>2025</u>	<u>DEC</u> <u>2025</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23856 2772 (11.8%)	23679 2740 (11.6%)			
MULTISOURCE	20814 (88.2%)	20939 (88.4%)			
THERAPEUTICALLY EQUIVALENT	20741 (87.9%)	20826 (88%)			

NOT THERAPEUTICALLY EQUIVALENT	73 (0.3%)	113 (0.5%)
EXCEPTIONS ⁴	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	43	13
NUMBER OF APPLICANTS	1197	1209

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	HETERO LABS LTD V	EQ 600MG BASE;300MG	A205412	001	Apr 16, 2025	Apr NEWA
----	-------------------	---------------------	---------	-----	--------------	----------

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

@ TEVA PHARMS USA

250MG

A208432 001 Oct 31, 2018 Mar DISC

@

500MG

A210726 001 Jan 26, 2023 Mar DISC

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB	GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Mar CMFD
----	---------------------	-------	---------	-----	--------------	----------

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP1	ASPIRO	1GM/100ML (10MG/ML)	A216617	001	Jul 27, 2022	Mar CTEC
AP	+! B BRAUN MEDICAL	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021	Mar CFTG
AP2	+!	1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021	Mar CFTG
>A>	! BAXTER HLTHCARE CORP	650MG/65ML (10MG/ML)	A214331	002	May 21, 2025	May NEWA
AP1		1GM/100ML (10MG/ML)	A214331	001	Sep 17, 2021	Mar CTEC
AP1	EUGIA PHARMA	1GM/100ML (10MG/ML)	A210969	001	Oct 21, 2020	Mar CTEC
AP	GLAND	500MG/50ML (10MG/ML)	A219215	001	Apr 02, 2025	Mar NFTG
AP2		1GM/100ML (10MG/ML)	A219215	002	Apr 02, 2025	Mar NFTG
AP1	HIKMA	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Mar CTEC
AP1	INFORLIFE	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Mar CTEC
AP1	MYLAN	1GM/100ML (10MG/ML)	A213255	001	Aug 07, 2020	Mar CTEC
AP1	! SANDOZ	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar CTEC
AP1	WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Mar CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

>A>	@ AVIV PHARMA	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May CAHN
>D>	@ NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ CHARTWELL 120MG/5ML;12MG/5ML

A089450 001 Oct 27, 1992 Feb DISC

! GENUS LIFESCIENCES 120MG/5ML;12MG/5ML

A087508 001 Feb CTEC

@ XTTRIUM LABS INC 120MG/5ML;12MG/5ML

A087006 001 Feb CAHN

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>A>	@ ANI PHARMS	300MG;15MG	A088629	002	Mar 06, 1985	May CAHN
>A>	@	300MG;30MG	A088629	003	Mar 06, 1985	May CAHN
>A>	@ +	300MG;60MG	A088629	001	Mar 06, 1985	May CAHN
>D>	@ NOSTRUM LABS INC	300MG;15MG	A088629	002	Mar 06, 1985	May CAHN
>D>	@	300MG;30MG	A088629	003	Mar 06, 1985	May CAHN
>D>	@ +	300MG;60MG	A088629	001	Mar 06, 1985	May CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ CHARTWELL 325MG/15ML;7.5MG/15ML

A040482 001 Sep 25, 2003 Feb DISC

AA	! WES PHARMA INC	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Feb CHRS
----	------------------	-----------------------	---------	-----	--------------	----------

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ CHARTWELL

300MG;5MG

A040658 001 Jan 19, 2006 Feb DISC

@

300MG;7.5MG

A040658 002 Mar 24, 2006 Feb DISC

@

300MG;10MG

A040658 003 Jun 23, 2004 Feb DISC

@

325MG;7.5MG

A040432 001 Jan 22, 2003 Feb DISC

@ RHODES PHARMS

300MG;5MG

A207808 001 Mar 30, 2018 Jan DISC

@

300MG;7.5MG

A207808 002 Mar 30, 2018 Jan DISC

@

300MG;10MG

A207808 003 Mar 30, 2018 Jan DISC

AA	! SPECGX LLC	300MG;5MG	A206718	001	Mar 31, 2017	Feb CHRS
----	--------------	-----------	---------	-----	--------------	----------

AA	!	300MG;7.5MG	A206718	002	Mar 31, 2017	Feb CHRS
----	---	-------------	---------	-----	--------------	----------

TABLET;ORAL					
HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
AA	!	300MG;10MG	A206718	003	Mar 31, 2017 Feb CHRS
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE</u>					
SOLUTION;ORAL					
OXYCODONE AND ACETAMINOPHEN					
AA	SANKALP LIFECARE	325MG/5ML; 5MG/5ML	A201448	001	Aug 26, 2021 Apr CAHN
TABLET;ORAL					
OXYCODONE AND ACETAMINOPHEN					
@	CHARTWELL	325MG; 5MG	A207834	001	Aug 15, 2019 Feb DISC
@		325MG; 7.5MG	A207834	002	Aug 15, 2019 Feb DISC
@		325MG; 10MG	A207834	003	Aug 15, 2019 Feb DISC
<u>ACETAZOLAMIDE</u>					
CAPSULE, EXTENDED RELEASE;ORAL					
ACETAZOLAMIDE					
>A>	AB	MPP PHARMA	500MG	A204691	001 Mar 29, 2016 May CAHN
>D>	AB	NOSTRUM LABS INC	500MG	A204691	001 Mar 29, 2016 May CAHN
TABLET;ORAL					
ACETAZOLAMIDE					
>A>	AB	AUROBINDO PHARMA LTD	125MG	A212089	001 May 30, 2025 May NEWA
>A>	AB		250MG	A212089	002 May 30, 2025 May NEWA
DIAMOX					
@ +	TEVA BRANDED PHARM	125MG	N008943	001	Feb CAHN
@ +		250MG	N008943	002	Feb CAHN
<u>ACETYLCYSTEINE</u>					
SOLUTION;INHALATION, ORAL					
ACETYLCYSTEINE					
AN	CONBA USA	10%	A214177	001	Mar 14, 2025 Mar NEWA
AN		20%	A214177	002	Mar 14, 2025 Mar NEWA
AN	SOMERSET THERAPS LLC	10%	A219194	001	Feb 12, 2025 Jan NEWA
AN		20%	A219194	002	Feb 12, 2025 Jan NEWA
<u>ACITRETIN</u>					
CAPSULE;ORAL					
ACITRETIN					
@	MYLAN	17.5MG	A203707	001	Sep 10, 2015 Apr CAHN
@		22.5MG	A203707	002	Sep 10, 2015 Apr CAHN
>A>	<u>ACOLTREMONE</u>				
>A>	SOLUTION/DROPS;OPHTHALMIC				
>A>	TRYPTYR				
>A>	+!	ALCON LABS INC	0.003%	N217370	001 May 28, 2025 May NEWA
<u>ACYCLOVIR</u>					
CREAM;TOPICAL					
ACYCLOVIR					
>D>	AB	CIPLA	5%	A212981	001 May 02, 2025 May DISC
>A>	@		5%	A212981	001 May 02, 2025 May DISC
	AB		5%	A212981	001 May 02, 2025 Apr NEWA
	BX	ZYDUS LIFESCIENCES	5%	A206770	001 Feb 28, 2023 Mar CTEC
OINTMENT;TOPICAL					
ACYCLOVIR					
@	APOTEX	5%	A210774	001	Sep 06, 2019 Jan DISC
@	CHARTWELL MOLECULAR	5%	A206437	001	Jul 31, 2017 Feb CAHN
>D>	BX	CIPLA	5%	A211794	001 Jan 18, 2019 May DISC
>A>	@		5%	A211794	001 Jan 18, 2019 May DISC
	BX		5%	A211794	001 Jan 18, 2019 Mar CTEC
<u>ACYCLOVIR SODIUM</u>					
INJECTABLE;INJECTION					
ACYCLOVIR SODIUM					
>D>	@	FRESENIUS KABI USA	EQ 50MG BASE/ML	A215404	001 Jun 25, 2024 May CMFD
>A>	AP		EQ 50MG BASE/ML	A215404	001 Jun 25, 2024 May CMFD
	@		EQ 50MG BASE/ML	A215404	001 Jun 25, 2024 Feb DISC

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
ALBUTEROL SULFATE

AB2 PADAGIS US EQ 0.09MG BASE/INH A203760 001 Feb 24, 2020 Mar CMFD
POWDER, METERED; INHALATION
PROAIR DIGIHALER

@ + TEVA BRANDED PHARM EQ 0.09MG BASE/INH N205636 002 Dec 21, 2018 Feb CAHN
PROAIR RESPICLICK

+! TEVA BRANDED PHARM EQ 0.09MG BASE/INH N205636 001 Mar 31, 2015 Feb CAHN
SOLUTION; INHALATION
ALBUTEROL SULFATE

AN RITEDOSE CORP EQ 0.5% BASE A218386 001 Mar 12, 2025 Feb NEWA
SYRUP; ORAL
ALBUTEROL SULFATE

@ COSETTE EQ 2MG BASE/5ML A074454 001 Sep 25, 1995 Jan DISC
TABLET; ORAL

ALBUTEROL SULFATE

>A> AB ACERTIS PHARMS EQ 2MG BASE A211397 001 Oct 26, 2018 May CAHN

>A> AB EQ 4MG BASE A211397 002 Oct 26, 2018 May CAHN

>D> AB VIRTUS PHARM EQ 2MG BASE A211397 001 Oct 26, 2018 May CAHN

>D> AB EQ 4MG BASE A211397 002 Oct 26, 2018 May CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

@ APOTEX EQ 5MG BASE A077982 001 Aug 04, 2008 Mar DISC

@ EQ 10MG BASE A077982 002 Aug 04, 2008 Mar DISC

@ EQ 35MG BASE A077982 003 Aug 04, 2008 Mar DISC

@ EQ 70MG BASE A077982 004 Aug 04, 2008 Mar DISC

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB AUROBINDO PHARMA LTD 100MG A215091 001 Apr 14, 2025 Apr NEWA

AB 300MG A215091 002 Apr 14, 2025 Apr NEWA

>A> AB INDOCO 200MG A204467 003 May 22, 2025 May NEWA

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@ APOTEX INC 0.25MG A077741 001 Jan 19, 2007 Mar DISC

@ 0.5MG A077741 002 Jan 19, 2007 Mar DISC

@ 1MG A077741 003 Jan 19, 2007 Mar DISC

@ 2MG A077741 004 Jan 19, 2007 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ APOTEX INC 0.5MG A078449 001 Nov 12, 2008 Mar DISC

@ 1MG A078449 004 Dec 23, 2015 Mar DISC

@ 2MG A078449 002 Nov 12, 2008 Mar DISC

@ 3MG A078449 003 Nov 12, 2008 Mar DISC

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

@ + VIATRIS 0.125MG N020700 001 Nov 19, 1996 Feb CAHN

@ + 0.25MG N020700 002 Nov 19, 1996 Feb CAHN

@ + 0.5MG N020700 003 Nov 19, 1996 Feb CAHN

@ + 1MG N020700 004 Nov 19, 1996 Feb CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMANTADINE HYDROCHLORIDE

>D> ZYDUS EQ 68.5MG BASE A214897 001 Aug 26, 2024 May DISC

>A> @ EQ 68.5MG BASE A214897 001 Aug 26, 2024 May DISC

GOCOVRI

>D> AB + SUPERNUS PHARMS EQ 68.5MG BASE N208944 001 Aug 24, 2017 May CTEC

>A> + EQ 68.5MG BASE N208944 001 Aug 24, 2017 May CTEC

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

@ BAJAJ 50MG/5ML A075819 001 Sep 11, 2002 Mar CAHN

AMCINONIDE

LOTION;TOPICAL
AMCINONIDE

!	SOLUBIOMIX	0.1%	A076329	001	Nov 06, 2002	Feb CAHN
---	------------	------	---------	-----	--------------	----------

AMINOCAPROIC ACID

SOLUTION;ORAL
AMINOCAPROIC ACID

AA	AJENAT PHARMS	0.25GM/ML	A213825	001	Apr 08, 2021	Jan CAHN
>A> AA	APOZEAL PHARMS	0.25GM/ML	A213216	001	May 19, 2025	May NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL
AMITRIPTYLINE HYDROCHLORIDE

BX	RUBICON	10MG	A215376	001	May 01, 2023	Mar CTEC
BX		25MG	A215376	002	May 01, 2023	Mar CTEC
BX		50MG	A215376	003	May 01, 2023	Mar CTEC
BX		75MG	A215376	004	May 01, 2023	Mar CTEC
BX		100MG	A215376	005	May 01, 2023	Mar CTEC
BX		150MG	A215376	006	May 01, 2023	Mar CTEC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@	MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Apr DISC
@		EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Apr DISC
	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Apr CTEC
!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Apr CTEC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

>A> AB	ALEMBIC	EQ 2.5MG BASE;EQ 10MG BASE	A217279	001	May 22, 2025	May NEWA
>A> AB		EQ 2.5MG BASE;EQ 20MG BASE	A217279	002	May 22, 2025	May NEWA
>A> AB		EQ 2.5MG BASE;EQ 40MG BASE	A217279	003	May 22, 2025	May NEWA
>A> AB		EQ 5MG BASE;EQ 10MG BASE	A217279	004	May 22, 2025	May NEWA
>A> AB		EQ 5MG BASE;EQ 20MG BASE	A217279	005	May 22, 2025	May NEWA
>A> AB		EQ 5MG BASE;EQ 40MG BASE	A217279	006	May 22, 2025	May NEWA
>A> AB		EQ 5MG BASE;EQ 80MG BASE	A217279	007	May 22, 2025	May NEWA
>A> AB		EQ 10MG BASE;EQ 10MG BASE	A217279	008	May 22, 2025	May NEWA
>A> AB		EQ 10MG BASE;EQ 20MG BASE	A217279	009	May 22, 2025	May NEWA
>A> AB		EQ 10MG BASE;EQ 40MG BASE	A217279	010	May 22, 2025	May NEWA
>A> AB		EQ 10MG BASE;EQ 80MG BASE	A217279	011	May 22, 2025	May NEWA
AB	APDM PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb CAHN
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb CAHN
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb CAHN
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb CAHN
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb CAHN
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb CAHN
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	CHARTWELL RX	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	Apr CAHN
@		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	Apr CAHN
@		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	Apr CAHN
@		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	Apr CAHN
@		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	Apr CAHN
@		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	Apr CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

>A> AB	PIRAMAL	EQ 5MG BASE;12.5MG;20MG	A210718	001	May 14, 2025	May NEWA
>A> AB		EQ 5MG BASE;12.5MG;40MG	A210718	002	May 14, 2025	May NEWA
>A> AB		EQ 5MG BASE;25MG;40MG	A210718	003	May 14, 2025	May NEWA
>A> AB		EQ 10MG BASE;12.5MG;40MG	A210718	004	May 14, 2025	May NEWA

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

>A> AB		EQ 10MG BASE;25MG;40MG	A210718	005	May 14, 2025	May NEWA
--------	--	------------------------	---------	-----	--------------	----------

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	HETERO LABS LTD V	EQ 5MG BASE;20MG	A209591	001	Feb 14, 2025	Feb NEWA
AB		EQ 5MG BASE;40MG	A209591	002	Feb 14, 2025	Feb NEWA
AB		EQ 10MG BASE;20MG	A209591	003	Feb 14, 2025	Feb NEWA
AB		EQ 10MG BASE;40MG	A209591	004	Feb 14, 2025	Feb NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	SOFIE	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Mar CAHN
----	-------	------------------------------------	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jan CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jan CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jan CMFD
AB		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jan CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jan CMFD

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

@	RHODES PHARMS	5MG	A213852	001	Sep 07, 2021	Jan DISC
@		10MG	A213852	002	Sep 07, 2021	Jan DISC

AMPHOTERICIN B

INJECTABLE, LIPOSOMAL;INJECTION

AMPHOTERICIN B

>A> AB	AVET LIFESCIENCES	50MG/VIAL	A215354	001	Jun 02, 2025	May NEWA
--------	-------------------	-----------	---------	-----	--------------	----------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@	HIKMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Mar DISC
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Mar DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

@	BARR LABS	EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Mar CAHN
@		EQ 1MG BASE	A076530	002	Apr 18, 2005	Mar CAHN

ANGIOTENSIN II ACETATE

SOLUTION;INTRAVENOUS

ANGIOTENSIN 11 ACETATE

>A> AP	GLAND	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	A216966	001	Jun 03, 2025	May NFTG
>D>	GIAPREZA					
	+! LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	May CFTG
>A> AP	+!	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	May CFTG

APALUTAMIDE

TABLET;ORAL

APALUTAMIDE

AB	ZYDUS	60MG	A217113	001	Mar 17, 2025	Mar NFTG
AB	ERLEADA					
	+ JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Mar CFTG

APIXABAN

FOR SUSPENSION;ORAL							
ELIQUIS SPRINKLE							
	+	BRISTOL	0.15MG	N220073	001	Apr 17, 2025	Apr NEWA
TABLET;ORAL							
APIXABAN							
	@	HETERO LABS LTD V	2.5MG	A210066	001	Nov 21, 2023	Apr DISC
	@		5MG	A210066	002	Nov 21, 2023	Apr DISC
AB		IMPAX	2.5MG	A209810	001	Feb 14, 2025	Feb NEWA
AB			5MG	A209810	002	Feb 14, 2025	Feb NEWA
AB		MACLEODS PHARMS LTD	2.5MG	A210067	001	Feb 27, 2025	Feb NEWA
AB			5MG	A210067	002	Feb 27, 2025	Feb NEWA
TABLET, FOR SUSPENSION;ORAL							
ELIQUIS							
	+	BRISTOL MYERS SQUIBB	0.5MG	N202155	003	Apr 17, 2025	Apr NEWA

APOMORPHINE HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS							
ONAPGO							
	+	MDD US	98MG/20ML (4.9MG/ML)	N214056	001	Feb 03, 2025	Feb NEWA

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION							
ARFORMOTEROL TARTRATE							
AN		AUCTA	EQ 0.015MG BASE/2ML	A218380	001	Feb 03, 2025	Jan NEWA
AN		MICRO LABS	EQ 0.015MG BASE/2ML	A218555	001	Mar 07, 2025	Feb NEWA
AN		SABA ILAC SANAYI	EQ 0.015MG BASE/2ML	A218429	001	Apr 25, 2025	Apr NEWA

ARGATROBAN

INJECTABLE;INTRAVENOUS							
ARGATROBAN IN SODIUM CHLORIDE							
AP	+	PLANO PHARMS	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	Mar CAHN

ARIPIRAZOLE

FILM;ORAL							
MEZOFY							
	+	CMG PHARM CO LTD	5MG	N211448	001	Apr 15, 2025	Apr NEWA
	+		10MG	N211448	002	Apr 15, 2025	Apr NEWA
	+		15MG	N211448	003	Apr 15, 2025	Apr NEWA
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR							
ABILIFY MAINTENA KIT							
	+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	Jan CTEC
	+		400MG/VIAL	N202971	002	Feb 28, 2013	Jan CTEC
ARIPIRAZOLE							
	@	MYLAN	300MG/VIAL	A216608	001	Dec 03, 2024	Jan DISC
	@		400MG/VIAL	A216608	002	Dec 03, 2024	Jan DISC
SOLUTION;ORAL							
ARIPIRAZOLE							
AA		VISTAPHARM LLC	1MG/ML	A212870	001	Dec 26, 2019	Jan CAHN

ARMODAFINIL

TABLET;ORAL							
NUVIGIL							
AB	+	NUVO PHARMS	50MG	N021875	001	Jun 15, 2007	Jan CAHN
	@ +		100MG	N021875	002	Mar 26, 2009	Jan CAHN
AB	+		150MG	N021875	003	Jun 15, 2007	Jan CAHN
AB	+		200MG	N021875	005	Mar 26, 2009	Jan CAHN
AB	+		250MG	N021875	004	Jun 15, 2007	Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL							
BUTALBITAL, ASPIRIN AND CAFFEINE							
>A> AA		MPP PHARMA	325MG;50MG;40MG	A078149	001	Jun 13, 2007	May CAHN
>D> AA		NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007	May CAHN

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

@	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Mar	DISC
@		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr	DISC
@		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr	DISC
@		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr	DISC

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

@	APOTEX	750MG/5ML	A209750	001	Oct 11, 2017	Mar	DISC
---	--------	-----------	---------	-----	--------------	-----	------

ATRASENTAN HYDROCHLORIDE

TABLET; ORAL

VANRAFIA

+	NOVARTIS	EQ 0.75MG BASE	N219208	001	Apr 02, 2025	Apr	NEWA
---	----------	----------------	---------	-----	--------------	-----	------

AVIBACTAM SODIUM; AZTREONAM

POWDER; INTRAVENOUS

EMBLAVEO

+	ABBVIE	EQ 0.5GM BASE/VIAL; 1.5GM/VIAL	N217906	001	Feb 07, 2025	Feb	NEWA
---	--------	--------------------------------	---------	-----	--------------	-----	------

>A> AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE

>A> CAPSULE, TABLET; ORAL

>A> AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)

>A>	+	VERASTEM INC	EQ 0.8MG BASE; EQ 200MG BASE	N219616	001	May 08, 2025	May	NEWA
-----	---	--------------	------------------------------	---------	-----	--------------	-----	------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

>A>	AP	RELIANCE LIFE	100MG/VIAL	A217453	001	May 20, 2025	May	NEWA
-----	----	---------------	------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTEPRO

@	+	NORVIUM BIOSCIENCE	0.137MG/SPRAY	N022203	001	Oct 15, 2008	Jan	CAHN
---	---	--------------------	---------------	---------	-----	--------------	-----	------

@			0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Jan	CAHN
---	--	--	----------------	---------	-----	--------------	-----	------

@	+	VIATRIS	0.137MG/SPRAY	N022203	001	Oct 15, 2008	Apr	CAHN
---	---	---------	---------------	---------	-----	--------------	-----	------

@			0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Apr	CAHN
---	--	--	----------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

@	BIONPHARMA	0.137MG/SPRAY	A090176	001	Jul 28, 2015	Jan	DISC
---	------------	---------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB		TEVA PHARMS USA INC	0.137MG/SPRAY; 0.05MG/SPRAY	A208436	001	Apr 08, 2025	Mar	NEWA
----	--	---------------------	-----------------------------	---------	-----	--------------	-----	------

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE

AB		ALKEM LABS LTD	EQ 40MG MEDOXOMIL; 12.5MG	A217490	001	Jan 21, 2025	Jan	NFTG
----	--	----------------	---------------------------	---------	-----	--------------	-----	------

AB			EQ 40MG MEDOXOMIL; 25MG	A217490	002	Jan 21, 2025	Jan	NFTG
----	--	--	-------------------------	---------	-----	--------------	-----	------

EDARBYCLOR

AB	+	AZURITY	EQ 40MG MEDOXOMIL; 12.5MG	N202331	001	Dec 20, 2011	Jan	CFTG
----	---	---------	---------------------------	---------	-----	--------------	-----	------

AB	+		EQ 40MG MEDOXOMIL; 25MG	N202331	002	Dec 20, 2011	Jan	CFTG
----	---	--	-------------------------	---------	-----	--------------	-----	------

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

AB		CHARTWELL RX	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Feb	CMFD
----	--	--------------	-------------------	---------	-----	--------------	-----	------

AB			EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Feb	CMFD
----	--	--	-------------------	---------	-----	--------------	-----	------

AB		ZHEJIANG POLY PHARM	EQ 100MG BASE/5ML	A217036	001	Jul 27, 2023	Mar	CAHN
----	--	---------------------	-------------------	---------	-----	--------------	-----	------

AB			EQ 200MG BASE/5ML	A217036	002	Jul 27, 2023	Mar	CAHN
----	--	--	-------------------	---------	-----	--------------	-----	------

ZITHROMAX

@	+	PFIZER	EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994	Apr	DISC
---	---	--------	--------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

AZITHROMYCIN

@	HOSPIRA	EQ 500MG BASE/VIAL	A065511	001	Jun 26, 2009	Apr	DISC
---	---------	--------------------	---------	-----	--------------	-----	------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT;OPHTHALMIC
LUMI-SPORYN

AT	+	CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Feb	CPOT
----	---	-------------------	--	---------	-----	--	-----	------

BACLOFENSOLUTION;ORAL
BACLOFEN

>D>		RUBICON	5MG/5ML	A214445	001	Dec 06, 2024	May	CAHN
>A>		RUBICON RESEARCH	5MG/5ML	A214445	001	Dec 06, 2024	May	CAHN
>A>	AA		10MG/5ML	A214445	002	Jun 03, 2025	May	NFTG
		OZOBAX DS						
>D>		+! METACEL PHARMS LLC	10MG/5ML	N208193	002	Oct 12, 2023	May	CFTG
>A>	AA	+!	10MG/5ML	N208193	002	Oct 12, 2023	May	CFTG
		TABLET;ORAL BACLOFEN						
AB		APPCO	5MG	A090334	003	Jan 31, 2025	Jan	NEWA

BALSALAZIDE DISODIUMCAPSULE;ORAL
BALSALAZIDE DISODIUM

AB		CARNEGIE	750MG	A219422	001	Apr 03, 2025	Mar	NEWA
----	--	----------	-------	---------	-----	--------------	-----	------

BECLOMETHASONE DIPROPIONATEAEROSOL, METERED;INHALATION
QVAR 40

@ +	TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000	Mar	CAHN
-----	--------------------	------------	---------	-----	--------------	-----	------

@ +	TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000	Mar	CAHN
-----	--------------------	------------	---------	-----	--------------	-----	------

AEROSOL, METERED;NASAL
QNASL

+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014	Feb	CAHN
+!		0.08MG/ACTUATION	N202813	001	Mar 23, 2012	Feb	CAHN

BENDAMUSTINE HYDROCHLORIDEPOWDER;INTRAVENOUS
BENDAMUSTINE HYDROCHLORIDE

>D>	AP	APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	May	DISC
>A>		@	25MG/VIAL	A204230	001	Jun 05, 2023	May	DISC
>D>	AP		100MG/VIAL	A204230	002	Jun 05, 2023	May	DISC
>A>		@	100MG/VIAL	A204230	002	Jun 05, 2023	May	DISC

BENZOYL PEROXIDECREAM;TOPICAL
EPSOLAY

>D>		+! GALDERMA LABS LP	5%	N214510	001	Apr 22, 2022	May	CAHN
>A>		+! MAYNE PHARMA	5%	N214510	001	Apr 22, 2022	May	CAHN

BENZOYL PEROXIDE; TRETINOINCREAM;TOPICAL
TWYNEO

>D>		+! GALDERMA LABS LP	3%;0.1%	N214902	001	Jul 26, 2021	May	CAHN
>A>		+! MAYNE PHARMA	3%;0.1%	N214902	001	Jul 26, 2021	May	CAHN

BENZTROPINE MESYLATETABLET;ORAL
BENZTROPINE MESYLATE

AA		QUAGEN	0.5MG	A212694	001	Feb 11, 2025	Jan	NEWA
AA			1MG	A212694	002	Feb 11, 2025	Jan	NEWA
AA			2MG	A212694	003	Feb 11, 2025	Jan	NEWA

BETAMETHASONE DIPROPIONATECREAM, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE

@	CHARTWELL MOLECULAR	EQ 0.05% BASE	A076603	001	Jan 23, 2004	Feb	CAHN
---	---------------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION; TOPICAL
 CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE
 @ PADAGIS ISRAEL 0.064%; 0.005%

A212367 001 Sep 11, 2020 Jan DISC

BEXAROTENE

CAPSULE; ORAL
 BEXAROTENE
 @ CIPLA

75MG

A210352 001 Dec 10, 2024 Jan DISC

BICALUTAMIDE

TABLET; ORAL
 BICALUTAMIDE
 @ APOTEX

50MG

A200274 001 May 21, 2015 Mar DISC

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC
 BIMATOPROST

AB MANKIND PHARMA 0.01%

A218196 001 Mar 17, 2025 Mar NFTG

AB LUMIGAN
 +! ABBVIE 0.01%

N022184 001 Aug 31, 2010 Mar CFTG

BISOPROLOL FUMARATE

TABLET; ORAL
 BISOPROLOL FUMARATE

AB RUBICON 2.5MG
 AB UNIQUE PHARM 5MG
 AB 10MG

A075643 003 Mar 07, 2025 Mar NEWA

A219044 001 Apr 16, 2025 Apr NEWA

A219044 002 Apr 16, 2025 Apr NEWA

ZEBETA

@ + TEVA BRANDED PHARM 5MG
 @ + 10MG

N019982 002 Jul 31, 1992 Apr CAHN

N019982 001 Jul 31, 1992 Apr CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
 ZIAC

AB + TEVA BRANDED PHARM 2.5MG; 6.25MG
 AB + 5MG; 6.25MG
 AB +! 10MG; 6.25MG

N020186 003 Mar 26, 1993 Apr CAHN

N020186 001 Mar 26, 1993 Apr CAHN

N020186 002 Mar 26, 1993 Apr CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
 BORTEZOMIB

>D> AP BAXTER HLTHCARE CORP 3.5MG/VIAL
 >A> @ 3.5MG/VIAL
 >A> AP MEDICAMEN BIOTECH 3.5MG/VIAL

A213823 001 May 02, 2022 May DISC

A213823 001 May 02, 2022 May DISC

A218688 001 Jun 02, 2025 May NEWA

BOSENTAN

TABLET, FOR SUSPENSION; ORAL
 BOSENTAN

AB NATCO PHARMA LTD 32MG
 AB TRACLEER
 AB +! ACTELION 32MG

A213154 001 Feb 05, 2025 Jan NFTG

N209279 001 Sep 05, 2017 Jan CFTG

BOSUTINIB MONOHYDRATE

TABLET; ORAL
 BOSULIF

>D> +! PF PRISM CV EQ 100MG BASE
 >A> AB +! EQ 100MG BASE
 >D> + EQ 500MG BASE
 >A> AB + EQ 500MG BASE
 >A> BOSUTINIB MONOHYDRATE
 >A> AB ALEMBIC EQ 100MG BASE
 >A> AB EQ 500MG BASE

N203341 001 Sep 04, 2012 May CFTG

N203341 001 Sep 04, 2012 May CFTG

N203341 002 Sep 04, 2012 May CFTG

N203341 002 Sep 04, 2012 May CFTG

A209543 001 May 23, 2025 May NFTG

A209543 002 May 23, 2025 May NFTG

BREXANOLONE

SOLUTION; INTRAVENOUS
 ZULRESSO

@ + SAGE THERAP 100MG/20ML (5MG/ML)

N211371 001 Jun 17, 2019 Jan DISC

BREXPIRAZOLE

TABLET; ORAL

BREXPIRAZOLE

AB		ALEMBIC	0.25MG	A213683	001	Jan 13, 2025	Jan NEWA
AB			0.5MG	A213683	002	Jan 13, 2025	Jan NEWA
AB			1MG	A213683	003	Jan 13, 2025	Jan NEWA
AB			2MG	A213683	004	Jan 13, 2025	Jan NEWA
AB			3MG	A213683	005	Jan 13, 2025	Jan NEWA
AB			4MG	A213683	006	Jan 13, 2025	Jan NEWA
	@	APOTEX	0.25MG	A213731	001	Feb 24, 2025	Mar DISC
AB			0.25MG	A213731	001	Feb 24, 2025	Feb NEWA
	@		0.5MG	A213731	002	Feb 24, 2025	Mar DISC
AB			0.5MG	A213731	002	Feb 24, 2025	Feb NEWA
	@		1MG	A213731	003	Feb 24, 2025	Mar DISC
AB			1MG	A213731	003	Feb 24, 2025	Feb NEWA
	@		2MG	A213731	004	Feb 24, 2025	Mar DISC
AB			2MG	A213731	004	Feb 24, 2025	Feb NEWA
	@		3MG	A213731	005	Feb 24, 2025	Mar DISC
AB			3MG	A213731	005	Feb 24, 2025	Feb NEWA
		REXULTI					
AB	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Jan CTEC
AB	+		0.5MG	N205422	002	Jul 10, 2015	Jan CTEC
AB	+		1MG	N205422	003	Jul 10, 2015	Jan CTEC
AB	+		2MG	N205422	004	Jul 10, 2015	Jan CTEC
AB	+		3MG	N205422	005	Jul 10, 2015	Jan CTEC
AB	+		4MG	N205422	006	Jul 10, 2015	Jan CTEC

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

	@	AMNEAL	0.2%;EQ 0.5% BASE	A217288	001	Dec 30, 2024	Jan DISC
AB		CAPLIN	0.2%;EQ 0.5% BASE	A219093	001	Feb 25, 2025	Feb NEWA

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

AA	+	XTTRIUM LABS INC	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Feb CAHN
		BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
>D>	@	BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	May CMFD
>A> AA			2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	May CMFD

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

	@	SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013	Feb DISC
	@		0.5MG/2ML	A201966	002	Sep 27, 2013	Feb DISC
	@		1MG/2ML	A201966	001	Sep 27, 2013	Feb DISC

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP		ASPIRO	0.25MG/ML	A218746	001	Feb 27, 2025	Feb NEWA
----	--	--------	-----------	---------	-----	--------------	----------

TABLET; ORAL

BUMETANIDE

AB		MANKIND PHARMA	0.5MG	A219291	001	Apr 03, 2025	Mar NEWA
AB			1MG	A219291	002	Apr 03, 2025	Mar NEWA
AB			2MG	A219291	003	Apr 03, 2025	Mar NEWA

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP		SOMERSET THERAPS LLC	EQ 0.3MG BASE/ML	A219302	001	Jan 30, 2025	Jan NEWA
----	--	----------------------	------------------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		DIFGEN PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A212756	003	Feb 13, 2025	Feb NEWA
AB			EQ 4MG BASE;EQ 1MG BASE	A212756	004	Feb 13, 2025	Feb NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB1	IPCA LABS LTD	100MG	A207874	001	May 02, 2025	Apr NEWA
AB1		150MG	A207874	002	May 02, 2025	Apr NEWA
AB1		200MG	A207874	003	May 02, 2025	Apr NEWA
@	SUN PHARM	150MG	A200216	001	Nov 30, 2020	Feb DISC
@		300MG	A203650	001	Dec 31, 2020	Feb DISC

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL
BUSPIRONE HYDROCHLORIDE

EPIC PHARMA LLC	7.5MG	A218628	001	Mar 13, 2025	Feb NEWA
	10MG	A218628	002	Mar 13, 2025	Feb NEWA
	15MG	A218628	003	Mar 13, 2025	Feb NEWA

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Apr CHRS
BX	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Mar CTEC
BX		7.5MG	A208972	002	Apr 16, 2019	Mar CTEC
BX		10MG	A208972	003	Apr 16, 2019	Mar CTEC
BX		15MG	A208972	004	Apr 16, 2019	Mar CTEC
BX		30MG	A208972	005	Apr 16, 2019	Mar CTEC
BX	INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Mar CTEC
BX		7.5MG	A209696	002	May 03, 2018	Mar CTEC
BX		10MG	A209696	003	May 03, 2018	Mar CTEC
BX		15MG	A209696	004	May 03, 2018	Mar CTEC
BX		30MG	A209696	005	May 03, 2018	Mar CTEC
AB	! UNICHEM	15MG	A210907	003	Nov 14, 2019	Apr CHRS

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

@ APOTEX	6MG/ML	A210448	001	May 07, 2019	Jan DISC
----------	--------	---------	-----	--------------	----------

BUTORPHANOL TARTRATE

SPRAY, METERED;NASAL
BUTORPHANOL TARTRATE

>D> AB	HIKMA	1MG/SPRAY	A075824	001	Mar 12, 2002	May CHRS
>A> AB	!	1MG/SPRAY	A075824	001	Mar 12, 2002	May CHRS
>D> AB	! RISING	1MG/SPRAY	A075759	001	Aug 08, 2001	May DISC
>A>	@	1MG/SPRAY	A075759	001	Aug 08, 2001	May DISC
	STADOL					
>D>	@ BRISTOL MYERS SQUIBB	1MG/SPRAY	N019890	001	Dec 12, 1991	May CRLD
>A>	@ +	1MG/SPRAY	N019890	001	Dec 12, 1991	May CRLD

CAFFEINE CITRATE

SOLUTION;ORAL
CAFFEINE CITRATE
@ SUN PHARM

EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090357	001	Sep 30, 2009	Feb DISC
------------------------------------	---------	-----	--------------	----------

CALCIUM ACETATE

CAPSULE;ORAL
CALCIUM ACETATE

>A> AB	MPP PHARMA	667MG	A203179	001	Oct 26, 2015	May CAHN
>D> AB	NOSTRUM LABS INC	667MG	A203179	001	Oct 26, 2015	May CAHN

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

@ + VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Feb CAHN
-------------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@ VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Feb CAHN
-----------------------	--	---------	-----	--------------	----------

INJECTABLE; INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Feb CAHN
---	---	---------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

@	+	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Feb CAHN
---	---	---------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Feb CAHN
---	--	---------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Feb CAHN
---	---	---------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Feb CAHN
---	--	---------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Feb CAHN
---	--	---------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

@	+	VANTIVE US HLTHCARE	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Feb CAHN
---	---	---------------------	---	---------	-----	--------------	----------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Feb CAHN
---	--	---------------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

+	!	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	001	Nov 30, 1984	Feb CTEC
---	---	-----------------	---	---------	-----	--------------	----------

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

+	!	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	002	Nov 30, 1984	Feb CTEC
---	---	-----------------	---	---------	-----	--------------	----------

SOLUTION;INTRAPERITONEAL									
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
	+	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2 MG/100ML;567MG/100ML;392MG/100ML	N018883	003	Nov 30, 1984	Feb	CTEC	
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	001		Feb	CAHN	
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	003		Feb	CAHN	
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	002		Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	001	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	002	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
@	+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	004	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	012	Jan 10, 1989	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	013	Jul 11, 1990	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER									
	+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	014	Jul 11, 1990	Feb	CTEC	
AT	+		18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	014	Jul 11, 1990	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	015	Jul 11, 1990	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	007	Jul 09, 1984	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	008	Jul 09, 1984	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	009	Jul 09, 1984	Feb	CAHN	
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	004		Feb	CAHN	
AT	+		25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	001	Dec 04, 1992	Feb	CAHN	
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;	N017512	005		Feb	CAHN	

SOLUTION;INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+	448MG/100ML 25.7MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N020163	002	Dec 04, 1992	Feb CAHN
----	---	--	---------	-----	--------------	----------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@	+	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N017512	011	Nov 18, 1985	Feb CAHN
---	---	---------------------	---	---------	-----	--------------	----------

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N017512	006		Feb CAHN
----	---	---------------------	--	---------	-----	--	----------

AT	+		25.7MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N020163	003	Dec 04, 1992	Feb CAHN
----	---	--	--	---------	-----	--------------	----------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314 GM/1000ML;2.21GM/1000ML;6.95GM /1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0. 314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0 .187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Feb CAHN
---	---	---------------------	--	---------	-----	--------------	----------

CANDESARTAN CILEXETIL

TABLET;ORAL

CANDESARTAN CILEXETIL

AB		ZYDUS LIFESCIENCES	4MG	A091390	001	Aug 23, 2017	Jan CMFD
AB			8MG	A091390	002	Aug 23, 2017	Jan CMFD
AB			16MG	A091390	003	Aug 23, 2017	Jan CMFD
AB			32MG	A091390	004	Aug 23, 2017	Jan CMFD

CAPECITABINE

TABLET;ORAL

CAPECITABINE

BX		TEYRO LABS	150MG	A217237	001	Oct 23, 2023	Mar CTEC
BX			500MG	A217237	002	Oct 23, 2023	Mar CTEC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

>A>	AB	ANI PHARMS	100MG	A076697	001	May 20, 2011	May CAHN
>A>	AB		200MG	A076697	002	May 20, 2011	May CAHN
>A>	AB		300MG	A076697	003	May 20, 2011	May CAHN
>D>	AB	NOSTRUM LABS INC	100MG	A076697	001	May 20, 2011	May CAHN
>D>	AB		200MG	A076697	002	May 20, 2011	May CAHN
>D>	AB		300MG	A076697	003	May 20, 2011	May CAHN

TABLET;ORAL

CARBAMAZEPINE

AB		ALEMBIC	200MG	A216623	001	Apr 16, 2025	Apr NEWA
----	--	---------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		ALKEM LABS LTD	100MG	A217277	001	Jan 14, 2025	Jan NEWA
AB			200MG	A217277	002	Jan 14, 2025	Jan NEWA
AB			400MG	A217277	003	Jan 14, 2025	Jan NEWA
@		OSMOTICA PHARM US	100MG	A215664	001	Oct 22, 2024	Apr DISC
@			200MG	A215664	002	Oct 22, 2024	Apr DISC
@			400MG	A215664	003	Oct 22, 2024	Apr DISC
AB		TORRENT	100MG	A212524	001	Jan 13, 2025	Jan NEWA
AB			200MG	A212524	002	Jan 13, 2025	Jan NEWA
AB			400MG	A212524	003	Jan 13, 2025	Jan NEWA
AB		YICHANG HUMANWELL	100MG	A219072	001	Jan 16, 2025	Jan NEWA
AB			200MG	A219072	002	Jan 16, 2025	Jan NEWA
AB			400MG	A219072	003	Jan 16, 2025	Jan NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	MACLEODS PHARMS LTD	12.5MG;200MG;50MG	A214495	001	Apr 15, 2025	Apr NEWA
AB		18.75MG;200MG;75MG	A214495	002	Apr 15, 2025	Apr NEWA
AB		25MG;200MG;100MG	A214495	003	Apr 15, 2025	Apr NEWA
AB		31.25MG;200MG;125MG	A214495	004	Apr 15, 2025	Apr NEWA
AB		37.5MG;200MG;150MG	A214495	005	Apr 15, 2025	Apr NEWA
AB		50MG;200MG;200MG	A214495	006	Apr 15, 2025	Apr NEWA

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

	@ APOTEX INC	10MG;100MG	A077120	001	Jun 02, 2008	Mar DISC
	@	25MG;100MG	A077120	002	Jun 02, 2008	Mar DISC
	@	25MG;250MG	A077120	003	Jun 02, 2008	Mar DISC
AB	ASCENT PHARMS INC	10MG;100MG	A218939	001	Jan 14, 2025	Jan NEWA
AB		25MG;100MG	A218939	002	Jan 14, 2025	Jan NEWA
AB		25MG;250MG	A218939	003	Jan 14, 2025	Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

	@ APOTEX	25MG;100MG	A076212	001	Jun 16, 2004	Mar DISC
	@	50MG;200MG	A076212	002	Jun 16, 2004	Mar DISC

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

	@ SENORES PHARMS	4MG	A090435	001	Apr 15, 2010	Jan CAHN
--	------------------	-----	---------	-----	--------------	----------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	FOSUN WANBANG	350MG	A081025	001	Apr 13, 1989	Jan CAHN
>A> AB	MPP PHARMA	250MG	A207237	001	May 11, 2017	May CAHN
>A> AA		350MG	A207237	002	Sep 21, 2020	May CAHN
>D> AB	NOSTRUM LABS INC	250MG	A207237	001	May 11, 2017	May CAHN
>D> AA		350MG	A207237	002	Sep 21, 2020	May CAHN
AA	POINTVIEW HLDINGS	350MG	A211789	001	Oct 20, 2021	Apr CAHN

CARVEDILOL

TABLET; ORAL

CARVEDILOL

AB	GRAVITI PHARMS	3.125MG	A076649	001	Sep 05, 2007	Feb CAHN
AB		6.25MG	A076649	002	Sep 05, 2007	Feb CAHN
AB		12.5MG	A076649	003	Sep 05, 2007	Feb CAHN
AB		25MG	A076649	004	Sep 05, 2007	Feb CAHN
	@ NORVIUM BIOSCIENCE	3.125MG	A077316	001	Sep 05, 2007	Feb CAHN
	@	6.25MG	A077316	002	Sep 05, 2007	Mar DISC
AB		6.25MG	A077316	002	Sep 05, 2007	Feb CAHN
	@	12.5MG	A077316	003	Sep 05, 2007	Apr DISC
AB		12.5MG	A077316	003	Sep 05, 2007	Feb CAHN
	@	25MG	A077316	004	Sep 05, 2007	Apr DISC
AB		25MG	A077316	004	Sep 05, 2007	Feb CAHN

CEDAZURIDINE; DECITABINE

TABLET; ORAL

INQOVI

	+! TAIHO ONCOLOGY	100MG;35MG	N212576	001	Jul 07, 2020	Feb CAHN
--	-------------------	------------	---------	-----	--------------	----------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

	QILU ANTIBIOTICS	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan CAHN
AP		EQ 1GM BASE/VIAL	A203661	001	Dec 28, 2015	Jan CAHN
		EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022	Jan CAHN
AP	!	EQ 10GM BASE/VIAL	A209217	001	Oct 17, 2018	Jan CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION							
CEFEPIME HYDROCHLORIDE							
	!	QILU ANTIBIOTICS	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan CAHN
AP	!		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan CAHN
AP	!		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

VANTIN

@ + PFIZER

EQ 50MG BASE/5ML

N050675 001 Aug 07, 1992 Mar CAHN

@ +

EQ 100MG BASE/5ML

N050675 002 Aug 07, 1992 Mar CAHN

TABLET; ORAL

VANTIN

@ + PFIZER

EQ 100MG BASE

N050674 001 Aug 07, 1992 Mar CAHN

@ +

EQ 200MG BASE

N050674 002 Aug 07, 1992 Mar CAHN

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

@ APOTEX INC

125MG/5ML

A065351 001 Feb 29, 2012 Mar DISC

@

250MG/5ML

A065351 002 Feb 29, 2012 Mar DISC

TABLET; ORAL

CEFPROZIL

@ APOTEX INC

250MG

A065327 001 Mar 26, 2008 Mar DISC

@

500MG

A065327 002 Mar 26, 2008 Mar DISC

CEFTOBIPROLE MEDOCARIL SODIUM

POWDER; INTRAVENOUS

ZEVTERA

+! ISTX

667MG/VIAL

N218275 001 Apr 03, 2024 Apr CMFD

@ +

667MG/VIAL

N218275 001 Apr 03, 2024 Mar CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AP QILU ANTIBIOTICS

EQ 10GM BASE/VIAL

A209218 001 Oct 17, 2018 Jan CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP QILU ANTIBIOTICS

EQ 250MG BASE/VIAL

A203702 001 Jun 29, 2016 Jan CAHN

AP

EQ 500MG BASE/VIAL

A203702 002 Jun 29, 2016 Jan CAHN

AP

EQ 1GM BASE/VIAL

A203702 003 Jun 29, 2016 Jan CAHN

AP

EQ 2GM BASE/VIAL

A203702 004 Jun 29, 2016 Jan CAHN

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

@ APOTEX

EQ 250MG BASE

A065069 001 Oct 02, 2002 Mar DISC

@

EQ 500MG BASE

A065069 002 Oct 02, 2002 Mar DISC

CELECOXIB

CAPSULE; ORAL

CELECOXIB

@ PANGEA

200MG

A212925 001 Dec 09, 2020 Feb CAHN

@

400MG

A212925 002 Dec 09, 2020 Feb CAHN

AB STRIDES PHARMA

100MG

A213127 001 Apr 29, 2025 Apr NEWA

AB

200MG

A213127 002 Apr 29, 2025 Apr NEWA

AB

400MG

A213127 003 Apr 29, 2025 Apr NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL

CETIRIZINE HYDROCHLORIDE

>D> @ BIONPHARMA

5MG/5ML

A078488 001 Oct 06, 2008 May CMFD

>A> AA

5MG/5ML

A078488 001 Oct 06, 2008 May CMFD

ZYRTEC

@ + J AND J CONSUMER INC

5MG/5ML

N020346 001 Sep 27, 1996 Feb CRLD

CETRORELIX ACETATEPOWDER; SUBCUTANEOUS
CETRORELIX ACETATE

>A>	AP	XIROMED	EQ 0.25MG BASE/VIAL	A218061	001	Jun 03, 2025	May	NEWA
-----	----	---------	---------------------	---------	-----	--------------	-----	------

CEVIMELINE HYDROCHLORIDECAPSULE; ORAL
CEVIMELINE HYDROCHLORIDE

BX		RUBICON	30MG	A216682	001	Apr 06, 2023	Mar	CTEC
----	--	---------	------	---------	-----	--------------	-----	------

CHENODIOLTABLET; ORAL
CTEXLI

		+! MIRUM	250MG	N219488	001	Feb 21, 2025	Feb	NEWA
--	--	----------	-------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION; ORAL
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE
@ APOZEAL PHARMS 4MG/5ML; 5MG/5ML; 60MG/5ML

A206660	001	May 15, 2017	Apr	CAHN
---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDETABLET; ORAL
CHLORPROMAZINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	10MG	A216788	001	Apr 25, 2025	Apr	NEWA
AB			25MG	A216788	002	Apr 25, 2025	Apr	NEWA
AB			50MG	A216788	003	Apr 25, 2025	Apr	NEWA
AB			100MG	A216788	004	Apr 25, 2025	Apr	NEWA
AB			200MG	A216788	005	Apr 25, 2025	Apr	NEWA
AB		ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Feb	CAHN
AB			25MG	A212630	002	Nov 29, 2021	Feb	CAHN
AB			50MG	A212630	003	Nov 29, 2021	Feb	CAHN
AB			100MG	A212630	004	Nov 29, 2021	Feb	CAHN
AB			200MG	A212630	005	Nov 29, 2021	Feb	CAHN

CHLORTHALIDONETABLET; ORAL
CHLORTHALIDONE

@	AIPING PHARM INC	25MG	A087380	001		Jan	CAHN
@		50MG	A087381	001		Jan	CAHN

	HEMICLOR						
	+! PRM PHARMA	12.5MG	N218647	001	Mar 17, 2025	Mar	NEWA

CHLORZOXAZONETABLET; ORAL
CHLORZOXAZONE

AA		AJENAT PHARMS	250MG	A215540	001	Jan 24, 2023	Jan	CAHN
AB		APPCO	375MG	A212047	001	Jan 27, 2023	Mar	CAHN
AB			750MG	A212047	002	Jan 27, 2023	Mar	CAHN
	@	CHARTWELL RX	250MG	A087981	001	Sep 20, 1983	Apr	CAHN

CHOLESTYRAMINEPOWDER; ORAL
CHOLESTYRAMINE LIGHT

AB		PHARMOBEDIANT CNSLTG	EQ 4GM RESIN/PACKET	A209599	001	Nov 12, 2020	Apr	CAHN
AB			EQ 4GM RESIN/SCOOPFUL	A209599	002	Nov 12, 2020	Apr	CAHN

CHOLINE FENOFIBRATECAPSULE, DELAYED RELEASE; ORAL
FENOFIBRIC ACID

AB		! AUROBINDO PHARMA LTD	EQ 135MG FENOFIBRIC ACID	A212598	002	Jul 25, 2019	Apr	CHRS
		TRILIPIX						
	@ +	ABBVIE	EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008	Apr	DISC

CICLOPIROXSHAMPOO; TOPICAL
CICLOPIROX

AT		! PADAGIS US	1%	A078594	001	Feb 16, 2010	Mar	CHRS
		LOPROX						
	@ +	BAUSCH	1%	N021159	001	Feb 28, 2003	Mar	DISC

CIDOFOVIR

INJECTABLE; INJECTION
CIDOFOVIR

>D>	AP	AVET LIFESCIENCES	EQ 75MG BASE/ML	A202501	001	Jul 26, 2012	May CDFR
>D>	AP	! MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May CDFR
		VISTIDE					
>D>		@ + GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May CDFR
>A>		SOLUTION; INTRAVENOUS					
>A>		CIDOFOVIR					
>A>	AP	AVET LIFESCIENCES	EQ 75MG BASE/ML	A202501	001	Jul 26, 2012	May CDFR
>A>	AP		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A202501	001	Jul 26, 2012	May CPOT
>A>	AP	! MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May CDFR
>A>	AP	!	EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A201276	001	Jun 27, 2012	May CPOT
>A>		VISTIDE					
>A>		@ + GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May CDFR
>A>		@ +	EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	N020638	001	Jun 26, 1996	May CPOT

CILOSTAZOL

TABLET; ORAL
CILOSTAZOL

@	SANKALP LIFECARE	50MG	A077708	001	Sep 28, 2009	Apr CAHN
@		100MG	A077708	002	Sep 28, 2009	Apr CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL
CINACALCET HYDROCHLORIDE

AB	PIRAMAL	EQ 30MG BASE	A210207	001	Aug 01, 2018	Jan CAHN
AB		EQ 60MG BASE	A210207	002	Aug 01, 2018	Jan CAHN
AB		EQ 90MG BASE	A210207	003	Aug 01, 2018	Jan CAHN

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC
CIPROFLOXACIN AND DEXAMETHASONE

AB	AMNEAL	0.3%; 0.1%	A216501	001	Mar 22, 2024	Apr CTNA
----	--------	------------	---------	-----	--------------	----------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION
CISATRACURIUM BESYLATE

AP	GLAND	EQ 2MG BASE/ML	A215516	001	May 24, 2022	Mar CAHN
AP		EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar CAHN
AP		EQ 10MG BASE/ML	A215516	002	May 24, 2022	Mar CAHN
	@ HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Feb DISC
AP	HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb CMS1
	CISATRACURIUM BESYLATE PRESERVATIVE FREE					
	@ HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Feb DISC
	@	EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Feb DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

@	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Mar DISC
@		EQ 20MG BASE	A077046	002	Nov 24, 2004	Mar DISC
@		EQ 40MG BASE	A077046	003	Nov 24, 2004	Mar DISC

CLARITHROMYCIN

TABLET; ORAL
CLARITHROMYCIN

@	JUBILANT CADISTA	250MG	A206714	001	Apr 25, 2019	Apr CAHN
@		500MG	A206714	002	Apr 25, 2019	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL
CLARITHROMYCIN

>A>	AB	MPP PHARMA	500MG	A203243	001	Feb 29, 2016	May CAHN
>D>	AB	NOSTRUM LABS INC	500MG	A203243	001	Feb 29, 2016	May CAHN

CLINDAMYCIN PHOSPHATEINJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

@	ALMAJECT	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Feb DISC
@		EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Feb DISC

CLOBAZAMSUSPENSION; ORAL
CLOBAZAM

@	VISTAPHARM LLC	2.5MG/ML	A210746	001	Jul 10, 2019	Jan CAHN
---	----------------	----------	---------	-----	--------------	----------

TABLET; ORAL
CLOBAZAM

AB	@	ESJAY PHARMA	5MG	A209308	003	Oct 19, 2021	Feb CAHN
			10MG	A209308	001	Oct 22, 2018	Feb CAHN
	@		20MG	A209308	002	Oct 22, 2018	Feb CAHN

CLOBETASOL PROPIONATELOTION; TOPICAL
CLOBETASOL PROPIONATE

>A>	@	BEACH PRODS	0.05%	A208667	001	Nov 29, 2016	May CAHN
>D>	@	PAI HOLDINGS PHARM	0.05%	A208667	001	Nov 29, 2016	May CAHN

IMPEKLO

@ +	NORVIUM BIOSCIENCE	0.05%	N213691	001	May 19, 2020	Jan CAHN
-----	--------------------	-------	---------	-----	--------------	----------

SUSPENSION/DROPS; OPHTHALMIC
BYQLOVI

>A>	+!	FORMOSA	0.05%	N218158	001	Mar 04, 2024	May CTNA
>D>		CLOBETASOL PROPIONATE					
>D>	+!	FORMOSA	0.05%	N218158	001	Mar 04, 2024	May CTNA
	+!		0.05%	N218158	001	Mar 04, 2024	Feb CAHN

CLONAZEPAMTABLET, ORALLY DISINTEGRATING; ORAL
CLONAZEPAM

@	SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014	Jan DISC
@		0.25MG	A078654	002	Aug 27, 2014	Jan DISC
@		0.5MG	A078654	003	Aug 27, 2014	Jan DISC
@		1MG	A078654	004	Aug 27, 2014	Jan DISC
@		2MG	A078654	005	Aug 27, 2014	Jan DISC

CLONIDINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
CLONIDINE HYDROCHLORIDE

AB1	@	RUBICON RESEARCH	0.1MG	A210680	001	Apr 30, 2018	Apr CAHN
		SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	Mar CMFD

CLOZAPINETABLET; ORAL
CLOZAPINE

@	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002	Apr DISC
@		50MG	A075713	003	Aug 19, 2005	Apr DISC
@		100MG	A075713	002	Nov 15, 2002	Apr DISC
@		200MG	A075713	004	Nov 07, 2017	Apr DISC

COBICISTAT; DARUNAVIR ETHANOLATETABLET; ORAL
PREZCOBIX

+	JANSSEN PRODS	150MG; EQ 675MG BASE	N205395	002	Mar 21, 2025	Mar NEWA
+!		150MG; EQ 800MG BASE	N205395	001	Jan 29, 2015	Mar CPOT
+!		150MG; 800MG	N205395	001	Jan 29, 2015	Mar CAIN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDESYRUP; ORAL
PROMETH VC W/ CODEINE

@	CHARTWELL RX	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088764	001	Oct 31, 1984	Apr CAHN
---	--------------	-------------------------------	---------	-----	--------------	----------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	CHARTWELL RX	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Apr	CAHN
>A> AA	! COSETTE	10MG/5ML; 6.25MG/5ML	A200386	001	Jun 29, 2012	May	CAHN
>D> AA	! TRIS PHARMA INC	10MG/5ML; 6.25MG/5ML	A200386	001	Jun 29, 2012	May	CAHN
AA	XTTRIUM LABS INC	10MG/5ML; 6.25MG/5ML	A088875	001	Dec 17, 1984	Feb	CAHN
	PROMETHAZINE WITH CODEINE						
@	PHARM ASSOC	10MG/5ML; 6.25MG/5ML	A040650	001	Jan 31, 2006	Jan	DISC

COLESEVELAM HYDROCHLORIDE

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	625MG	A204893	001	Apr 18, 2025	Apr	NEWA
----	---------------------	-------	---------	-----	--------------	-----	------

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

@	NEXUS	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004	Apr	DISC
---	-------	--------------------	---------	-----	--------------	-----	------

COPPER

SYSTEM; INTRAUTERINE

MIUDELLA

+	! SEBELA WOMENS HLTH	N/A	N218201	001	Feb 24, 2025	Feb	NEWA
---	----------------------	-----	---------	-----	--------------	-----	------

COPPER CU-64 DOTATATE

SOLUTION; INTRAVENOUS

DETECTNET

+	! CURIUM	4mL (1mCi/ML)	N213227	001	Sep 03, 2020	Jan	CAHN
---	----------	---------------	---------	-----	--------------	-----	------

CROMOLYN SODIUM

CONCENTRATE; ORAL

GASTROCROM

AA	+	! VIATRIS SPECIALTY	100MG/5ML	N020479	001	Feb 29, 1996	Feb	CAHN
----	---	---------------------	-----------	---------	-----	--------------	-----	------

SOLUTION; INHALATION

CROMOLYN SODIUM

AN	FERA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Apr	CAHN
----	-----------------	---------	---------	-----	--------------	-----	------

CUPRIC SULFATE

INJECTABLE; INJECTION

CUPRIC SULFATE

!	AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	Jan	CTEC
@	APOTEX CORP	EQ 0.4MG COPPER/ML	A218745	001	Aug 19, 2024	Jan	DISC

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP	MEITHEAL	1MG/ML	A214316	001	Nov 15, 2024	Apr	CAHN
----	----------	--------	---------	-----	--------------	-----	------

DODEX

@	ACCORD HLTHCARE	1MG/ML	A083022	001		Jan	DISC
---	-----------------	--------	---------	-----	--	-----	------

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

>D>	!	ALCON LABS INC	0.2%; 1%	A084300	001		May	CRLD
>A>	+	!	0.2%; 1%	A084300	001		May	CRLD

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB	TRI-SOURCE PHARMA	25MG	A218282	001	Dec 03, 2024	Apr	CAHN
AB		50MG	A218282	002	Dec 03, 2024	Apr	CAHN

CYCLOSPORINE

EMULSION; OPHTHALMIC

CYCLOSPORINE

@	APOTEX	0.05%	A207606	001	Jan 12, 2023	Apr	DISC
BX		0.05%	A207606	001	Jan 12, 2023	Mar	CTEC

SOLUTION;ORAL
CYCLOSPORINE
@ ABBVIE

100MG/ML

A065025 001 Mar 03, 2000 Feb DISC

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL
DABIGATRAN ETEXILATE MESYLATE

>A>	AB	AUROBINDO PHARMA	EQ 75MG BASE	A208039	001	May 14, 2025	May NEWA
>A>	AB		EQ 110MG BASE	A208039	002	May 14, 2025	May NEWA
>A>	AB		EQ 150MG BASE	A208039	003	May 14, 2025	May NEWA
	AB	DR REDDYS	EQ 75MG BASE	A208048	001	Jan 28, 2025	Jan NEWA
	AB		EQ 110MG BASE	A208048	002	Jan 28, 2025	Jan NEWA
	AB		EQ 150MG BASE	A208048	003	Jan 28, 2025	Jan NEWA
	AB	MYLAN	EQ 75MG BASE	A208067	001	Feb 03, 2025	Jan NEWA
	AB		EQ 150MG BASE	A208067	002	Feb 03, 2025	Jan NEWA

DACARBAZINE

INJECTABLE;INJECTION
DACARBAZINE
@ HOSPIRA

200MG/VIAL

A075940 001 Oct 18, 2001 Mar DISC

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL
AMPYRA

AB	+	MERZ	10MG	N022250	001	Jan 22, 2010	Feb CAHN
----	---	------	------	---------	-----	--------------	----------

DAPSONE

GEL;TOPICAL
DAPSONE

AB		AUROBINDO PHARMA LTD	5%	A218457	001	Apr 04, 2025	Mar NEWA
----	--	----------------------	----	---------	-----	--------------	----------

TABLET;ORAL
DAPSONE

AB		SOLIS PHARMS	25MG	A203887	001	May 06, 2016	Apr CAHN
AB			100MG	A203887	002	May 06, 2016	Apr CAHN

DAPTOMYCIN

POWDER;INTRAVENOUS
DAPTOMYCIN

	@	FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jan DISC
>D>	+	MAIA PHARMS INC	350MG/VIAL	N217630	001	Nov 21, 2024	May DISC
>A>	@ +		350MG/VIAL	N217630	001	Nov 21, 2024	May DISC
>D>	+		500MG/VIAL	N217630	002	Nov 21, 2024	May DISC
>A>	@ +		500MG/VIAL	N217630	002	Nov 21, 2024	May DISC

DARUNAVIR

TABLET;ORAL
DARUNAVIR

AB		ANNORA PHARMA	600MG	A216168	001	Jan 21, 2025	Jan NEWA
AB			800MG	A216168	002	Jan 21, 2025	Jan NEWA

DASATINIB

TABLET;ORAL
DASATINIB

AB		BIOCON PHARMA	20MG	A217217	001	Mar 03, 2025	Feb NEWA
AB			50MG	A217217	002	Mar 03, 2025	Feb NEWA
AB			70MG	A217217	003	Mar 03, 2025	Feb NEWA
AB			80MG	A217217	004	Mar 03, 2025	Feb NEWA
AB			100MG	A217217	005	Mar 03, 2025	Feb NEWA
AB			140MG	A217217	006	Mar 03, 2025	Feb NEWA
AB		DR REDDYS	20MG	A213383	001	Mar 03, 2025	Feb NEWA
AB			50MG	A213383	002	Mar 03, 2025	Feb NEWA
AB			70MG	A213383	003	Mar 03, 2025	Feb NEWA
AB			80MG	A213383	004	Mar 03, 2025	Feb NEWA
AB			100MG	A213383	005	Mar 03, 2025	Feb NEWA
AB			140MG	A213383	006	Mar 03, 2025	Feb NEWA
AB		EUGIA PHARMA	20MG	A216547	001	Apr 22, 2025	Apr NEWA
AB			50MG	A216547	002	Apr 22, 2025	Apr NEWA
AB			70MG	A216547	003	Apr 22, 2025	Apr NEWA
AB			80MG	A216547	004	Apr 22, 2025	Apr NEWA
AB			100MG	A216547	005	Apr 22, 2025	Apr NEWA
AB			140MG	A216547	006	Apr 22, 2025	Apr NEWA
AB		ZYDUS PHARMS	20MG	A218719	001	Mar 03, 2025	Feb NEWA

TABLET; ORAL
DASATINIB

AB		50MG	A218719	002	Mar 03, 2025	Feb NEWA
AB		70MG	A218719	003	Mar 03, 2025	Feb NEWA
AB		80MG	A218719	004	Mar 03, 2025	Feb NEWA
AB		100MG	A218719	005	Mar 03, 2025	Feb NEWA
AB		140MG	A218719	006	Mar 03, 2025	Feb NEWA

PHYRAGO

+	HANDA THERAP	20MG	N216099	001	Dec 05, 2023	Jan CAHN
+		50MG	N216099	002	Dec 05, 2023	Jan CAHN
+		70MG	N216099	003	Dec 05, 2023	Jan CAHN
+		80MG	N216099	004	Dec 05, 2023	Jan CAHN
+	!	100MG	N216099	005	Dec 05, 2023	Jan CAHN
+		140MG	N216099	006	Dec 05, 2023	Jan CAHN

DECITABINE

INJECTABLE; INTRAVENOUS
DECITABINE

AP	ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Apr CHRS
AP	! DR REDDYS	50MG/VIAL	A203131	001	Jul 11, 2013	Apr CHRS

DEFERASIROX

TABLET; ORAL
DEFERASIROX

AB	JUBILANT GENERICS	90MG	A211660	001	Apr 11, 2025	Apr NEWA
AB		180MG	A211660	002	Apr 11, 2025	Apr NEWA
AB		360MG	A211660	003	Apr 11, 2025	Apr NEWA
@	SUN PHARM	90MG	A211641	001	Jan 02, 2020	Apr DISC
@		180MG	A211641	003	Jun 15, 2020	Apr DISC
@		360MG	A211641	002	Jan 02, 2020	Apr DISC

DEFLAZACORT

TABLET; ORAL
DEFLAZACORT

AB	SUN PHARM	6MG	A217741	001	Mar 18, 2025	Mar NEWA
AB		18MG	A217741	002	Mar 18, 2025	Mar NEWA
AB		30MG	A217741	003	Mar 18, 2025	Mar NEWA
AB		36MG	A217741	004	Mar 18, 2025	Mar NEWA
	JAYTHARI					
AB	ZYDUS LIFESCIENCES	6MG	A219254	001	Apr 08, 2025	Mar NEWA
AB		18MG	A219254	002	Apr 08, 2025	Mar NEWA
AB		30MG	A219254	003	Apr 08, 2025	Mar NEWA
AB		36MG	A219254	004	Apr 08, 2025	Mar NEWA

DESLORATADINE

TABLET; ORAL
DESLORATADINE

AB	AJENAT PHARMS	5MG	A078355	001	Apr 19, 2012	Jan CAHN
----	---------------	-----	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

TABLET; ORAL
DESMOPRESSIN ACETATE

>D>	AB	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May DISC
>A>	@		0.1MG	A201831	001	May 28, 2015	May DISC
>D>	AB		0.2MG	A201831	002	May 28, 2015	May DISC
>A>	@		0.2MG	A201831	002	May 28, 2015	May DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
AVERI

	AVION PHARMS	0.15MG; 0.03MG	A218933	001	May 02, 2025	Apr NEWA
	TABLET; ORAL-28					
	AVERI					
AB	AVION PHARMS	0.15MG; 0.03MG	A218933	002	May 02, 2025	Apr NEWA

DESONIDE

OINTMENT; TOPICAL

>D>		DESOWEN					
>D>	AB	GALDERMA LABS LP	0.05%	A071425	001	Jun 15, 1988	May DISC
>A>	@		0.05%	A071425	001	Jun 15, 1988	May DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE SUCCINATE

AB	MACLEODS PHARMS LTD	EQ 50MG BASE	A211427	001	Jan 15, 2025	Jan NEWA
AB		EQ 100MG BASE	A211427	002	Jan 15, 2025	Jan NEWA
AB	MEDICAP LABS	EQ 50MG BASE	A204805	001	May 07, 2019	Feb CAHN
AB		EQ 100MG BASE	A204805	002	May 07, 2019	Feb CAHN

DEUTETRABENAZINE

TABLET;ORAL
AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Feb CAHN
+		6MG	N208082	001	Apr 03, 2017	Jan CTEC
+		9MG	N208082	002	Apr 03, 2017	Feb CAHN
+		9MG	N208082	002	Apr 03, 2017	Jan CTEC
+		12MG	N208082	003	Apr 03, 2017	Feb CAHN
+		12MG	N208082	003	Apr 03, 2017	Jan CTEC

DEUTETRABENAZINE

@	AUROBINDO PHARMA LTD	6MG	A215971	001	Dec 26, 2024	Jan DISC
@		9MG	A215971	002	Dec 26, 2024	Jan DISC
@		12MG	A215971	003	Dec 26, 2024	Jan DISC

DEXAMETHASONE

TABLET;ORAL

DEXAMETHASONE

AB	+	HIKMA	0.5MG	A084612	002		Apr CMS1
AB	+		0.75MG	A084612	003		Apr CMS1
AB	+	!	1MG	A084612	004	Sep 15, 1983	Apr CMS1
AB	+		1.5MG	A084612	005		Apr CMS1
AB	+	!	2MG	A084612	006		Apr CMS1
AB	+	!	6MG	A084612	007	Sep 15, 1983	Apr CMS1

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

POLMON

!	CARWIN PHARM ASSOC	2MG/5ML	A202520	001	Jul 16, 2018	Mar CAHN
!	CARWIN PHARMS	2MG/5ML	A202520	001	Jul 16, 2018	Feb CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

>A>	AP	HIKMA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	A206407	003	May 30, 2025	May NFTG		
>D>	AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	May CAHN		
>A>	AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	May CAHN		
>D>	AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	May CAHN		
>A>	AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	May CAHN		
		PRECEDEX							
>D>		+	!	HOSPIRA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020	May CFTG
>A>	AP	+	!		EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020	May CFTG

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	MEDICAP LABS	5MG	A078992	001	Nov 23, 2021	Feb CAHN
AB		10MG	A078992	002	Nov 23, 2021	Feb CAHN
AB		15MG	A078992	003	Nov 18, 2013	Feb CAHN
AB		30MG	A078992	004	Nov 18, 2013	Feb CAHN
AB		20MG	A078992	005	Nov 23, 2021	Feb CAHN
AB		40MG	A078992	006	Nov 23, 2021	Feb CAHN

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

@	RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017	Jan DISC
@		5MG	A208756	002	Nov 20, 2017	Jan DISC
@		10MG	A208756	003	Nov 20, 2017	Jan DISC

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION
DEXRAZOXANE HYDROCHLORIDE

AP	MSN	EQ 250MG BASE/VIAL	A216748	001	Mar 26, 2025	Mar NEWA
AP		EQ 500MG BASE/VIAL	A216748	002	Mar 26, 2025	Mar NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

AA	! PAI HOLDINGS	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	Apr CAHN
----	----------------	---------------------	---------	-----	--------------	----------

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>A> AA	COSETTE	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	May CAHN
>D> AA	TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	May CAHN

PROMETHAZINE W/ DEXTROMETHORPHAN

AA	XTTRIUM LABS INC	15MG/5ML;6.25MG/5ML	A088864	001	Jan 04, 1985	Feb CAHN
----	------------------	---------------------	---------	-----	--------------	----------

DIAZEPAM

INJECTABLE;INJECTION
DIAZEPAM

>A> AP	GALENICUM HLTH	50MG/10ML (5MG/ML)	A216422	001	May 19, 2025	May NEWA
--------	----------------	--------------------	---------	-----	--------------	----------

DIAZOXIDE CHOLINE

TABLET, EXTENDED RELEASE;ORAL
VYKAT XR

+	SOLENO THERAP	25MG	N216665	001	Mar 26, 2025	Mar NEWA
+		75MG	N216665	002	Mar 26, 2025	Mar NEWA
+	!	150MG	N216665	003	Mar 26, 2025	Mar NEWA

DICLOFENAC POTASSIUM

FOR SOLUTION;ORAL
DICLOFENAC POTASSIUM

AB	TORRENT	50MG	A215891	001	Jan 22, 2025	Jan NEWA
----	---------	------	---------	-----	--------------	----------

TABLET;ORAL

DICLOFENAC POTASSIUM

AB	RK PHARMA	50MG	A075463	001	Jul 26, 1999	Mar CHRS
AB	! RUBICON	50MG	A075229	001	Nov 20, 1998	Mar CHRS

DICLOFENAC SODIUM

GEL;TOPICAL
DICLOFENAC SODIUM

BX	ALEMBIC	3%	A212351	001	Jul 27, 2022	Mar CTEC
----	---------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AB	ENCUBE	2%	A217646	001	Apr 09, 2025	Mar NEWA
----	--------	----	---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

AB	AUROBINDO PHARMA USA	50MG	A075281	002	Feb 12, 2002	Apr CMFD
AB		75MG	A075281	003	Feb 12, 2002	Apr CMFD

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB	NOVAST LABS	100MG	A216275	001	Sep 23, 2022	Apr CAHN
----	-------------	-------	---------	-----	--------------	----------

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DICYCLOMINE HYDROCHLORIDE

@ NEXUS

		10MG/ML	A206468	001	Feb 01, 2019	Apr DISC
--	--	---------	---------	-----	--------------	----------

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

>A> AB	PRINSTON INC	20MG	A218310	001	Jun 06, 2025	May NEWA
AB	RUBICON RESEARCH	20MG	A216736	001	Dec 14, 2022	Mar CAHN
	!	40MG	A216736	002	Mar 25, 2025	Mar NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TENUATE DOSPAN

@ +	ANI PHARMS	75MG	N012546	001		Apr CAHN
-----	------------	------	---------	-----	--	----------

DIFELIKEFALIN ACETATESOLUTION; INTRAVENOUS
KORSUVA

+! VIFOR INTL

EQ 0.065MG BASE/1.3ML (EQ
0.05MG BASE/ML)

N214916 001 Aug 23, 2021 Apr CAHN

DIFLUPREDNATEEMULSION; OPHTHALMIC
DIFLUPREDNATE

AB MYLAN LABS LTD

0.05%

A212566 001 Mar 20, 2025 Mar NEWA

AB UPSHER SMITH LABS

0.05%

A218191 001 Feb 11, 2025 Jan NEWA

DIHYDROERGOTAMINE MESYLATEINJECTABLE; INJECTION
DIHYDROERGOTAMINE MESYLATE

@ CIPLA

1MG/ML

A212334 001 Sep 20, 2024 Jan DISC

POWDER; NASAL
ATZUMI

+! SATSUMA PHARMS

EQ 5.2MG BASE

N217901 001 Apr 30, 2025 Apr NEWA

SOLUTION; SUBCUTANEOUS

>A> BREKIYA (AUTOINJECTOR)

+! AMNEAL

1MG/ML

N215400 001 May 14, 2025 May NEWA

>A>

SPRAY, METERED; NASAL
DIHYDROERGOTAMINE MESYLATE

AB AGGREGA

0.5MG/SPRAY

A215228 001 Feb 26, 2025 Feb NEWA

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

AB1 AMTA

60MG

A219073 001 Mar 24, 2025 Mar NEWA

AB1

90MG

A219073 002 Mar 24, 2025 Mar NEWA

AB1

120MG

A219073 003 Mar 24, 2025 Mar NEWA

@ SUN PHARM

120MG

A203023 001 Jun 08, 2017 Apr DISC

@

180MG

A203023 002 Jun 08, 2017 Mar DISC

@

240MG

A203023 003 Jun 08, 2017 Mar DISC

@

300MG

A203023 004 Jun 08, 2017 Feb DISC

AB1 UTOPIC PHARMS

60MG

A219073 001 Mar 24, 2025 Apr CAHN

AB1

90MG

A219073 002 Mar 24, 2025 Apr CAHN

AB1

120MG

A219073 003 Mar 24, 2025 Apr CAHN

SOLUTION; INTRAVENOUS

DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

+! HQ SPCLT PHARMA

100MG/100ML (1MG/ML)

N218038 001 Feb 21, 2025 Feb NEWA

+!

250MG/250ML (1MG/ML)

N218038 002 Feb 21, 2025 Feb NEWA

DIMETHYL FUMARATECAPSULE, DELAYED RELEASE; ORAL
DIMETHYL FUMARATE

@ CIPLA

120MG

A210305 001 Sep 24, 2020 Feb DISC

@

240MG

A210305 002 Sep 24, 2020 Feb DISC

DIPHENHYDRAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP ! NORVIUM BIOSCIENCE

50MG/ML

A040498 001 Jul 12, 2005 Feb CAHN

DIPYRIDAMOLETABLET; ORAL
DIPYRIDAMOLE

AB BARR LABS

75MG

A087717 001 Oct 03, 1990 Mar CAHN

DIVALPROEX SODIUMTABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

@ APOTEX

EQ 125MG VALPROIC ACID

A077615 003 Jul 29, 2008 Mar DISC

@

EQ 250MG VALPROIC ACID

A077615 002 Jul 29, 2008 Mar DISC

@

EQ 500MG VALPROIC ACID

A077615 001 Jul 29, 2008 Mar DISC

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

AP	!	AMNEAL	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Apr CHRS
AP	!		80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Apr CHRS
AP	!		160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Apr CHRS
>A>	AP	GUANGDONG SUNHO	20MG/ML (20MG/ML)	A213768	001	May 13, 2025	May NEWA
>A>	AP		80MG/4ML (20MG/ML)	A213768	002	May 13, 2025	May NEWA
		TAXOTERE					
	@ +	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010	Apr DISC
	@ +		80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010	Apr DISC
AP	+		160MG/8ML (20MG/ML)	N020449	005	Apr 13, 2012	Apr CHRS
		SOLUTION; INTRAVENOUS					
		BEIZRAY					
	@ +	ZHUHAI	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024	Apr DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

@	INDICUS PHARMA	5MG	A201634	001	Jun 13, 2012	Apr DISC
@		10MG	A201634	002	Jun 13, 2012	Apr DISC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB		AMNEAL	10MG; 7MG	A208328	003	Feb 27, 2025	Feb NFTG
AB			10MG; 21MG	A208328	004	Feb 27, 2025	Feb NEWA
		NAMZARIC					
AB	+	ABBVIE	10MG; 7MG	N206439	003	Jul 18, 2016	Feb CFTG

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		SOMERSET THERAPS LLC	EQ 2% BASE	A215004	001	Feb 11, 2025	Jan NEWA
----	--	----------------------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT2		IDENTIRX	EQ 2% BASE; EQ 0.5% BASE	A216308	001	Feb 18, 2025	Feb NEWA
-----	--	----------	--------------------------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB		APPCO	EQ 1MG BASE	A209013	001	Apr 17, 2018	Mar CAHN
AB			EQ 2MG BASE	A209013	002	Apr 17, 2018	Mar CAHN
AB			EQ 4MG BASE	A209013	003	Apr 17, 2018	Mar CAHN
AB			EQ 8MG BASE	A209013	004	Apr 17, 2018	Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

@	ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Jan DISC
AB	PTS CONSULTING	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar CAHN
AB		EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar CAHN
AB		EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar CAHN
AB		EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar CAHN
AB		EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar CAHN
BX	ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CTEC
BX		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CTEC
BX		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CTEC
BX		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CTEC
BX		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CTEC
BX		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CTEC

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

BX		MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar CTEC
BX			EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar CTEC

DOXYCYCLINECAPSULE;ORAL
DOXYCYCLINE

AB	MACLEODS PHARMS LTD	40MG	A210381	001	Mar 27, 2025	Mar NEWA
AB	PRINSTON INC	40MG	A217098	001	Jan 27, 2025	Jan NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

	@ BIONPHARMA	EQ 50MG BASE	A209393	001	Dec 10, 2020	Apr CAHN
	@	EQ 100MG BASE	A209393	002	Dec 10, 2020	Apr CAHN
AB	! HIKMA INTL PHARMS	EQ 100MG BASE	A062396	001	May 07, 1984	Feb CHRS
	VIBRAMYCIN					
	@ + PFIZER	EQ 100MG BASE	N050007	002		Feb DISC

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

	@ AMNEAL	EQ 100MG BASE/VIAL	A217487	001	Dec 04, 2024	Jan DISC
AP	PRECISION DOSE INC	EQ 100MG BASE/VIAL	A217078	001	Feb 21, 2025	Feb NEWA

TABLET;ORAL

DOXYCYCLINE HYCLATE

>A>	@ AVIV PHARMA	EQ 100MG BASE	A209560	001	Apr 15, 2024	May CAHN
>D>	@ NOSTRUM LABS INC	EQ 100MG BASE	A209560	001	Apr 15, 2024	May CAHN

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB	JUBILANT CADISTA	100MG	A214391	001	Feb 18, 2021	Apr CAHN
AB		200MG	A214391	002	Feb 18, 2021	Apr CAHN
AB		300MG	A214391	003	Feb 18, 2021	Apr CAHN

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

>A>	@ AVIV PHARMA	0.5MG	A204705	001	Nov 20, 2015	May CAHN
>D>	@ NOSTRUM LABS INC	0.5MG	A204705	001	Nov 20, 2015	May CAHN

EDARAVONE

SOLUTION;INTRAVENOUS

EDARAVONE

	@ LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr DISC
--	---------------------	-----------------------	---------	-----	--------------	----------

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

>A> AB	NORVIUM BIOSCIENCE	600MG	A204869	001	Mar 12, 2018	May CAHN
>D> AB	STRIDES PHARMA	600MG	A204869	001	Mar 12, 2018	May CAHN

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

	@ CHARTWELL RX	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Apr CAHN
--	----------------	-------------------	---------	-----	--------------	----------

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL

VANIQA

	@ + ABBVIE	13.9%	N021145	001	Jul 27, 2000	Feb CAHN
--	------------	-------	---------	-----	--------------	----------

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

	@ APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jan DISC
--	----------	--------------	---------	-----	--------------	----------

ELTROMBOPAG OLAMINE

TABLET;ORAL

ELTROMBOPAG OLAMINE

AB	HETERO LABS LTD V	EQ 12.5MG ACID	A206788	001	Jan 17, 2025	Jan NFTG
AB		EQ 25MG ACID	A206788	002	Jan 17, 2025	Jan NFTG
AB		EQ 50MG ACID	A206788	003	Jan 17, 2025	Jan NFTG
AB		EQ 75MG ACID	A206788	004	Jan 17, 2025	Jan NFTG

TABLET;ORAL

PROMACTA

AB	+	NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Jan CFTG
AB	+		EQ 25MG ACID	N022291	001	Nov 20, 2008	Jan CFTG
AB	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Jan CFTG
AB	+		EQ 75MG ACID	N022291	003	Sep 08, 2009	Jan CFTG

ELUXADOLINE

TABLET;ORAL

ELUXADOLINE

AB		ZYDUS PHARMS	75MG	A213522	001	Mar 14, 2025	Mar NFTG
AB			100MG	A213522	002	Mar 14, 2025	Mar NFTG
VIBERZI							
AB	+	ABBVIE	75MG	N206940	001	May 27, 2015	Mar CFTG
AB	+		100MG	N206940	002	May 27, 2015	Mar CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

COMPLERA

>D>	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	May CFTG
>A>	AB	+	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	May CFTG
>A>		EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE					
>A>	AB	MYLAN	200MG;EQ 25MG BASE;300MG	A208452	001	May 20, 2025	May NFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		HETERO LABS LTD III	100MG;150MG	A201806	002	Mar 03, 2025	Feb NEWA
AB			133MG;200MG	A201806	003	Mar 03, 2025	Feb NEWA
AB			167MG;250MG	A201806	004	Mar 03, 2025	Feb NEWA

ENFUVRTIDE

INJECTABLE;SUBCUTANEOUS

FUZEON

@	+	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003	Mar DISC
---	---	-------	-----------	---------	-----	--------------	----------

ENTECAVIR

TABLET;ORAL

ENTECAVIR

>D>	AB	BRECKENRIDGE	0.5MG	A208721	001	Mar 15, 2018	May DISC
>A>		@	0.5MG	A208721	001	Mar 15, 2018	May DISC
>D>	AB		1MG	A208721	002	Mar 15, 2018	May DISC
>A>		@	1MG	A208721	002	Mar 15, 2018	May DISC

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

@		ZYDUS PHARMS	40MG	A209667	001	Sep 26, 2024	Feb DISC
---	--	--------------	------	---------	-----	--------------	----------

XTANDI

+	!	ASTELLAS	40MG	N203415	001	Aug 31, 2012	Feb CTEC
---	---	----------	------	---------	-----	--------------	----------

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

>D>	+	DR REDDYS LABS SA	47MG/10ML (4.7MG/ML)	N213536	004	Dec 07, 2023	May DISC
>A>	@	+	47MG/10ML (4.7MG/ML)	N213536	004	Dec 07, 2023	May DISC

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

AKOVAZ

AP3	+	EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Mar CTEC
-----	---	--------------	-------------------	---------	-----	--------------	----------

EMERPHED

AP1	+	NEXUS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Mar CTEC
AP	+		50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Jan CFTG

EPHEDRINE SULFATE

AP2	+	ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Mar CTEC
AP	+		25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Feb CFTG
AP2	+		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Mar CTEC
AP	+		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Feb CFTG
AP2		FRESENIUS KABI USA	25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Mar CTEC
AP			25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Feb NFTG
AP2			50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Mar CTEC

SOLUTION;INTRAVENOUS
EPHEDRINE SULFATE

AP		50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Feb NFTG
AP1	GLAND	50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Mar CTEC
AP		50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Jan NFTG
AP3	HIKMA	25MG/5ML (5MG/ML)	A217721	001	Oct 11, 2024	Mar CTEC

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

@	RENOVA PHARMS	0.05%	A090870	001	Mar 14, 2011	Feb CAHN
---	---------------	-------	---------	-----	--------------	----------

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR

EPI E Z PEN JR

>D>	@	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	004	Aug 03, 1995	May CAHN
>A>	@	VIATRIS	0.15MG/DELIVERY	N019430	004	Aug 03, 1995	May CAHN
		EPIPEN E Z PEN					
>D>	@	MYLAN SPECIALITY LP	0.3MG/DELIVERY	N019430	003	Aug 03, 1995	May CAHN
>A>	@	VIATRIS	0.3MG/DELIVERY	N019430	003	Aug 03, 1995	May CAHN

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

EPIPEN

>D>	AB	+	MYLAN SPECIALITY LP	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	May CAHN
>A>	AB	+	VIATRIS	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	May CAHN
			EPIPEN JR.					
>D>	AB	+	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	May CAHN
>A>	AB	+	VIATRIS	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	May CAHN
>A>			TWINJECT					
>A>	@		IMPAX	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May CTNA
>A>	@			EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May CTNA
>D>			TWINJECT 0.15					
>D>	@		IMPAX	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May CTNA
>D>			TWINJECT 0.3					
>D>	@		IMPAX	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May CTNA

SOLUTION;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
EPINEPHRINE

AP	GLAND PHARMA LTD	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Jan NFTG
----	------------------	--------------------	---------	-----	--------------	----------

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
EPINEPHRINE

AP	+	BPI LABS	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Jan CFTG
	+	FRESENIUS KABI USA	30MG/30ML (1MG/ML)	N215425	001	Mar 13, 2025	Mar NEWA
AP		GLAND	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Mar CDFR

SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

>A>	AP	GLAND	1MG/ML (1MG/ML)	A218144	001	Jun 03, 2025	May NEWA	
		SPRAY;NASAL						
		NEFFY						
		+	ARS PHARMS OPERATION	1MG/SPRAY	N214697	002	Mar 05, 2025	Apr CHRS
		+		1MG/SPRAY	N214697	002	Mar 05, 2025	Mar NEWA

EPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N218475	001	Feb 28, 2025	Feb NEWA
---	----------------------	---------------------------------------	---------	-----	--------------	----------

EPLERENONE

TABLET;ORAL

EPLERENONE

@	THINKRX	25MG	A203896	001	Feb 02, 2017	Mar CAHN
@		50MG	A203896	002	Feb 02, 2017	Mar CAHN

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP	MEITHEAL	2MG/ML	A213599	001	May 09, 2024	Apr CAHN
AP		75MG/100ML	A213599	002	May 09, 2024	Apr CAHN

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

ERIBULIN MESYLATE

AP	CHIA TAI TIANQING	1MG/2ML (0.5MG/ML)	A218743	001	Mar 04, 2025	Feb NEWA
AP	JIANGXI KVVIT PHARM	1MG/2ML (0.5MG/ML)	A218281	001	Jun 28, 2024	Apr CAHN
>A> AP	SANDOZ	1MG/2ML (0.5MG/ML)	A214310	001	Jun 09, 2025	May NEWA

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

@	APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019	Jan DISC
@		EQ 100MG BASE	A208396	002	Nov 05, 2019	Jan DISC
@		EQ 150MG BASE	A208396	003	Nov 05, 2019	Jan DISC
@	SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019	Jan DISC
@		EQ 100MG BASE	A210300	002	Nov 05, 2019	Feb DISC
@		EQ 150MG BASE	A210300	003	Nov 05, 2019	Jan DISC

ERTUGLIFLOZIN

TABLET; ORAL

ERTUGLIFLOZIN

@	HETERO LABS LTD V	5MG	A217071	001	Sep 17, 2024	Apr DISC
@		15MG	A217071	002	Sep 17, 2024	Apr DISC
@	HIKMA	5MG	A216842	001	Jan 21, 2025	Feb DISC
AB		5MG	A216842	001	Jan 21, 2025	Jan NEWA
@		15MG	A216842	002	Jan 21, 2025	Feb DISC
AB		15MG	A216842	002	Jan 21, 2025	Jan NEWA
	STEGLATRO					
+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Apr CTEC
+	!	15MG	N209803	002	Dec 19, 2017	Apr CTEC

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

@	AZURITY	EQ 250MG BASE	A060359	001		Apr DISC
---	---------	---------------	---------	-----	--	----------

ESLICARBAZEPINE ACETATE

TABLET; ORAL

ESLICARBAZEPINE ACETATE

AB	APOTEX	200MG	A211236	001	Dec 07, 2023	Apr CMFD
AB		400MG	A211236	002	Dec 07, 2023	Apr CMFD
AB		600MG	A211236	003	Dec 07, 2023	Apr CMFD
AB		800MG	A211236	004	Dec 07, 2023	Apr CMFD
AB	LUPIN LTD	200MG	A211246	001	Mar 27, 2024	Mar CMFD
AB		400MG	A211246	002	Mar 27, 2024	Mar CMFD
AB		600MG	A211246	003	Mar 27, 2024	Mar CMFD
AB		800MG	A211246	004	Mar 27, 2024	Mar CMFD
>D>	@	TORRENT	A211227	001	Feb 27, 2024	May CMFD
>A> AB		200MG	A211227	001	Feb 27, 2024	May CMFD
>D>	@	400MG	A211227	002	Feb 27, 2024	May CMFD
>A> AB		400MG	A211227	002	Feb 27, 2024	May CMFD
>D>	@	600MG	A211227	003	Feb 27, 2024	May CMFD
>A> AB		600MG	A211227	003	Feb 27, 2024	May CMFD
>D>	@	800MG	A211227	004	Feb 27, 2024	May CMFD
>A> AB		800MG	A211227	004	Feb 27, 2024	May CMFD

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

AB	GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Apr CAHN
AB		EQ 40MG BASE	A213859	002	Nov 18, 2020	Apr CAHN
@	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Feb DISC
@		EQ 40MG BASE	A078003	002	Jan 26, 2015	Feb DISC

FOR SUSPENSION, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE/PACKET	A218948	001	Apr 15, 2025	Apr NEWA
AB		EQ 10MG BASE/PACKET	A219213	001	Apr 15, 2025	Apr NEWA
AB		EQ 20MG BASE/PACKET	A218948	002	Apr 15, 2025	Apr NEWA
AB		EQ 40MG BASE/PACKET	A218948	003	Apr 15, 2025	Apr NEWA
AB	TORRENT	EQ 2.5MG BASE/PACKET	A212651	001	Mar 05, 2025	Feb NEWA
AB		EQ 5MG BASE/PACKET	A212651	002	Mar 05, 2025	Feb NEWA
AB		EQ 10MG BASE/PACKET	A212652	001	Mar 05, 2025	Feb NEWA
AB		EQ 20MG BASE/PACKET	A212651	003	Mar 05, 2025	Feb NEWA

FOR SUSPENSION, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

AB		EQ 40MG BASE/PACKET	A212651	004	Mar 05, 2025	Feb NEWA
----	--	---------------------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

@	NORVIUM BIOSCIENCE	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Feb CAHN
@		EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Feb CAHN

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	YANGTZE	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jan NEWA
----	---------	-------------------	---------	-----	--------------	----------

ESTRADIOL

CREAM;VAGINAL
ESTRADIOL

AB	ENCUBE	0.01%	A209767	001	Mar 05, 2018	Jan CAHN
----	--------	-------	---------	-----	--------------	----------

GEL;TRANSDERMAL
ESTRADIOL

AB	ENCUBE	0.1% (0.25GM/PACKET)	A218507	001	Mar 05, 2025	Feb NEWA
AB		0.1% (0.5GM/PACKET)	A218507	002	Mar 05, 2025	Feb NEWA
AB		0.1% (0.75GM/PACKET)	A218507	003	Mar 05, 2025	Feb NEWA
AB		0.1% (1.25GM/PACKET)	A218507	005	Mar 05, 2025	Feb NEWA
AB		0.1% (1GM/PACKET)	A218507	004	Mar 05, 2025	Feb NEWA

GEL, METERED;TRANSDERMAL
ELESTRIN

+	VIATRIS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Feb CAHN
---	---------	---------------------------	---------	-----	--------------	----------

TABLET;ORAL
ESTRADIOL

@	RUBICON RESEARCH	0.5MG	A040114	003	Mar 14, 1996	Apr CAHN
@		1MG	A040114	001	Mar 14, 1996	Apr CAHN
@		2MG	A040114	002	Mar 14, 1996	Apr CAHN

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

>A>	@	AVIV PHARMA	1MG	A203087	001	May 08, 2019	May CAHN
>A>	@		2MG	A203087	002	May 08, 2019	May CAHN
>A>	@		3MG	A203087	003	May 08, 2019	May CAHN
>D>	@	NOSTRUM LABS INC	1MG	A203087	001	May 08, 2019	May CAHN
>D>	@		2MG	A203087	002	May 08, 2019	May CAHN
>D>	@		3MG	A203087	003	May 08, 2019	May CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

GENCEPT 10/11-28

@	BARR LABS	0.035MG,0.035MG;0.5MG,1MG	A072697	001	Feb 28, 1992	Mar CAHN
---	-----------	---------------------------	---------	-----	--------------	----------

NORTREL 0.5/35-28

AB	BARR LABS	0.035MG;0.5MG	A072695	001	Feb 28, 1992	Mar CAHN
----	-----------	---------------	---------	-----	--------------	----------

NORTREL 1/35-28

AB	!	BARR LABS	0.035MG;1MG	A072696	001	Feb 28, 1992	Mar CAHN
----	---	-----------	-------------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL
KAITLIB FE

AB	!	LUPIN LTD	0.025MG;0.8MG	A203448	001	Dec 17, 2015	Apr CHRS
----	---	-----------	---------------	---------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

@	+	TEVA BRANDED PHARM	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Apr DISC
---	---	--------------------	---------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	BARR LABS	0.02MG;1MG	A090938	001	Dec 01, 2014	Mar CAHN
----	-----------	------------	---------	-----	--------------	----------

TABLET;ORAL-21

JUNEL 1/20

AB	BARR LABS	0.02MG;1MG	A076380	001	May 30, 2003	Mar CAHN
----	-----------	------------	---------	-----	--------------	----------

TABLET;ORAL-28

BLISOVI FE 1.5/30

AB	LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015	Apr CTEC
----	-----------	--------------	---------	-----	--------------	----------

EVEROLIMUSTABLET; ORAL
EVEROLIMUS

AB	BIOCON PHARMA	0.25MG	A216140	001	Apr 09, 2025	Mar NEWA
AB		0.5MG	A216140	002	Apr 09, 2025	Mar NEWA
AB		0.75MG	A216140	003	Apr 09, 2025	Mar NEWA
AB		1MG	A216140	004	Apr 09, 2025	Mar NEWA
	@ MYLAN	2.5MG	A212936	001	Jun 08, 2020	Mar DISC
	@	5MG	A212936	002	Jun 08, 2020	Mar DISC
	@	7.5MG	A212936	003	Jun 08, 2020	Mar DISC
	@	10MG	A212936	004	Jun 08, 2020	Mar DISC

TABLET, FOR SUSPENSION; ORAL
EVEROLIMUS

AB	AMNEAL	2MG	A218863	001	Jan 10, 2025	Jan NEWA
AB		3MG	A218863	002	Jan 10, 2025	Jan NEWA
AB		5MG	A218863	003	Jan 10, 2025	Jan NEWA
AB	NATCO	2MG	A217640	001	Jan 28, 2025	Jan NEWA
AB		3MG	A217640	002	Jan 28, 2025	Jan NEWA
AB		5MG	A217640	003	Jan 28, 2025	Jan NEWA

EXENATIDE SYNTHETICINJECTABLE; SUBCUTANEOUS
BYETTA

	@ + ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Apr DISC
	@ +	600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Apr DISC

EXENATIDE SYNTHETIC

	! AMNEAL	300MCG/1.2ML (250MCG/ML)	A206697	001	Nov 19, 2024	Apr CTEC
AP	!	300MCG/1.2ML (250MCG/ML)	A206697	001	Nov 19, 2024	Apr CHRS
	!	600MCG/2.4ML (250MCG/ML)	A206697	002	Nov 19, 2024	Apr CTEC
AP	!	600MCG/2.4ML (250MCG/ML)	A206697	002	Nov 19, 2024	Apr CHRS

SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON BCISE

	@ + ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Mar DISC
--	--------------------	-------------------------	---------	-----	--------------	----------

EZETIMIBE; SIMVASTATINTABLET; ORAL
EZETIMIBE AND SIMVASTATIN

AB	TORRENT	10MG; 10MG	A209461	001	Jan 27, 2025	Jan NEWA
AB		10MG; 20MG	A209461	002	Jan 27, 2025	Jan NEWA
AB		10MG; 40MG	A209461	003	Jan 27, 2025	Jan NEWA
AB		10MG; 80MG	A209461	004	Jan 27, 2025	Jan NEWA

FAMOTIDINEFOR SUSPENSION; ORAL
FAMOTIDINE

AB	APPCO	40MG/5ML	A217655	001	Jun 16, 2023	Mar CAHN
>A> AB	LANNETT CO INC	40MG/5ML	A217982	001	Jun 02, 2025	May NEWA

TABLET; ORAL
FAMOTIDINE

	@ APOTEX	20MG	A075611	001	Jul 23, 2001	Mar DISC
	@	40MG	A075611	002	Jul 23, 2001	Mar DISC
AB	BEXIMCO PHARMS USA	20MG	A218631	001	Mar 25, 2025	Mar NEWA
AB		40MG	A218631	002	Mar 25, 2025	Mar NEWA

FAMOTIDINE; IBUPROFENTABLET; ORAL
IBUPROFEN AND FAMOTIDINE

AB	ENDO OPERATIONS	26.6MG; 800MG	A203658	001	Mar 22, 2024	Feb CTNA
	@ TORRENT	26.6MG; 800MG	A215925	001	Mar 18, 2024	Feb CTNA
AB	ZYDUS PHARMS	26.6MG; 800MG	A218684	001	Feb 20, 2025	Feb NEWA

FEBUXOSTATTABLET; ORAL
FEBUXOSTAT

AB	MSN	40MG	A210461	001	Dec 30, 2019	Jan CTEC
AB		80MG	A210461	002	Dec 30, 2019	Jan CTEC

FELBAMATETABLET; ORAL
FELBAMATE

>D>	AB	ALVOGEN	400MG	A204595	001	Jan 11, 2016	May DISC
>A>	@		400MG	A204595	001	Jan 11, 2016	May DISC
>D>	AB		600MG	A204595	002	Jan 11, 2016	May DISC
>A>	@		600MG	A204595	002	Jan 11, 2016	May DISC

FENOFIBRATECAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

AB	CHARTWELL RX	43MG	A090859	001	Mar 01, 2012	Apr CAHN
AB		130MG	A090859	002	Mar 01, 2012	Apr CAHN

TABLET; ORAL
FENOFIBRATE

AB	CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Mar CTEC
AB		120MG	A217732	002	Sep 07, 2023	Mar CTEC
	@ MYLAN	54MG	A076520	001	Oct 25, 2007	Feb DISC
	@	160MG	A076520	003	Oct 25, 2007	Feb DISC
	@ SUN PHARM	48MG	A200884	001	Sep 07, 2017	Jan DISC
	@	145MG	A200884	002	Sep 07, 2017	Apr DISC

FINASTERIDE; TADALAFILCAPSULE; ORAL
FINASTERIDE AND TADALAFIL
NOVITIUM PHARMA

5MG; 5MG

A218499 001 Mar 19, 2025 Mar NEWA

FITUSIRAN SODIUMSOLUTION; SUBCUTANEOUS
QFITLIA

+! GENZYME CORP

EQ 20MG BASE/0.2ML (EQ 20MG
BASE/0.2ML)

N219019 001 Mar 28, 2025 Mar NEWA

+!

EQ 50MG BASE/0.5ML (EQ 50MG
BASE/0.5ML)

N219019 002 Mar 28, 2025 Mar NEWA

FLUDEOXYGLUCOSE F-18INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	BAMF	20-400mCi/ML	A216125	001	Mar 11, 2025	Feb NEWA
AP	SOFIE	20-300mCi/ML	A204463	001	Oct 21, 2014	Mar CAHN

FLUOCINONIDECREAM; TOPICAL
FLUOCINONIDE

AB1	ENCUBE	0.05%	A211410	001	Oct 16, 2018	Feb CMFD
-----	--------	-------	---------	-----	--------------	----------

GEL; TOPICAL
FLUOCINONIDE

AB	PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Feb CMFD
----	------------	-------	---------	-----	--------------	----------

SOLUTION; TOPICAL
FLUOCINONIDE

AT	QUAGEN	0.05%	A216389	001	Feb 26, 2025	Feb NEWA
	@ SAPTALIS PHARMS	0.05%	A207554	001	Mar 18, 2019	Feb CAHN

FLUORESCEIN SODIUMINJECTABLE; INTRAVENOUS
AK-FLUOR 25%

>D>	AP	+! LONG GROVE PHARMS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008	May DISC
>A>	@ +		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008	May DISC

FLUORESCEIN SODIUM

AP	NEXUS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215709	001	Sep 25, 2023	Mar CAHN
>D>	AP	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	May CTEC
>A>	!	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	May CTEC
AP		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Mar CAHN

FLUORODOPA F-18SOLUTION;INTRAVENOUS
FLUORODOPA F18

+! FEINSTEIN 1-40mCi/ML N200655 001 Oct 10, 2019 Feb CPOT

FLUOROURACILCREAM;TOPICAL
FLUOROURACIL

AB ENCUBE 5% A216942 001 Feb 12, 2025 Jan NEWA

INJECTABLE;INJECTION
FLUOROURACIL

>D> AP ! ACCORD HLTHCARE 2.5GM/50ML (50MG/ML) A040798 002 Apr 26, 2007 May DISC
 >A> @ 2.5GM/50ML (50MG/ML) A040798 002 Apr 26, 2007 May DISC
 >D> AP ALEMBIC 2.5GM/50ML (50MG/ML) A217295 001 Mar 03, 2023 May CHRS
 >A> AP ! 2.5GM/50ML (50MG/ML) A217295 001 Mar 03, 2023 May CHRS
 AP KINDOS 5GM/100ML (50MG/ML) A215699 001 Feb 06, 2025 Jan NEWA

FLUOXETINE HYDROCHLORIDESOLUTION;ORAL
FLUOXETINE HYDROCHLORIDE

AA SOLIS PHARMS EQ 20MG BASE/5ML A075292 001 Feb 07, 2002 Apr CAHN

TABLET;ORAL
FLUOXETINE HYDROCHLORIDE

@ APPCO EQ 10MG BASE A211696 001 Jan 30, 2019 Feb CAHN
 @ EQ 20MG BASE A211696 002 Jan 30, 2019 Feb CAHN
 AB ! AUROBINDO PHARMA LTD EQ 60MG BASE A213265 001 Jun 10, 2020 Apr CHRS
 @ CHARTWELL RX EQ 10MG BASE A211444 001 Sep 13, 2022 Mar CAHN
 @ EQ 20MG BASE A211444 002 Sep 13, 2022 Mar CAHN
 @ + TWI PHARMS EQ 60MG BASE N202133 001 Oct 06, 2011 Apr DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINECAPSULE;ORAL
SYMBYAX

@ + LILLY EQ 25MG BASE;EQ 3MG BASE N021520 001 Apr 09, 2007 Feb DISC
 @ + EQ 25MG BASE;EQ 6MG BASE N021520 002 Dec 24, 2003 Feb DISC
 @ + EQ 25MG BASE;EQ 12MG BASE N021520 004 Dec 24, 2003 Feb DISC
 @ + EQ 50MG BASE;EQ 6MG BASE N021520 003 Dec 24, 2003 Feb DISC
 @ + EQ 50MG BASE;EQ 12MG BASE N021520 005 Dec 24, 2003 Feb DISC

FLUPHENAZINE HYDROCHLORIDETABLET;ORAL
FLUPHENAZINE HYDROCHLORIDE

AB ZAMEER PHARMS 1MG A215141 001 Oct 20, 2021 Feb CAHN
 AB 2.5MG A215141 002 Oct 20, 2021 Feb CAHN
 AB 5MG A215141 003 Oct 20, 2021 Feb CAHN
 AB 10MG A215141 004 Oct 20, 2021 Feb CAHN

FLURANDRENOLIDECREAM;TOPICAL
CORDRAN SP

>D> @ + ALMIRALL 0.025% N012806 003 May CAHN
 >D> @ + 0.05% N012806 002 May CAHN
 >A> @ + INA PHARMS 0.025% N012806 003 May CAHN
 >A> @ + 0.05% N012806 002 May CAHN

LOTION;TOPICAL
CORDRAN

>D> @ + ALMIRALL 0.05% N013790 001 May CAHN
 >A> @ + INA PHARMS 0.05% N013790 001 May CAHN

OINTMENT;TOPICAL
CORDRAN

>D> @ + ALMIRALL 0.025% N012806 004 May CAHN
 >D> @ + 0.05% N012806 001 May CAHN
 >A> @ + INA PHARMS 0.025% N012806 004 May CAHN
 >A> @ + 0.05% N012806 001 May CAHN

FLUTICASONE PROPIONATEOINTMENT;TOPICAL
FLUTICASONE PROPIONATE

@ CHARTWELL RX 0.005% A076300 001 May 14, 2004 Mar CAHN

SPRAY, METERED;NASAL							
FLUTICASONE PROPIONATE							
>A>	AB	RUBICON RESEARCH	0.05MG/SPRAY	A218321	001	Jun 05, 2025	May NEWA
<u>FOLIC ACID</u>							
TABLET;ORAL							
FOLIC ACID							
AA		AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Mar CAHN
<u>FORMOTEROL FUMARATE</u>							
SOLUTION;INHALATION							
FORMOTEROL FUMARATE							
AN		DEVA HOLDING AS	0.02MG/2ML	A218308	001	Feb 11, 2025	Jan NEWA
AN		DR REDDYS	0.02MG/2ML	A215907	001	Jan 30, 2025	Jan NEWA
PERFOROMIST							
AN		+! VIATRIS SPECIALTY	0.02MG/2ML	N022007	001	May 11, 2007	Feb CAHN
<u>FOSAPREPITANT DIMEGLUMINE</u>							
POWDER;INTRAVENOUS							
FOSAPREPITANT DIMEGLUMINE							
@		PIRAMAL CRITICAL	EQ 150MG BASE/VIAL	A214683	001	May 16, 2023	Apr DISC
@		PRAXGEN	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Jan CAHN
<u>FOSFOMYCIN TROMETHAMINE</u>							
FOR SOLUTION;ORAL							
FOSFOMYCIN TROMETHAMINE							
>A>	AA	PRECISION DOSE INC	EQ 3GM BASE/PACKET	A217187	001	Jun 03, 2025	May NEWA
<u>FOSINOPRIL SODIUM</u>							
TABLET;ORAL							
FOSINOPRIL SODIUM							
@		APOTEX	10MG	A076906	001	May 17, 2005	Mar DISC
@			20MG	A076906	002	May 17, 2005	Mar DISC
@			40MG	A076906	003	May 17, 2005	Mar DISC
<u>FROVATRIPTAN SUCCINATE</u>							
TABLET;ORAL							
FROVATRIPTAN SUCCINATE							
AB		LEADING	EQ 2.5MG BASE	A216998	001	Apr 16, 2025	Apr NEWA
<u>FUROSEMIDE</u>							
TABLET;ORAL							
FUROSEMIDE							
@		NORVIUM BIOSCIENCE	80MG	A070082	001	Oct 29, 1986	Feb CAHN
<u>GABAPENTIN</u>							
SOLUTION;ORAL							
GABAPENTIN							
AA		AJENAT PHARMS	250MG/5ML	A091286	001	Mar 14, 2016	Jan CAHN
AA		PAI HOLDINGS PHARM	250MG/5ML	A211330	001	Dec 03, 2019	Apr CMFD
TABLET;ORAL							
GABAPENTIN							
@		APOTEX	100MG	A077894	001	Oct 10, 2006	Mar DISC
@			300MG	A077894	002	Oct 10, 2006	Mar DISC
@			400MG	A077894	003	Oct 10, 2006	Mar DISC
		IVAX SUB TEVA PHARMS	300MG	A076017	002	Apr 28, 2004	Mar CTEC
<u>GADOBUTROL</u>							
SOLUTION;INTRAVENOUS							
GADOBUTROL							
AP		HAINAN POLY PHARM	1.20944GM/2ML (604.72MG/ML)	A217480	003	Apr 16, 2025	Apr NEWA
AP			6.0472GM/10ML (604.72MG/ML)	A217480	004	Apr 16, 2025	Apr NEWA
AP			18.1416GM/30ML (604.72MG/ML)	A217480	005	Apr 16, 2025	Apr NEWA
AP			39.3068GM/65ML (604.72MG/ML)	A217480	006	Apr 16, 2025	Apr NEWA
<u>GADOTERIDOL</u>							
INJECTABLE;INJECTION							
GADOTERIDOL							
AP		HAINAN POLY	279.3MG/ML	A218749	001	Feb 11, 2025	Jan NFTG
PROHANCE							
AP		+! BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992	Jan CFTG

GALLIUM GA-68 GOZETOTIDEPOWDER; INTRAVENOUS
GOZELLIX

+! TELIX INNOVATIONS N/A N219592 001 Mar 20, 2025 Mar NEWA

GANCICLOVIRSOLUTION; INTRAVENOUS
GANZYK-RTU

@ + EXELA PHARMA 500MG/250ML (2MG/ML) N209347 001 Feb 17, 2017 Apr DISC

GANIRELIX ACETATEINJECTABLE; INJECTION
GANIRELIX ACETATE

AP QILU 250MCG/0.5ML A218855 001 Apr 23, 2025 Apr NEWA

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN

>A> @ CAPLIN 0.5% A213542 001 Nov 03, 2021 May CAHN

>D> @ TORRENT 0.5% A213542 001 Nov 03, 2021 May CAHN

GEFITINIBTABLET; ORAL
GEFITINIB

>A> AB CIPLA 250MG A211826 001 May 16, 2025 May NEWA

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

>D> AP HIKMA INTL PHARMS EQ 200MG BASE/VIAL A206617 001 Jun 25, 2021 May DISC

>A> @ EQ 200MG BASE/VIAL A206617 001 Jun 25, 2021 May DISC

>D> AP EQ 1GM BASE/VIAL A206617 002 Jun 25, 2021 May DISC

>A> @ EQ 1GM BASE/VIAL A206617 002 Jun 25, 2021 May DISC

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

@ APOTEX 600MG A075034 001 Jul 20, 1998 Mar DISC

GEPOTIDACIN MESYLATETABLET; ORAL
BLUJEP

+! GLAXOSMITHKLINE EQ 750MG BASE N218230 001 Mar 25, 2025 Mar NEWA

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
GLATIRAMER ACETATE

AP CHEMI SPA 20MG/ML A208468 001 May 07, 2025 Apr NEWA

AP 40MG/ML A208468 002 May 07, 2025 Apr NEWA

GLIMEPIRIDETABLET; ORAL
AMARYL

@ + SANOFI AVENTIS US 1MG N020496 001 Nov 30, 1995 Feb DISC

@ + 2MG N020496 002 Nov 30, 1995 Feb DISC

@ + 4MG N020496 003 Nov 30, 1995 Feb DISC

GLIMEPIRIDE

AB ! DR REDDYS LABS LTD 1MG A077091 001 Oct 06, 2005 Feb CHRS

GLIPIZIDETABLET; ORAL
GLIPIZIDE

@ AIPING PHARM INC 5MG A074305 001 Apr 07, 1995 Jan CAHN

@ 10MG A074305 002 Apr 07, 1995 Jan CAHN

AB OXFORD PHARMS 5MG A074378 001 Nov 28, 1994 Apr CMFD

AB 10MG A074378 002 Nov 28, 1994 Apr CMFD

TABLET, EXTENDED RELEASE; ORAL
GLUCOTROL XL

@ + PFIZER 2.5MG N020329 003 Aug 10, 1999 Apr DISC

AB + 5MG N020329 001 Apr 26, 1994 Apr CMFD

AB + 10MG N020329 002 Apr 26, 1994 Apr CHRS

GLUCAGON

SOLUTION; INTRAVENOUS
GVOKE VIALDX
+! XERIS

1MG/0.2ML (1MG/0.2ML)

N212097 006 Mar 14, 2025 Mar NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE
@ XIROMED

0.2MG/ML

A212227 001 Mar 04, 2021 Jan DISC

POWDER; INHALATION
SEEBRI

>D>

@ + NOVARTIS

15.6MCG/INH

N207923 001 Oct 29, 2015 May CTNA

>D>

SEEBRI NEOHALER

>A>

@ + NOVARTIS

15.6MCG/INH

N207923 001 Oct 29, 2015 May CTNA

>A>

SOLUTION; ORAL
GLYCOPYRROLATE

AA

MSN

1MG/5ML

A216084 001 Apr 08, 2025 Mar NEWA

TABLET; ORAL
GLYCOPYRROLATE

AA

CHARTWELL RX

1MG

A040847 001 Mar 21, 2008 Feb CAHN

AA

2MG

A040847 002 Mar 21, 2008 Feb CAHN

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER; INHALATION
UTIBRON

>D>

@ + NOVARTIS

15.6MCG/INH; 27.5MCG/INH

N207930 001 Oct 29, 2015 May CTNA

>D>

UTIBRON NEOHALER

>A>

@ + NOVARTIS

15.6MCG/INH; 27.5MCG/INH

N207930 001 Oct 29, 2015 May CTNA

>A>

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT

SAPTALIS PHARMS

0.025MG/ML; EQ 1.75MG
BASE/ML; 10,000 UNITS/ML

A065187 001 Oct 28, 2005 Feb CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL
GRANISETRON HYDROCHLORIDE
INTRA SANA LABS

EQ 2MG BASE/10ML

A219282 001 Mar 17, 2025 Mar NEWA

TABLET; ORAL
GRANISETRON HYDROCHLORIDE
@ APOTEX INC

EQ 1MG BASE

A078843 001 Feb 27, 2008 Mar DISC

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HYDROCHLORIDE

BX

RUBICON

EQ 1MG BASE

A216762 001 Oct 17, 2023 Mar CTEC

BX

EQ 2MG BASE

A216762 002 Oct 17, 2023 Mar CTEC

TABLET, EXTENDED RELEASE; ORAL
GUANFACINE HYDROCHLORIDE

AB

FOSUN WANBANG

EQ 1MG BASE

A217638 001 Jun 12, 2024 Mar CMFD

@

EQ 1MG BASE

A217638 001 Jun 12, 2024 Jan CAHN

AB

@

EQ 2MG BASE

A217638 002 Jun 12, 2024 Mar CMFD

AB

@

EQ 2MG BASE

A217638 002 Jun 12, 2024 Jan CAHN

AB

@

EQ 3MG BASE

A217638 003 Jun 12, 2024 Mar CMFD

AB

@

EQ 3MG BASE

A217638 003 Jun 12, 2024 Jan CAHN

AB

@

EQ 4MG BASE

A217638 004 Jun 12, 2024 Mar CMFD

AB

@

EQ 4MG BASE

A217638 004 Jun 12, 2024 Jan CAHN

AB

RUBICON

EQ 1MG BASE

A219689 001 Apr 15, 2025 Apr NEWA

AB

EQ 2MG BASE

A219689 002 Apr 15, 2025 Apr NEWA

AB

EQ 3MG BASE

A219689 003 Apr 15, 2025 Apr NEWA

AB

EQ 4MG BASE

A219689 004 Apr 15, 2025 Apr NEWA

HALCINONIDE

SOLUTION; TOPICAL
HALCINONIDE

! ENCUBE

0.1%

A217671 001 May 29, 2024 Mar CMFD

@

0.1%

A217671 001 May 29, 2024 Jan DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL
ULTRAVATE

+	!	LACER PHARMA	0.05%	N208183	001	Nov 06, 2015	Apr CMFD
@	+		0.05%	N208183	001	Nov 06, 2015	Jan CAHN

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL
DUOBRII

AB	+	!	BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019	Apr CFTG
			HALOBETASOL PROPIONATE AND TAZAROTENE					
AB			TARO	0.01%;0.045%	A217190	001	May 02, 2025	Apr NFTG

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL

AB			APPCO	0.5MG	A211061	001	Jan 08, 2020	Feb CAHN
AB				1MG	A211061	002	Jan 08, 2020	Feb CAHN
AB				2MG	A211061	003	Jan 08, 2020	Feb CAHN
AB				5MG	A211061	004	Jan 08, 2020	Feb CAHN
AB				10MG	A211061	005	Jan 08, 2020	Feb CAHN
AB				20MG	A211061	006	Jan 08, 2020	Feb CAHN

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

>A>	AO		CAPLIN	EQ 50MG BASE/ML	A219168	001	May 13, 2025	May NEWA
>A>	AO			EQ 100MG BASE/ML	A219168	002	May 13, 2025	May NEWA

HALOPERIDOL LACTATE

INJECTABLE;INJECTION
HALOPERIDOL

@		FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Feb DISC
---	--	--------------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

@		B BRAUN MEDICAL	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Jan DISC		
		HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jan CTEC		
>D>	AP	MYLAN LABS LTD	1,000 UNITS/ML	A203851	001	Nov 30, 2017	May CAHN		
>D>	AP		5,000 UNITS/ML	A203851	002	Nov 30, 2017	May CAHN		
>D>	AP		10,000 UNITS/ML	A203851	003	Nov 30, 2017	May CAHN		
>D>	AP		20,000 UNITS/ML	A203852	001	Nov 30, 2017	May CAHN		
>A>	AP	NORVIUM BIOSCIENCE	1,000 UNITS/ML	A203851	001	Nov 30, 2017	May CAHN		
>A>	AP		5,000 UNITS/ML	A203851	002	Nov 30, 2017	May CAHN		
>A>	AP		10,000 UNITS/ML	A203851	003	Nov 30, 2017	May CAHN		
>A>	AP		20,000 UNITS/ML	A203852	001	Nov 30, 2017	May CAHN		
AP		PLANO PHARMS	1,000 UNITS/ML	A091682	001	Jun 08, 2011	Mar CAHN		
AP			5,000 UNITS/ML	A091682	002	Jun 08, 2011	Mar CAHN		
AP			10,000 UNITS/ML	A201002	001	Jun 08, 2011	Mar CAHN		
		HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
		+	!	B BRAUN	5,000 UNITS/100ML	N019953	003	Mar 25, 2025	Mar NEWA
		+	!		10,000 UNITS/100ML	N019953	004	Mar 25, 2025	Mar NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

@		APOZEAL PHARMS	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Apr CAHN
@		SANKALP LIFECARE	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Apr CAHN
AA		XTTRIUM LABS INC	1.5MG/5ML;5MG/5ML	A088008	001	Mar 03, 1983	Feb CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

>A>	AP		KINDOS	20MG/ML	A217501	001	Jun 02, 2025	May NEWA
-----	----	--	--------	---------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL							
MICROZIDE							
AB	+! TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996	Apr	CAHN
FOR SUSPENSION;ORAL							
INZIRQO							
	+! NOVITIUM PHARMA	10MG/ML	N219141	001	Jan 28, 2025	Jan	NEWA
TABLET;ORAL							
HYDROCHLOROTHIAZIDE							
AB	UNICHEM	12.5MG	A040907	003	Apr 03, 2025	Mar	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL							
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE							
AB	SENORES PHARMS	25MG;50MG	A215789	001	Jan 08, 2025	Jan	NEWA
AB		25MG;100MG	A215789	002	Jan 08, 2025	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL							
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
@	APOTEX	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan	DISC
@		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan	DISC
@		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan	DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL							
TELMISARTAN AND HYDROCHLOROTHIAZIDE							
AB	MANKIND PHARMA	12.5MG;40MG	A218406	001	Mar 03, 2025	Feb	NEWA
AB		12.5MG;80MG	A218406	002	Mar 03, 2025	Feb	NEWA
AB		25MG;80MG	A218406	003	Mar 03, 2025	Feb	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL							
TRIAMTERENE AND HYDROCHLOROTHIAZIDE							
AB	MACLEODS PHARMS LTD	25MG;37.5MG	A214611	001	Jan 28, 2025	Jan	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL							
HYDROCODONE							
@	STRIDES PHARMA	5MG;200MG	A077723	003	Nov 06, 2006	Apr	CAHN
HYDROCODONE BITARTRATE AND IBUPROFEN							
@	STRIDES PHARMA	7.5MG;200MG	A077723	001	Nov 06, 2006	Apr	CAHN
@		10MG;200MG	A077723	002	Nov 06, 2006	Apr	CAHN

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL							
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
@	APOZEAL PHARMS	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Apr	CAHN

HYDROCORTISONE

LOTION;TOPICAL							
ALA-SCALP							
	+ LEGACY PHARMA	2%	A083231	001		Mar	CRLD
>A>	SOLUTION;ORAL						
>A>	KHINDIVI						
>A>	+! ETON	1MG/ML	N218980	001	May 28, 2025	May	NEWA
TABLET;ORAL							
HYDROCORTISONE							
AB	NOVITIUM PHARMA	5MG	A217881	001	May 02, 2025	Apr	NEWA
AB		10MG	A217881	002	May 02, 2025	Apr	NEWA
AB		20MG	A217881	003	May 02, 2025	Apr	NEWA

HYDROCORTISONE ACETATE

AEROSOL, METERED;RECTAL							
CORTIFOAM							
	+! VIATRIS	10%	N017351	001	Feb 10, 1982	Feb	CAHN
CREAM;TOPICAL							
MICORT-HC							
@	LEGACY PHARMA	2%	A040398	001	Mar 29, 2002	Jan	CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

@	SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Feb CAHN
---	-----------------	-------------------------------------	---------	-----	--------------	----------

SUSPENSION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Feb CAHN
----	-----------------	-------------------------------------	---------	-----	--------------	----------

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

AA	BIONPHARMA	10MG/5ML	A219289	001	Apr 28, 2025	Apr NEWA
----	------------	----------	---------	-----	--------------	----------

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@	APPCO	10MG	A040812	001	Mar 12, 2008	Apr CAHN
---	-------	------	---------	-----	--------------	----------

@		25MG	A040812	002	Mar 12, 2008	Apr CAHN
---	--	------	---------	-----	--------------	----------

@		50MG	A040812	003	Mar 12, 2008	Apr CAHN
---	--	------	---------	-----	--------------	----------

AB	!	GRAVITI PHARMS	50MG	A217652	003	Aug 17, 2023	Mar CHRS
----	---	----------------	------	---------	-----	--------------	----------

AB	+	PLIVA	50MG	A088619	001	Jan 10, 1986	Mar CHRS
----	---	-------	------	---------	-----	--------------	----------

@ +	STRIDES PHARMA	50MG	A087604	001	Jan 22, 1982	Mar CRLD
-----	----------------	------	---------	-----	--------------	----------

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB	BARR LABS	EQ 50MG HYDROCHLORIDE	A088487	001	Jun 15, 1984	Mar CAHN
----	-----------	-----------------------	---------	-----	--------------	----------

		EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984	Mar CAHN
--	--	------------------------	---------	-----	--------------	----------

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

ICATIBANT ACETATE

@	CAPLIN	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213054	001	Oct 05, 2020	Apr CAHN
---	--------	------------------------------------	---------	-----	--------------	----------

ICODEXTRIN

SOLUTION;INTRAPERITONEAL

EXTRANEAL

+	VANTIVE US HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002	Feb CAHN
---	---------------------	-------------	---------	-----	--------------	----------

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	CSPC OUYI	EQ 100MG BASE	A212193	001	Apr 21, 2025	Apr NEWA
----	-----------	---------------	---------	-----	--------------	----------

AB		EQ 400MG BASE	A212193	002	Apr 21, 2025	Apr NEWA
----	--	---------------	---------	-----	--------------	----------

AB	HETERO LABS LTD V	EQ 100MG BASE	A212975	001	Apr 14, 2025	Apr NEWA
----	-------------------	---------------	---------	-----	--------------	----------

AB		EQ 400MG BASE	A212975	002	Apr 14, 2025	Apr NEWA
----	--	---------------	---------	-----	--------------	----------

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

@	APOTEX INC	5%	A091308	001	Apr 06, 2012	Mar DISC
---	------------	----	---------	-----	--------------	----------

INDOCYANINE GREEN

INJECTABLE;INJECTION

IC-GREEN

>D>	@ +	RENEW PHARMS	25MG/VIAL	N011525	001	May CMFD
-----	-----	--------------	-----------	---------	-----	----------

>A>	AP	+	25MG/VIAL	N011525	001	May CMFD
-----	----	---	-----------	---------	-----	----------

INDOCYANINE GREEN

>D>	!	RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	May CTEC
-----	---	--------------	-----------	---------	-----	--------------	----------

>A>	AP	!	25MG/VIAL	A040811	001	Nov 21, 2007	May CTEC
-----	----	---	-----------	---------	-----	--------------	----------

INDOMETHACIN

SUPPOSITORY;RECTAL

INDOMETHACIN

AB	AMNEAL	50MG	A215399	001	Feb 24, 2025	Feb NEWA
----	--------	------	---------	-----	--------------	----------

IOMEPROL

SOLUTION; INTRA-ARTERIAL

IOMERVU

@ +	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216016	002	Nov 27, 2024	Mar DISC
@ +		17.5GM IODINE/50ML (350MG IODINE/ML)	N216016	006	Nov 27, 2024	Mar DISC
@ +		20GM IODINE/50ML (400MG IODINE/ML)	N216016	010	Nov 27, 2024	Mar DISC
@ +		25GM IODINE/100ML (250MG IODINE/ML)	N216016	001	Nov 27, 2024	Mar DISC
@ +		30GM IODINE/100ML (300MG IODINE/ML)	N216016	003	Nov 27, 2024	Mar DISC
@ +		35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Mar DISC
@ +		40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Mar DISC
@ +		60GM IODINE/150ML (400MG IODINE/ML)	N216016	012	Nov 27, 2024	Mar DISC
@ +		45GM IODINE/150ML (300MG IODINE/ML)	N216016	004	Nov 27, 2024	Mar DISC
@ +		52.5GM IODINE/150ML (350MG IODINE/ML)	N216016	008	Nov 27, 2024	Mar DISC
@ +		60GM IODINE/200ML (300MG IODINE/ML)	N216016	005	Nov 27, 2024	Mar DISC
@ +		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Mar DISC
@ +		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Mar DISC

SOLUTION; INTRAVENOUS

IOMERVU

@ +	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216017	002	Nov 27, 2024	Mar DISC
@ +		17.5GM IODINE/50ML (350MG IODINE/ML)	N216017	006	Nov 27, 2024	Mar DISC
@ +		20GM IODINE/50ML (400MG IODINE/ML)	N216017	010	Nov 27, 2024	Mar DISC
@ +		25GM IODINE/100ML (250MG IODINE/ML)	N216017	001	Nov 27, 2024	Mar DISC
@ +		30GM IODINE/100ML (300MG IODINE/ML)	N216017	003	Nov 27, 2024	Mar DISC
@ +		35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Mar DISC
@ +		40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Mar DISC
@ +		60GM IODINE/150ML (400MG IODINE/ML)	N216017	012	Nov 27, 2024	Mar DISC
@ +		45GM IODINE/150ML (300MG IODINE/ML)	N216017	004	Nov 27, 2024	Mar DISC
@ +		52.5GM IODINE/150ML (350MG IODINE/ML)	N216017	008	Nov 27, 2024	Mar DISC
@ +		60GM IODINE/200ML (300MG IODINE/ML)	N216017	005	Nov 27, 2024	Mar DISC
@ +		70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Mar DISC
@ +		80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Mar DISC

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

AB	LUPIN	0.021MG/SPRAY	A217912	001	Feb 07, 2025	Jan NEWA
AB		0.042MG/SPRAY	A217886	001	Jan 27, 2025	Jan NEWA
AB	RUBICON	0.021MG/SPRAY	A219222	001	Jan 14, 2025	Jan NEWA

ISONIAZID

SYRUP; ORAL

ISONIAZID

AA	CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997	Feb CMFD
AA	+! CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Feb CTEC

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

AB1	MYLAN PHARMS INC	30MG	A075945	004	Mar 17, 2025	Mar NEWA
>A> AB2	ISOTRETINOIN ZYDUS PHARMS	10MG	A216633	001	May 22, 2025	May NEWA

CAPSULE;ORAL					
ISOTRETINOIN					
>A>	AB2	20MG	A216633	002	May 22, 2025 May NEWA
>A>	AB2	25MG	A216633	003	May 22, 2025 May NEWA
>A>	AB2	30MG	A216633	004	May 22, 2025 May NEWA
>A>	AB2	35MG	A216633	005	May 22, 2025 May NEWA
>A>	AB2	40MG	A216633	006	May 22, 2025 May NEWA
<u>ITRACONAZOLE</u>					
CAPSULE;ORAL					
ITRACONAZOLE					
AB	RISING	100MG	A205724	001	Dec 13, 2016 Feb CMFD
<u>IVABRADINE HYDROCHLORIDE</u>					
TABLET;ORAL					
IVABRADINE HYDROCHLORIDE					
AB	MSN	EQ 5MG BASE	A213483	001	Apr 28, 2025 Apr NEWA
AB		EQ 7.5MG BASE	A213483	002	Apr 28, 2025 Apr NEWA
<u>IVERMECTIN</u>					
TABLET;ORAL					
IVERMECTIN					
AB	RUBICON	3MG	A215922	001	Jan 22, 2025 Jan NEWA
		6MG	A215922	002	Jan 22, 2025 Jan NFTG
<u>KETAMINE HYDROCHLORIDE</u>					
INJECTABLE;INJECTION					
KETAMINE HYDROCHLORIDE					
AP	FRESENIUS KABI USA	EQ 100MG BASE/ML	A215808	003	Apr 18, 2025 Apr NEWA
<u>KETOCONAZOLE</u>					
GEL;TOPICAL					
XOLEGEL					
>D>	@ + ALMIRALL	2%	N021946	001	Jul 28, 2006 May CAHN
>A>	@ + INA PHARMS	2%	N021946	001	Jul 28, 2006 May CAHN
SHAMPOO;TOPICAL					
KETOCONAZOLE					
AB	ZYDUS LIFESCIENCES	2%	A218559	001	Mar 07, 2025 Feb NEWA
<u>LACOSAMIDE</u>					
SOLUTION;INTRAVENOUS					
LACOSAMIDE					
>A>	AP WESTMINSTER PHARMS	200MG/20ML (10MG/ML)	A218706	001	May 23, 2025 May NEWA
SOLUTION;ORAL					
LACOSAMIDE					
>D>	@ APOTEX	10MG/ML	A206355	001	Sep 26, 2022 May CMFD
>A>	AA	10MG/ML	A206355	001	Sep 26, 2022 May CMFD
	@	10MG/ML	A206355	001	Sep 26, 2022 Feb DISC
<u>LACTULOSE</u>					
FOR SOLUTION;ORAL					
LACTULOSE					
AA	! CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997 Mar CTEC
AA	!	20GM/PACKET	A074712	002	Dec 10, 1997 Mar CTEC
AA	PAI HOLDINGS	10GM/PACKET	A217914	001	Mar 14, 2025 Mar NEWA
AA		20GM/PACKET	A217914	002	Mar 14, 2025 Mar NEWA
SOLUTION;ORAL					
LACTULOSE					
	@ VISTAPHARM LLC	10GM/15ML	A074138	001	Sep 30, 1992 Jan CAHN
<u>LAMIVUDINE</u>					
TABLET;ORAL					
LAMIVUDINE					
AB	APPCO	150MG	A206974	001	Nov 21, 2016 Mar CAHN
AB		300MG	A206974	002	Nov 21, 2016 Mar CAHN
	@ NORVIUM BIOSCIENCE	150MG	A078545	001	Mar 05, 2019 Feb CAHN
	@	300MG	A078545	002	Mar 05, 2019 Feb CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

>A>	AB	NORVIUM BIOSCIENCE	150MG;300MG	A079128	001	May 13, 2015	May CAHN
>D>	AB	STRIDES PHARMA	150MG;300MG	A079128	001	May 13, 2015	May CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@	AIPING PHARM INC	25MG	A078645	001	Jan 27, 2009	Jan CAHN
@		100MG	A078645	002	Jan 27, 2009	Jan CAHN
@		150MG	A078645	003	Jan 27, 2009	Jan CAHN
@		200MG	A078645	004	Jan 27, 2009	Jan CAHN

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

LANTHANUM CARBONATE

AB	ALKEM LABS LTD	EQ 500MG BASE	A202329	001	Mar 13, 2025	Mar NEWA
AB		EQ 750MG BASE	A202329	002	Mar 13, 2025	Mar NEWA
AB		EQ 1GM BASE	A202329	003	Mar 13, 2025	Mar NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

@	CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Apr CAHN
AT	MICRO LABS	0.005%	A219306	001	Apr 14, 2025	Apr NEWA

LATANOPROSTENE BUNOD

SOLUTION/DROPS; OPHTHALMIC

LATANOPROSTENE BUNOD

AB	GLAND	0.024%	A217387	001	Apr 29, 2025	Apr NFTG
	VYZULTA					
AB	+! BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017	Apr CFTG

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

AB	FOSUN WANBANG	10MG	A077087	001	Sep 13, 2005	Jan CAHN
AB		20MG	A077087	002	Sep 13, 2005	Jan CAHN

LENALIDOMIDE

CAPSULE; ORAL

LENALIDOMIDE

AB	AMNEAL	2.5MG	A216213	001	Jan 31, 2025	Jan NEWA	
AB		5MG	A216213	002	Jan 31, 2025	Jan NEWA	
AB		10MG	A216213	003	Jan 31, 2025	Jan NEWA	
AB		15MG	A216213	004	Jan 31, 2025	Jan NEWA	
AB		20MG	A216213	005	Jan 31, 2025	Jan NEWA	
AB		25MG	A216213	006	Jan 31, 2025	Jan NEWA	
AB	BIOCON PHARMA	2.5MG	A215759	001	Mar 03, 2025	Feb NEWA	
AB		5MG	A215759	002	Mar 03, 2025	Feb NEWA	
AB		10MG	A215759	003	Mar 03, 2025	Feb NEWA	
AB		15MG	A215759	004	Mar 03, 2025	Feb NEWA	
AB		20MG	A215759	005	Mar 03, 2025	Feb NEWA	
AB		25MG	A215759	006	Mar 03, 2025	Feb NEWA	
>A>	AB	DEVA HOLDING AS	2.5MG	A217554	001	May 22, 2025	May NEWA
>A>	AB		5MG	A217554	002	May 22, 2025	May NEWA
>A>	AB		10MG	A217554	003	May 22, 2025	May NEWA
>A>	AB		15MG	A217554	004	May 22, 2025	May NEWA
>A>	AB		20MG	A217554	005	May 22, 2025	May NEWA
>A>	AB		25MG	A217554	006	May 22, 2025	May NEWA

LEUPROLIDE ACETATE

SOLUTION; SUBCUTANEOUS

LEUPROLIDE ACETATE

>A>	AP	ENDO OPERATIONS	14MG/2.8ML (1MG/0.2ML)	A217437	001	Jun 09, 2025	May NEWA
-----	----	-----------------	------------------------	---------	-----	--------------	----------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

@	MANKIND PHARMA	EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Apr	DISC
@		EQ 0.021% BASE	A218770	002	Oct 21, 2024	Apr	DISC
@		EQ 0.042% BASE	A218770	003	Oct 21, 2024	Apr	DISC

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM IN SODIUM CHLORIDE

AP	CAPLIN	500MG/100ML (5MG/ML)	A219562	001	Jan 16, 2025	Jan	NEWA
AP		1GM/100ML (10MG/ML)	A219562	002	Jan 16, 2025	Jan	NEWA
AP		1.5GM/100ML (15MG/ML)	A219562	003	Jan 16, 2025	Jan	NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA	AJENAT PHARMS	100MG/ML	A090461	001	Sep 30, 2010	Jan	CAHN
>D>	@ BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	May	CMFD
>A> AA		100MG/ML	A079120	001	Jan 16, 2009	May	CMFD

TABLET; ORAL

LEVETIRACETAM

@	CHINA RESOURCES	500MG	A205102	004	Dec 16, 2015	Jan	CAHN
@		1GM	A205102	003	Dec 16, 2015	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

@	APOTEX	1GM	A202958	001	Feb 25, 2015	Mar	DISC
---	--------	-----	---------	-----	--------------	-----	------

TABLET, FOR SUSPENSION; ORAL
SPRITAM

+	APRECIA PHARMS	500MG	N207958	002	Jul 31, 2015	Apr	CHRS
@ +		750MG	N207958	003	Jul 31, 2015	Apr	DISC
@ +		1GM	N207958	004	Jul 31, 2015	Apr	DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	SYNTHON BV	5MG	A090229	001	Nov 26, 2010	Feb	CAHN
----	------------	-----	---------	-----	--------------	-----	------

LEVODOPA

POWDER; INHALATION

INBRIJA

+	MERZ	42MG	N209184	001	Dec 21, 2018	Feb	CAHN
---	------	------	---------	-----	--------------	-----	------

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

@	APOTEX INC	250MG	A090787	001	Sep 29, 2011	Mar	DISC
@		500MG	A090787	002	Sep 29, 2011	Mar	DISC
@		750MG	A090787	003	Sep 29, 2011	Mar	DISC

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

AB	ACERTIS PHARMS	2MG	A211484	001	Dec 13, 2018	Apr	CAHN
BX	NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021	Mar	CTEC
BX		2MG	A213479	001	Jul 01, 2020	Mar	CTEC
BX		3MG	A213479	002	Jan 12, 2021	Mar	CTEC
AB		3MG	A213479	002	Jan 12, 2021	Mar	CHRS
	! SUN PHARM INDS INC	3MG	A213906	002	Apr 25, 2023	Mar	CTEC
AB	!	3MG	A213906	002	Apr 25, 2023	Mar	CHRS

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

>A>	AP	ONESOURCE SPECIALTY	100MCG/VIAL	A216729	001	Mar 05, 2025	May	CAHN
>A>	AP		200MCG/VIAL	A216729	002	Mar 05, 2025	May	CAHN
>A>	AP		500MCG/VIAL	A216729	003	Mar 05, 2025	May	CAHN
>D>	AP	STERISCIENCE	100MCG/VIAL	A216729	001	Mar 05, 2025	May	CAHN
	AP		100MCG/VIAL	A216729	001	Mar 05, 2025	Feb	NEWA
>D>	AP		200MCG/VIAL	A216729	002	Mar 05, 2025	May	CAHN
	AP		200MCG/VIAL	A216729	002	Mar 05, 2025	Feb	NEWA
>D>	AP		500MCG/VIAL	A216729	003	Mar 05, 2025	May	CAHN
	AP		500MCG/VIAL	A216729	003	Mar 05, 2025	Feb	NEWA

SOLUTION;ORAL
THYQUIDITY

+! STEVENS J 100MCG/5ML N214047 001 Nov 30, 2020 Apr CAHN

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

EUTHYROX

AB2	EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr CAHN
AB2		0.05MG	N021292	002	May 31, 2002	Apr CAHN
AB2		0.075MG	N021292	003	May 31, 2002	Apr CAHN
AB2		0.088MG	N021292	004	May 31, 2002	Apr CAHN
AB2		0.1MG	N021292	005	May 31, 2002	Apr CAHN
AB2		0.112MG	N021292	006	May 31, 2002	Apr CAHN
AB2		0.125MG	N021292	007	May 31, 2002	Apr CAHN
AB2		0.137MG	N021292	008	May 31, 2002	Apr CAHN
AB2		0.15MG	N021292	009	May 31, 2002	Apr CAHN
AB2		0.175MG	N021292	010	May 31, 2002	Apr CAHN
AB2		0.2MG	N021292	011	May 31, 2002	Apr CAHN
@		0.3MG	N021292	012	May 31, 2002	Apr CAHN
	LEVOTHYROXINE SODIUM					
@	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jan DISC
@		0.15MG	A216414	002	Jul 16, 2024	Jan DISC
@		0.175MG	A216414	003	Jul 16, 2024	Jan DISC
@		0.2MG	A216414	004	Jul 16, 2024	Jan DISC
@		0.3MG	A216414	005	Jul 16, 2024	Jan DISC
AB1,AB2, AB3,AB4	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.025MG	A211417	001	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.05MG	A211417	002	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.05MG	A211417	002	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.075MG	A211417	003	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.075MG	A211417	003	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.088MG	A211417	004	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.088MG	A211417	004	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.1MG	A211417	005	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.1MG	A211417	005	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.112MG	A211417	006	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.112MG	A211417	006	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.125MG	A211417	007	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.125MG	A211417	007	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.137MG	A211417	008	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.137MG	A211417	008	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.15MG	A211417	009	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.15MG	A211417	009	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.175MG	A211417	010	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.175MG	A211417	010	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.2MG	A211417	011	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.2MG	A211417	011	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.3MG	A211417	012	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.3MG	A211417	012	Dec 21, 2022	Feb CTEC

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

BX	ALEMBIC	5%	A211469	001	Nov 23, 2018	Mar CTEC
AT	CHARTWELL RX	5%	A208660	001	Jan 05, 2021	Apr CAHN

PATCH; TOPICAL

LIDOCAINE

AB	AVEVA	1.8%	A217221	001	Mar 25, 2025	Mar NFTG
AB	ZTLIDO					
AB	+! SCILEX PHARMS	1.8%	N207962	001	Feb 28, 2018	Mar CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

AP	ANTHEA PHARMA	1%	A219535	001	Apr 02, 2025	Mar NEWA
----	---------------	----	---------	-----	--------------	----------

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

AT	XTTRIUM LABS INC	2%	A087872	001	Nov 18, 1982	Feb CAHN
----	------------------	----	---------	-----	--------------	----------

SOLUTION; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	XTTRIUM LABS INC	4%	A087881	001	Nov 18, 1982	Feb CAHN
----	------------------	----	---------	-----	--------------	----------

LINEZOLID

SOLUTION; INTRAVENOUS

LINEZOLID

AP	NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	Feb CAHN
AP		600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	Feb CAHN

LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS

LIRAGLUTIDE

AP	NANJING KING-FRIEND	18MG/3ML (6MG/ML)	A218115	001	Apr 02, 2025	Mar NEWA
----	---------------------	-------------------	---------	-----	--------------	----------

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	GRANULES	10MG	A218987	001	Jan 29, 2025	Jan NEWA
AB		20MG	A218987	002	Jan 29, 2025	Jan NEWA
AB		30MG	A218987	003	Jan 29, 2025	Jan NEWA
AB		40MG	A218987	004	Jan 29, 2025	Jan NEWA
AB		50MG	A218987	005	Jan 29, 2025	Jan NEWA
AB		60MG	A218987	006	Jan 29, 2025	Jan NEWA
AB		70MG	A218987	007	Jan 29, 2025	Jan NEWA
AB	SANDOZ	20MG	A202836	001	Jul 26, 2024	Jan CMFD
AB		30MG	A202836	002	Jul 26, 2024	Jan CMFD
AB		40MG	A202836	003	Jul 26, 2024	Jan CMFD
AB		50MG	A202836	004	Jul 26, 2024	Jan CMFD
AB		60MG	A202836	005	Jul 26, 2024	Jan CMFD
AB		70MG	A202836	006	Jul 26, 2024	Jan CMFD

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

	@ NORVIUM BIOSCIENCE	450MG	A202219	001	Aug 08, 2012	Mar DISC
AB		450MG	A202219	001	Aug 08, 2012	Feb CAHN

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

ALOMIDE

>D>						
>D>	+! NOVARTIS	EQ 0.1% BASE	N020191	001	Sep 23, 1993	May DISC
>A>	@ +	EQ 0.1% BASE	N020191	001	Sep 23, 1993	May DISC

LOFEXIDINE HYDROCHLORIDE

TABLET; ORAL

LOFEXIDINE HYDROCHLORIDE

AB	MSN	EQ 0.18MG BASE	A218699	001	Feb 24, 2025	Feb NEWA
	LUCEMYRA					
>A> AB	+! BIOCRRX PHARMS	EQ 0.18MG BASE	N209229	001	May 16, 2018	May CAHN
>D> AB	+! USWM	EQ 0.18MG BASE	N209229	001	May 16, 2018	May CAHN

LORAZEPAMINJECTABLE; INJECTION
LORAZEPAM

>A>	@	AVIV PHARMA	1MG/0.5ML	A 074551	003	Sep 12, 1996	May CAHN
	@		2MG/ML	A 074535	001	Sep 12, 1996	Apr CAHN
>A>	@		2MG/ML	A 074551	001	Sep 12, 1996	May CAHN
	@		4MG/ML	A 074535	002	Sep 12, 1996	Apr CAHN
>A>	@		4MG/ML	A 074551	002	Sep 12, 1996	May CAHN
>D>	@	DR REDDYS	1MG/0.5ML	A 074551	003	Sep 12, 1996	May CAHN
>D>	@		2MG/ML	A 074551	001	Sep 12, 1996	May CAHN
>D>	@		4MG/ML	A 074551	002	Sep 12, 1996	May CAHN
	@	HOSPIRA	2MG/ML	A 074282	001	May 27, 1994	Apr DISC
	@		4MG/ML	A 074282	002	May 27, 1994	Apr DISC

LOSARTAN POTASSIUMSUSPENSION; ORAL
ARB LI

+! SCIENTURE 10MG/ML

N218772 001 Mar 13, 2025 Mar NEWA

TABLET; ORAL

LOSARTAN POTASSIUM

@	APOTEX	25MG
@		50MG
@		100MG

A 218551	001	Jun 04, 2024	Jan DISC
A 218551	002	Jun 04, 2024	Jan DISC
A 218551	003	Jun 04, 2024	Jan DISC

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEPREDNOL ETABONATE

>A>	AB	AMNEAL	0.5%	A 217484	001	May 20, 2025	May NEWA
	AB	PADAGIS US	0.5%	A 215204	001	Jan 29, 2025	Jan NEWA

LOVASTATIN

>D> TABLET, EXTENDED RELEASE; ORAL

>D> ALTOPREV

>D>	+	COVIS	20MG	N 021316	002	Jun 26, 2002	May DISC
>A>	@	+	20MG	N 021316	002	Jun 26, 2002	May DISC
>D>	+		40MG	N 021316	003	Jun 26, 2002	May DISC
>A>	@	+	40MG	N 021316	003	Jun 26, 2002	May DISC
>D>	+	!	60MG	N 021316	004	Jun 26, 2002	May DISC
>A>	@	+	60MG	N 021316	004	Jun 26, 2002	May DISC

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB	CHARTWELL RX	20MG	A 212091	001	Dec 28, 2020	Mar CAHN
AB		40MG	A 212091	002	Dec 28, 2020	Mar CAHN
AB		60MG	A 212091	003	Dec 28, 2020	Mar CAHN
AB		80MG	A 212091	004	Dec 28, 2020	Mar CAHN
AB		120MG	A 212091	005	Dec 28, 2020	Mar CAHN
AB	TORRENT	60MG	A 208055	005	Jan 13, 2025	Jan NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

>A>	AP	ASPIRO	1GM/2ML (500MG/ML)	A 219777	001	May 28, 2025	May NFTG
>A>	AP		5GM/10ML (500MG/ML)	A 219777	002	May 28, 2025	May NEWA
>A>	AP		10GM/20ML (500MG/ML)	A 219777	003	May 28, 2025	May NEWA
>A>	AP		25GM/50ML (500MG/ML)	A 219777	004	May 28, 2025	May NFTG
>D>	+	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N 019316	002	Sep 08, 1986	May CFTG
>A>	AP	+	1GM/2ML (500MG/ML)	N 019316	002	Sep 08, 1986	May CFTG
>D>	+		25GM/50ML (500MG/ML)	N 019316	004	Jan 29, 2016	May CFTG
>A>	AP	+	25GM/50ML (500MG/ML)	N 019316	004	Jan 29, 2016	May CFTG

MARALIXIBAT CHLORIDE

TABLET; ORAL

LIVMARLI

+	MIRUM	EQ 10MG BASE	N 219485	001	Apr 10, 2025	Apr NEWA
+		EQ 15MG BASE	N 219485	002	Apr 10, 2025	Apr NEWA
+		EQ 20MG BASE	N 219485	003	Apr 10, 2025	Apr NEWA
+	!	EQ 30MG BASE	N 219485	004	Apr 10, 2025	Apr NEWA

MEROPENEMINJECTABLE; INJECTION
MEROPENEM

AP	!	ACS DOBFAR	500MG/VIAL	A091404	001	Oct 26, 2011	Apr	CHRS
AP	!		1GM/VIAL	A091404	002	Oct 26, 2011	Apr	CHRS
		MERREM IV						
	@ +	PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Apr	DISC
	@ +		1GM/VIAL	N050706	001	Jun 21, 1996	Apr	DISC

MESALAMINEENEMA; RECTAL
MESALAMINE

AB		NOVITIUM PHARMA	4GM/60ML	A215269	001	Apr 16, 2025	Apr	NEWA
		SUPPOSITORY; RECTAL						
		MESALAMINE						
>D>	AB	MYLAN	1GM	A204354	001	Nov 24, 2015	May	CAHN
>A>	AB	NORVIUM BIOSCIENCE	1GM	A204354	001	Nov 24, 2015	May	CAHN
	AB	RISING	1GM	A219028	001	Apr 14, 2025	Apr	NEWA
		TABLET, DELAYED RELEASE; ORAL						
		MESALAMINE						
AB		AMNEAL	800MG	A215067	001	Feb 18, 2025	Feb	NEWA

MESNATABLET; ORAL
MESNA

AB		RICONPHARMA LLC	400MG	A218871	001	Jan 13, 2025	Jan	NFTG
		MESNEX						
AB	+!	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002	Jan	CFTG

METFORMIN HYDROCHLORIDESOLUTION; ORAL
METFORMIN HYDROCHLORIDE

AB		ANNORA PHARMA	500MG/5ML	A215008	001	Mar 13, 2025	Mar	NEWA
AB		BIONPHARMA	500MG/5ML	A219151	001	Apr 14, 2025	Apr	NEWA
AB		VISTAPHARM LLC	500MG/5ML	A212677	001	Aug 19, 2022	Jan	CAHN

TABLET; ORAL
METFORMIN HYDROCHLORIDE

	@	APOTEX	500MG	A075984	001	Apr 23, 2002	Mar	DISC
	@		500MG	A090666	001	Dec 07, 2011	Mar	DISC
	@		850MG	A075984	002	Apr 23, 2002	Mar	DISC
	@		850MG	A090666	002	Dec 07, 2011	Mar	DISC
	@		1GM	A075984	003	Apr 23, 2002	Mar	DISC
	@		1GM	A090666	003	Dec 07, 2011	Mar	DISC
		TABLET, EXTENDED RELEASE; ORAL						
		METFORMIN HYDROCHLORIDE						
AB1		MEDICAP LABS	500MG	A202306	001	Feb 23, 2017	Feb	CAHN
AB			750MG	A202306	002	Feb 23, 2017	Feb	CAHN
>A>	AB2	MPP PHARMA	500MG	A203832	001	Dec 26, 2017	May	CAHN
>A>	AB2		1GM	A203832	002	Dec 26, 2017	May	CAHN
>D>	AB2	NOSTRUM LABS INC	500MG	A203832	001	Dec 26, 2017	May	CAHN
>D>	AB2		1GM	A203832	002	Dec 26, 2017	May	CAHN
	@	SUN PHARM	500MG	A202917	001	Aug 01, 2016	Jan	DISC
	@		1GM	A202917	002	Aug 01, 2016	Jan	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDETABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

>D>	@	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	May	CMFD
>A>	AB		500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	May	CMFD
>D>	@		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	May	CMFD
>A>	AB		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	May	CMFD

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB		DR REDDYS LABS SA	500MG;EQ 5MG BASE	A207678	001	Aug 09, 2023	Jan	CTNA
AB			1GM;EQ 2.5MG BASE	A207678	002	Aug 09, 2023	Jan	CTNA
AB	!		1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Jan	CTNA

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL
JANUMET XR

>D>	+	MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	May CFTG
>A>	AB	+	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	May CFTG
>D>		+	1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	May CFTG
>A>	AB	+	1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	May CFTG
>D>		+!	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	May CFTG
>A>	AB	+!	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	May CFTG
>A>		SITAGLIPTIN AND METFORMIN HYDROCHLORIDE					
>A>	AB	ENDO OPERATIONS	500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	May NFTG
>A>	AB		1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	May NFTG
>A>	AB		1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	May NFTG

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

METHADONE HYDROCHLORIDE

AP		HIKMA	10MG/ML	A218609	001	May 05, 2025	Apr NEWA
		TABLET, FOR SUSPENSION; ORAL					
		METHADONE HYDROCHLORIDE					
AA		VISTAPHARM LLC	40MG	A075082	001	Mar 25, 1998	Jan CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

>D>	AB	+	ESJAY PHARMA	1GM	N017681	001	May DISC
>A>		@ +		1GM	N017681	001	May DISC
		METHENAMINE HIPPURATE					
AB		ZYDUS LIFESCIENCES	1GM	A219661	001	Mar 10, 2025	Feb NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB		AIPING PHARM INC	5MG	A040547	001	Feb 18, 2005	Mar CAHN
AB			10MG	A040547	002	Feb 18, 2005	Mar CAHN
		@	20MG	A040547	004	Feb 18, 2005	Mar CAHN
AB		SQUARE PHARMS PLC	5MG	A218830	001	Feb 05, 2025	Jan NEWA
AB			10MG	A218830	002	Feb 05, 2025	Jan NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

>A>	AA		BOSTAL	500MG	A200958	001	Oct 21, 2011	May CAHN
>A>	AA			750MG	A200958	002	Oct 21, 2011	May CAHN
>A>	AB	!		1GM	A200958	003	Dec 06, 2021	May CAHN
>D>	AA		HANGZHOU BINJIANG	500MG	A200958	001	Oct 21, 2011	May CAHN
>D>	AA			750MG	A200958	002	Oct 21, 2011	May CAHN
>D>	AB	!		1GM	A200958	003	Dec 06, 2021	May CAHN
	AA		POINTVIEW HLDINGS	500MG	A212623	001	Apr 30, 2021	Apr CAHN
	AA			750MG	A212623	002	Apr 30, 2021	Apr CAHN

METHYLENE BLUE

SOLUTION; INTRAVENOUS

METHYLENE BLUE

AP		HIKMA	50MG/10ML (5MG/ML)	A216959	001	Dec 17, 2024	Jan CAHN
AP		MEITHEAL	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan CAHN
AP		NANJING KING-FRIEND	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan NEWA

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

METHYLNALTREXONE BROMIDE

		@	ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Mar DISC
		@		12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Mar DISC
>A>	AP		MYLAN LABS LTD	12MG/0.6ML (12MG/0.6ML)	A208592	001	May 28, 2025	May NFTG
		RELISTOR						
		+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Mar CTEC
		+		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Mar CTEC

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT

+ NEOS THERAPS INC 34.6MG N205489 004 Aug 19, 2024 Apr CMFD

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ESJAY PHARMA 5MG/5ML

A201466 001 Nov 12, 2013 Feb CAHN

@ 10MG/5ML

A201466 002 Nov 12, 2013 Feb CAHN

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ STRIDES PHARMA 2.5MG

A204954 001 Jan 26, 2017 Apr CAHN

@ 5MG

A204954 002 Jan 26, 2017 Apr CAHN

@ 10MG

A204954 003 Jan 26, 2017 Apr CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB HIKMA 80MG/ML

A219145 001 Apr 16, 2025 Apr NEWA

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 25

@ BAUSCH 25MG

A087147 001 Apr DISC

BP 25MG

A087147 001 Mar CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ VISTAPHARM LLC EQ 5MG BASE/5ML

A075051 001 Jan 26, 2001 Jan CAHN

METOPROLOL TARTRATE

SOLUTION;ORAL

LOPRESSOR

+! RUBICON 10MG/ML

N219373 001 Apr 10, 2025 Apr NEWA

TABLET;ORAL

METOPROLOL TARTRATE

AB SCIEGEN PHARMS INC 25MG

A208955 001 Feb 05, 2020 Jan CAHN

AB 50MG

A208955 002 Feb 05, 2020 Jan CAHN

AB 100MG

A208955 003 Feb 05, 2020 Jan CAHN

@ SUN PHARM INDS INC 25MG

A076670 001 Jan 15, 2004 Apr DISC

METRONIDAZOLE

CREAM;TOPICAL

METRONIDAZOLE

BX ZYDUS LIFESCIENCES 0.75%

A217128 001 Apr 21, 2023 Mar CTEC

GEL;VAGINAL

METRONIDAZOLE

@ ENCUBE 1.3%

A216795 001 Mar 18, 2024 Jan DISC

NUVESSA

+! CHEMO RESEARCH SL 1.3%

N205223 001 Mar 24, 2014 Jan CTEC

METYROSINE

CAPSULE;ORAL

METYROSINE

AB CEROVENE INC 250MG

A218620 001 Apr 09, 2025 Mar NEWA

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MICAFUNGIN SODIUM

AP QILU PHARM HAINAN EQ 50MG BASE/VIAL

A219273 001 Apr 03, 2025 Mar NEWA

AP EQ 100MG BASE/VIAL

A219273 002 Apr 03, 2025 Mar NEWA

MIDAZOLAM

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

>A> B BRAUN MEDICAL 50MG/50ML (1MG/ML)

A218454 001 May 01, 2025 May CAHN

>A> 100MG/100ML (1MG/ML)

A218454 002 May 01, 2025 May CAHN

>D> STERINOVA INC 50MG/50ML (1MG/ML)

A218454 001 May 01, 2025 May CAHN

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

		50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	Apr NFTG
>D>		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	May CAHN
		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	Apr NFTG

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

	@	CHARTWELL RX	100MG	A209325	001	Feb 03, 2022	Mar CAHN
AB	@	NAVINTA LLC	100MG	A219111	001	Mar 14, 2025	Mar NEWA
	@	VERANOVA	100MG	A209325	001	Feb 03, 2022	Feb CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

	@	HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Apr DISC
	@		25MG	A205147	002	Oct 03, 2024	Apr DISC
	@		50MG	A205147	003	Oct 03, 2024	Apr DISC
	@		100MG	A205147	004	Oct 03, 2024	Apr DISC
		SAVELLA					
	+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Apr CTEC
	+		25MG	N022256	002	Jan 14, 2009	Apr CTEC
	+		50MG	N022256	003	Jan 14, 2009	Apr CTEC
	+		100MG	N022256	004	Jan 14, 2009	Apr CTEC

MINOCYCLINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMROSI

	+	JOURNEY	EQ 40MG BASE	N219015	001	Nov 01, 2024	Mar CPOT
--	---	---------	--------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

MINOCIN

>D>	AP	+	REMPEX	EQ 100MG BASE/VIAL	N050444	001	May CTEC
>A>		+		EQ 100MG BASE/VIAL	N050444	001	May CTEC

MINOCYCLINE HYDROCHLORIDE

AP		NEXUS	EQ 100MG BASE/VIAL	A214934	001	Oct 24, 2024	Mar CAHN
----	--	-------	--------------------	---------	-----	--------------	----------

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

>D>	AB		APOTEX	25MG	A209434	001	Jan 02, 2025	May DISC
>A>		@		25MG	A209434	001	Jan 02, 2025	May DISC
>D>	AB			50MG	A209434	002	Jan 02, 2025	May DISC
>A>		@		50MG	A209434	002	Jan 02, 2025	May DISC
	AB		SAWAI USA	50MG	A217061	001	May 06, 2025	Apr NEWA

MIRDAMETINIB

CAPSULE;ORAL

GOMEKLI

	+	SPRINGWORKS	1MG	N219389	001	Feb 11, 2025	Feb NEWA
	+		2MG	N219389	002	Feb 11, 2025	Feb NEWA

TABLET, FOR SUSPENSION;ORAL

GOMEKLI

	+	SPRINGWORKS	1MG	N219379	001	Feb 11, 2025	Feb NEWA
--	---	-------------	-----	---------	-----	--------------	----------

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP		ACCORD HLTHCARE	20MG/VIAL	A064144	002	Apr 30, 1998	Apr CMFD
	@		20MG/VIAL	A064144	002	Apr 30, 1998	Jan DISC
AP	!	MEITHEAL	20MG/VIAL	A214505	002	Sep 08, 2022	Jan CHRS

MODAFINIL

TABLET;ORAL

PROVIGIL

AB	+	NUVO PHARMS	100MG	N020717	001	Dec 24, 1998	Jan CAHN
AB	+		200MG	N020717	002	Dec 24, 1998	Jan CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

@	APOTEX INC	7.5MG
@		15MG

A078454	001	Jun 02, 2008	Mar DISC
A078454	002	Jun 02, 2008	Mar DISC

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

@	CHARTWELL MOLECULAR	0.1%
---	---------------------	------

A076591	001	Apr 18, 2007	Feb CAHN
---------	-----	--------------	----------

SPRAY, METERED; NASAL

MOMETASONE FUROATE

>A> AB	NASPRESS	0.05MG/SPRAY
--------	----------	--------------

A211706	001	May 15, 2025	May NEWA
---------	-----	--------------	----------

MORPHINE SULFATE

SOLUTION; ORAL

MORPHINE SULFATE

AA	+	HIKMA	20MG/5ML
	+		20MG/5ML
	@	RHODES PHARMS	10MG/5ML
	@		20MG/5ML
	@		100MG/5ML
	@	SANKALP LIFECARE	10MG/5ML
	@		20MG/5ML
	@		100MG/5ML
AA		WINDER LABS LLC	10MG/5ML
	@		10MG/5ML
AA			20MG/5ML
	@		20MG/5ML
AA			100MG/5ML
	@		100MG/5ML

N022195	002	Mar 17, 2008	Apr CTEC
N022195	002	Mar 17, 2008	Feb CTEC
A206308	001	Jun 22, 2017	Jan DISC
A206420	001	Jul 12, 2016	Jan DISC
A206308	002	Jun 22, 2017	Jan DISC
A201011	001	Feb 05, 2014	Apr CAHN
A201011	002	Feb 05, 2014	Apr CAHN
A201011	003	Oct 06, 2016	Apr CAHN
A211454	001	Feb 12, 2021	Apr CMFD
A211454	001	Feb 12, 2021	Feb DISC
A211454	002	Feb 12, 2021	Apr CMFD
A211454	002	Feb 12, 2021	Feb DISC
A211454	003	Feb 12, 2021	Apr CMFD
A211454	003	Feb 12, 2021	Feb DISC

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

@	NOVEL LABS INC	15MG
@		30MG
@		60MG
@		100MG
@		200MG

A203602	001	Dec 16, 2015	Feb DISC
A203602	002	Dec 16, 2015	Feb DISC
A203602	003	Dec 16, 2015	Feb DISC
A203602	004	Dec 16, 2015	Feb DISC
A203602	005	Dec 16, 2015	Feb DISC

MOTIXAFORTIDE ACETATE

POWDER; SUBCUTANEOUS

APHEXDA

+	!	AYRMID PHARMA	EQ 62MG BASE/VIAL
---	---	---------------	-------------------

N217159	001	Sep 08, 2023	Mar CAHN
---------	-----	--------------	----------

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1		MANKIND PHARMA	EQ 0.5% BASE
	@	NORVIUM BIOSCIENCE	EQ 0.5% BASE

A217988	001	Jan 27, 2025	Jan NEWA
A206447	001	Mar 30, 2020	Feb CAHN

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

>A> AB	ENCUBE	2%
--------	--------	----

A217943	001	May 13, 2025	May NEWA
---------	-----	--------------	----------

MUPIROCIN CALCIUM

CREAM; TOPICAL

MUPIROCIN

BX		ALEMBIC	EQ 2% BASE
----	--	---------	------------

A213053	001	Nov 16, 2021	Mar CTEC
---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

FOR SUSPENSION; ORAL

MYCOPHENOLATE MOFETIL

	@	TEVA PHARMS USA	200MG/ML
AB		VISTAPHARM LLC	200MG/ML

A211272	001	Jan 25, 2022	Apr DISC
A210370	001	Feb 12, 2019	Jan CAHN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE; ORAL
MYCOPHENOLIC SODIUM

AB	FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Jan CAHN
AB		EQ 360MG BASE	A216637	002	May 29, 2024	Jan CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

@	FRESENIUS	EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	Apr DISC
---	-----------	-------------------	---------	-----	--------------	----------

NALBUPHINE HYDROCHLORIDE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
NALBUPHINE

@	ABRAXIS PHARM	10MG/ML (10MG/ML)	A070751	001	Jul 02, 1986	Mar CPOT	
@		10MG/ML	A070751	001	Jul 02, 1986	Mar CDFR	
@		20MG/ML (20MG/ML)	A070752	001	Sep 24, 1986	Mar CPOT	
@		20MG/ML	A070752	001	Sep 24, 1986	Mar CDFR	
@		200MG/10ML (20MG/ML)	A070752	002	Sep 24, 1986	Mar NEWA	
	NALBUPHINE HYDROCHLORIDE						
@	ABBOTT	20MG/ML (20MG/ML)	A070917	001	Feb 03, 1989	Mar CPOT	
@		20MG/ML	A070917	001	Feb 03, 1989	Mar CDFR	
@	ABRAXIS PHARM	100MG/10ML (10MG/ML)	A070751	002	Jul 02, 1986	Mar NEWA	
@	DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	Mar CDFR	
@		20MG/ML	A074471	002	Mar 19, 1998	Mar CDFR	
@		100MG/10ML (10MG/ML)	A074471	001	Mar 19, 1998	Mar CPOT	
@		200MG/10ML (20MG/ML)	A074471	002	Mar 19, 1998	Mar CPOT	
AP	!	HOSPIRA	10MG/ML (10MG/ML)	A070914	001	Feb 03, 1989	Mar CPOT
AP	!		10MG/ML	A070914	001	Feb 03, 1989	Mar CDFR
AP	!		10MG/ML	A070915	001	Feb 03, 1989	Mar CDFR
AP	!		20MG/ML (20MG/ML)	A070916	001	Feb 03, 1989	Mar CPOT
AP	!		20MG/ML	A070916	001	Feb 03, 1989	Mar CDFR
AP	!		20MG/ML	A070918	001	Feb 03, 1989	Mar CDFR
AP	!		100MG/10ML (10MG/ML)	A070915	001	Feb 03, 1989	Mar CPOT
AP	!		200MG/10ML (20MG/ML)	A070918	001	Feb 03, 1989	Mar CPOT
@	IGI LABS INC	10MG/ML (10MG/ML)	A072070	001	Apr 10, 1989	Mar CPOT	
@		10MG/ML	A072070	001	Apr 10, 1989	Mar CDFR	
@		10MG/ML (10MG/ML)	A072071	001	Apr 10, 1989	Mar CPOT	
@		10MG/ML	A072071	001	Apr 10, 1989	Mar CDFR	
@		10MG/ML (10MG/ML)	A072072	001	Apr 10, 1989	Mar CPOT	
@		10MG/ML	A072072	001	Apr 10, 1989	Mar CDFR	
@		20MG/ML (20MG/ML)	A072073	001	Apr 10, 1989	Mar CPOT	
@		20MG/ML	A072073	001	Apr 10, 1989	Mar CDFR	
@		20MG/ML (20MG/ML)	A072074	001	Apr 10, 1989	Mar CPOT	
@		20MG/ML	A072074	001	Apr 10, 1989	Mar CDFR	
@		20MG/ML (20MG/ML)	A072075	001	Apr 10, 1989	Mar CPOT	
@		20MG/ML	A072075	001	Apr 10, 1989	Mar CDFR	
@		100MG/10ML (10MG/ML)	A072070	002	Apr 10, 1989	Mar NEWA	
@		200MG/10ML (20MG/ML)	A072073	002	Apr 10, 1989	Mar NEWA	
@	RISING	10MG/ML	A206506	001	Feb 06, 2019	Mar CDFR	
@		10MG/ML (10MG/ML)	A207595	001	Jan 11, 2019	Mar CPOT	
@		10MG/ML	A207595	001	Jan 11, 2019	Mar CDFR	
@		20MG/ML	A206506	002	Feb 06, 2019	Mar CDFR	
@		20MG/ML (20MG/ML)	A207595	002	Jan 11, 2019	Mar CPOT	
@		20MG/ML	A207595	002	Jan 11, 2019	Mar CDFR	
@		100MG/10ML (10MG/ML)	A206506	001	Feb 06, 2019	Mar CPOT	
@		200MG/10ML (20MG/ML)	A206506	002	Feb 06, 2019	Mar CPOT	
AP	SOMERSET THERAPS LLC	10MG/ML	A216049	001	Sep 19, 2024	Mar CDFR	
AP		10MG/ML (10MG/ML)	A216050	001	Sep 19, 2024	Mar CPOT	
AP		10MG/ML	A216050	001	Sep 19, 2024	Mar CDFR	
AP		20MG/ML	A216049	002	Sep 19, 2024	Mar CDFR	
AP		20MG/ML (20MG/ML)	A216050	002	Sep 19, 2024	Mar CPOT	
AP		20MG/ML	A216050	002	Sep 19, 2024	Mar CDFR	
AP		100MG/10ML (10MG/ML)	A216049	001	Sep 19, 2024	Mar CPOT	
AP		200MG/10ML (20MG/ML)	A216049	002	Sep 19, 2024	Mar CPOT	
	NUBAIN						
@ +	ENDO OPERATIONS	10MG/ML (10MG/ML)	N018024	001		Mar CPOT	
@ +		10MG/ML	N018024	001		Mar CDFR	
@ +		20MG/ML (20MG/ML)	N018024	002	May 27, 1982	Mar CPOT	
@ +		20MG/ML	N018024	002	May 27, 1982	Mar CDFR	
@ +		20MG/2ML (10MG/ML)	N018024	004		Mar NEWA	
@ +		100MG/10ML (10MG/ML)	N018024	003		Mar NEWA	

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
NUBAIN

@ + 200MG/10ML (20MG/ML) N018024 005 Mar 02, 1984 Mar NEWA

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZURNAI (AUTOINJECTOR)

@ + PURDUE PHARMA LP EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML) N218590 001 Aug 07, 2024 Jan DISC

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
NALOXONE HYDROCHLORIDE

>A> AP BAXTER HLTHCARE CORP 1MG/ML A214785 002 Jun 03, 2025 May NEWA
SPRAY;NASAL
KLOXXADO
>D> AB +! HIKMA 8MG/SPRAY N212045 001 Apr 29, 2021 May CTEC
>A> +! 8MG/SPRAY N212045 001 Apr 29, 2021 May CTEC
AB +! 8MG/SPRAY N212045 001 Apr 29, 2021 Apr CFTG
>D> NALOXONE HYDROCHLORIDE
>D> AB PADAGIS ISRAEL 8MG/SPRAY A216719 001 Apr 24, 2025 May DISC
>A> @ 8MG/SPRAY A216719 001 Apr 24, 2025 May DISC
AB 8MG/SPRAY A216719 001 Apr 24, 2025 Apr NFTG

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL
NEBIVOLOL HYDROCHLORIDE

AB MACLEODS PHARMS LTD EQ 2.5MG BASE A212661 001 Jan 28, 2025 Jan NEWA
AB EQ 5MG BASE A212661 002 Jan 28, 2025 Jan NEWA
AB EQ 10MG BASE A212661 003 Jan 28, 2025 Jan NEWA
AB EQ 20MG BASE A212661 004 Jan 28, 2025 Jan NEWA

NEOMYCIN SULFATE

TABLET;ORAL
NEOMYCIN SULFATE

>A> @ AVIV PHARMA 500MG A065468 001 Mar 29, 2010 May CAHN
>D> @ NOSTRUM LABS INC 500MG A065468 001 Mar 29, 2010 May CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

>A> NEOSTIGMINE METHYLSULFATE
>A> AP AVET LIFESCIENCES 5MG/10ML (0.5MG/ML) A208230 001 Nov 25, 2022 May CTNA
>A> AP 10MG/10ML (1MG/ML) A208230 002 Nov 25, 2022 May CTNA
>D> NEOSTIGMINE METHYLSULFATE
>D> AP AVET LIFESCIENCES 5MG/10ML (0.5MG/ML) A208230 001 Nov 25, 2022 May CTNA
>D> AP 10MG/10ML (1MG/ML) A208230 002 Nov 25, 2022 May CTNA

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB ZYDUS PHARMS 500MG A203285 001 Apr 28, 2025 Apr NEWA
AB 750MG A203285 002 Apr 28, 2025 Apr NEWA
AB 1GM A203285 003 Apr 28, 2025 Apr NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION
NICARDIPINE HYDROCHLORIDE

@ AMNEAL 25MG/10ML (2.5MG/ML) A215406 001 Oct 31, 2024 Jan DISC

NILOTINIB D-TARTRATE

CAPSULE;ORAL
NILOTINIB D-TARTRATE

+ CIPLA EQ 50MG BASE N218922 001 Feb 19, 2025 Feb NEWA
+ EQ 150MG BASE N218922 002 Feb 19, 2025 Feb NEWA
+! EQ 200MG BASE N218922 003 Feb 19, 2025 Feb NEWA

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL
NILOTINIB HYDROCHLORIDE

AB APOTEX EQ 50MG BASE A203640 001 Jan 05, 2024 Apr CMFD
AB EQ 150MG BASE A203640 002 Jan 05, 2024 Apr CMFD
AB EQ 200MG BASE A203640 003 Jan 05, 2024 Apr CMFD

CAPSULE;ORAL
TASIGNA

AB	+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr CTEC
AB	+		EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr CTEC
AB	+	!	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr CTEC

NIMODIPINESOLUTION;ORAL
NIMODIPINE

AB		ALKEM LABS LTD	6MG/ML	A213409	001	Jan 22, 2025	Jan NFTG
		NYMALIZE					
AB	+	!	AZURITY	N203340	002	Apr 08, 2020	Jan CFTG

NITAZOXANIDE

TABLET;ORAL

NITAZOXANIDE

AB		ANI PHARMS	500MG	A214844	001	Feb 03, 2025	Apr CAHN
AB		ANNORA PHARMA	500MG	A218701	001	Apr 15, 2025	Apr NEWA
AB	!	RISING	500MG	A213820	001	Nov 27, 2020	Jan CTEC
AB		ZENARA	500MG	A214844	001	Feb 03, 2025	Jan NEWA

NITRIC OXIDE

GAS; INHALATION

NOXIVENT

@		LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr DISC
---	--	-----------------	--------	---------	-----	--------------	----------

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

AB		APPCO	25MG/5ML	A208909	001	Jan 14, 2025	Jan NEWA
AB		STRIDES PHARMA	25MG/5ML	A201355	001	Aug 14, 2013	Apr CAHN

NITROGLYCERIN

OINTMENT;TRANSDERMAL

NITROGLYCERIN

AB		ENCUBE	2%	A218235	001	Apr 15, 2025	Apr NFTG
AB	+	!	FOUGERA PHARMS INC	A087355	001	Jul 08, 1988	Apr CFTG

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP		ASPIRO	EQ 1MG BASE/ML	A219163	001	Jan 31, 2025	Jan NEWA
AP		BIOCON PHARMA	EQ 1MG BASE/ML	A219443	001	Mar 21, 2025	Mar NEWA

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT		AUROBINDO PHARMA	100,000 UNITS/GM	A219527	001	Mar 21, 2025	Mar NEWA
	@	CHARTWELL RX	100,000 UNITS/GM	A065315	001	May 31, 2006	Apr CAHN

SUSPENSION;ORAL

NYSTATIN

AA		XTTRIUM LABS INC	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jan CAHN
----	--	------------------	------------------	---------	-----	--------------	----------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		CHARTWELL RX	100,000 UNITS/GM;0.1%	A208326	001	Oct 26, 2016	Apr CAHN
----	--	--------------	-----------------------	---------	-----	--------------	----------

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

@		AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb DISC
---	--	--------	------	---------	-----	--------------	----------

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

>A>	AP	QILU	10MG/VIAL	A218116	001	May 16, 2025	May NEWA
>A>	AP	UBI	10MG/VIAL	A211072	001	Jun 11, 2025	May NEWA

OLICERIDINE

SOLUTION; INTRAVENOUS

OLINVYK

@ + TREVENA

1MG/ML (1MG/ML)

N210730 001 Oct 30, 2020 Jan DISC

@ +

2MG/2ML (1MG/ML)

N210730 002 Oct 30, 2020 Jan DISC

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

AB JUBILANT GENERICS

5MG

A205482 001 Apr 24, 2017 Mar CMFD

AB

20MG

A205482 002 Apr 24, 2017 Mar CMFD

AB

40MG

A205482 003 Apr 24, 2017 Mar CMFD

OMAVELOXOLONE

CAPSULE; ORAL

SKYCLARYS

+! BIOGEN US

50MG

N216718 001 Feb 28, 2023 Jan CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZA

AB +! WAYLIS THERAP

1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

N021654 001 Nov 10, 2004 Feb CAHN

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

>D> @ IPCA LABS LTD

4MG

A209389 001 Oct 30, 2023 May CMFD

>A> AB

4MG

A209389 001 Oct 30, 2023 May CMFD

>D> @

8MG

A209389 002 Oct 30, 2023 May CMFD

>A> AB

8MG

A209389 002 Oct 30, 2023 May CMFD

@ NORVIUM BIOSCIENCE

4MG

A078139 001 Jun 25, 2007 Feb CAHN

@

8MG

A078139 002 Jun 25, 2007 Feb CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

@ HIKMA FARMACEUTICA

EQ 2MG BASE/ML

A076781 001 Dec 26, 2006 Mar DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@ APOTEX

EQ 4MG BASE

A077306 001 Jun 25, 2007 Mar DISC

@

EQ 8MG BASE

A077306 002 Jun 25, 2007 Mar DISC

>D> @

EQ 4MG BASE

A203761 001 Jan 23, 2014 May CMFD

>A> AB

EQ 4MG BASE

A203761 001 Jan 23, 2014 May CMFD

>D> @

EQ 8MG BASE

A203761 002 Jan 23, 2014 May CMFD

>A> AB

EQ 8MG BASE

A203761 002 Jan 23, 2014 May CMFD

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

AB ZHEJIANG POLY PHARM

EQ 75MG BASE

A218009 001 Nov 24, 2023 Mar CAHN

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

AB JUBILANT GENERICS

EQ 6MG BASE/ML

A213695 001 Mar 03, 2025 Feb NEWA

OSPEMIFENE

TABLET; ORAL

OSPEMIFENE

@ HETERO LABS LTD V

60MG

A215574 001 Feb 13, 2024 Apr DISC

OSPHERA

+! DUCHESNAY

60MG

N203505 001 Feb 26, 2013 Apr CTEC

OXALIPLATIN

INJECTABLE; INTRAVENOUS

OXALIPLATIN

AP HETERO LABS LTD VI

50MG/10ML (5MG/ML)

A217925 001 Jan 27, 2025 Jan NEWA

AP

100MG/20ML (5MG/ML)

A217925 002 Jan 27, 2025 Jan NEWA

OXAZEPAMCAPSULE;ORAL
OXAZEPAM

AB	LEADING	10MG	A218261	001	Mar 03, 2025	Feb NEWA
AB		15MG	A218261	002	Mar 03, 2025	Feb NEWA
AB		30MG	A218261	003	Mar 03, 2025	Feb NEWA

OXCARBAZEPINETABLET, EXTENDED RELEASE;ORAL
OXCARBAZEPINE

AB	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Apr CMFD
AB		300MG	A217659	002	Feb 22, 2024	Apr CMFD
AB		600MG	A217659	003	Feb 22, 2024	Apr CMFD
>D> AB	AUROBINDO PHARMA LTD	150MG	A219241	001	Apr 30, 2025	May DISC
>A> @		150MG	A219241	001	Apr 30, 2025	May DISC
AB		150MG	A219241	001	Apr 30, 2025	Apr NEWA
>D> AB		300MG	A219241	002	Apr 30, 2025	May DISC
>A> @		300MG	A219241	002	Apr 30, 2025	May DISC
AB		300MG	A219241	002	Apr 30, 2025	Apr NEWA
>D> AB		600MG	A219241	003	Apr 30, 2025	May DISC
>A> @		600MG	A219241	003	Apr 30, 2025	May DISC
AB		600MG	A219241	003	Apr 30, 2025	Apr NEWA
AB	RICONPHARMA LLC	150MG	A215796	001	Nov 22, 2024	Apr CMFD
AB		300MG	A215796	002	Nov 22, 2024	Apr CMFD
AB		600MG	A215796	003	Nov 22, 2024	Apr CMFD

OXYCODONE HYDROCHLORIDESOLUTION;ORAL
OXYCODONE HYDROCHLORIDE

@	PHARM ASSOC	100MG/5ML	A206822	001	Aug 15, 2017	Apr DISC
@	VISTAPHARM LLC	100MG/5ML	A202537	001	Jul 30, 2012	Jan CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

@	NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017	Feb DISC
@		10MG	A204021	002	Jun 12, 2017	Feb DISC
@		15MG	A204021	003	Jun 12, 2017	Feb DISC
@		20MG	A204021	004	Jun 12, 2017	Feb DISC
@		30MG	A204021	005	Jun 12, 2017	Feb DISC

PACLITAXELPOWDER;INTRAVENOUS
PACLITAXEL

AB	CIPLA	100MG/VIAL	A209657	001	Apr 10, 2025	Mar NEWA
>A> AB	SHUANGCHENG	100MG/VIAL	A216355	001	May 15, 2025	May NEWA

PALBOCICLIB

TABLET;ORAL

PALBOCICLIB

@	ZYDUS LIFESCIENCES	75MG	A215570	001	Jun 05, 2024	Apr CAHN
@		100MG	A215570	002	Jun 05, 2024	Apr CAHN
@		125MG	A215570	003	Jun 05, 2024	Apr CAHN

PALIPERIDONETABLET, EXTENDED RELEASE;ORAL
PALIPERIDONE

AB	DR REDDYS	3MG	A205559	001	Feb 19, 2025	Feb NEWA
AB		6MG	A205559	002	Feb 19, 2025	Feb NEWA
AB		9MG	A205559	003	Feb 19, 2025	Feb NEWA

PANTOPRAZOLE SODIUMFOR SUSPENSION, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 40MG BASE	A217923	001	Mar 31, 2025	Mar NEWA
AB	CIPLA	EQ 40MG BASE	A217458	001	Mar 31, 2025	Mar NEWA

INJECTABLE;INTRAVENOUS

PANTOPRAZOLE SODIUM

AP	ALEMBIC	EQ 40MG BASE/VIAL	A219230	001	Mar 31, 2025	Mar NEWA
>A> AP	DEVA HOLDING AS	EQ 40MG BASE/VIAL	A215074	001	May 16, 2025	May NEWA

POWDER;INTRAVENOUS

PANTOPRAZOLE SODIUM

>D> @	FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	May CMFD
-------	--------------------	-------------------	---------	-----	--------------	----------

POWDER; INTRAVENOUS
PANTOPRAZOLE SODIUM

>A>	AP		EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	May CMFD
		@	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Feb DISC
>D>		+! HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	May CTEC
>A>	AP	+!	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	May CTEC
		+!	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Feb CTEC

TABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

AB		GRAVITI PHARMS	EQ 20MG BASE	A219087	001	Jan 16, 2025	Jan NEWA
AB			EQ 40MG BASE	A219087	002	Jan 16, 2025	Jan NEWA
		@ INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Jan DISC

PARICALCITOLCAPSULE; ORAL
PARICALCITOL

AB		CHARTWELL RX	1MCG	A091412	001	Jun 24, 2014	Apr CAHN
AB			2MCG	A091412	002	Jun 24, 2014	Apr CAHN
AB			4MCG	A091412	003	Jun 24, 2014	Apr CAHN

SOLUTION; INTRAVENOUS
PARICALCITOL

AP		CAPLIN	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr CAHN
AP			0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr CAHN
AP			0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr CAHN

PEMETREXED DISODIUMPOWDER; INTRAVENOUS
PEMETREXED DISODIUM

>D>	AP	BAXTER HLTHCARE CORP	EQ 100MG BASE/VIAL	A214436	001	Aug 18, 2022	May DISC
>A>		@	EQ 100MG BASE/VIAL	A214436	001	Aug 18, 2022	May DISC
>D>	AP		EQ 500MG BASE/VIAL	A214436	002	Aug 18, 2022	May DISC
>A>		@	EQ 500MG BASE/VIAL	A214436	002	Aug 18, 2022	May DISC

PENCICLOVIRCREAM; TOPICAL
PENCICLOVIR

BX		TORRENT	1%	A216981	001	Aug 07, 2023	Mar CTEC
----	--	---------	----	---------	-----	--------------	----------

PERAMPANELTABLET; ORAL
FYCOMPA

>D>		+ CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	May CFTG
>A>	AB	+	2MG	N202834	001	Oct 22, 2012	May CFTG
>D>		+	4MG	N202834	002	Oct 22, 2012	May CFTG
>A>	AB	+	4MG	N202834	002	Oct 22, 2012	May CFTG
>D>		+	6MG	N202834	003	Oct 22, 2012	May CFTG
>A>	AB	+	6MG	N202834	003	Oct 22, 2012	May CFTG
>D>		+	8MG	N202834	004	Oct 22, 2012	May CFTG
>A>	AB	+	8MG	N202834	004	Oct 22, 2012	May CFTG
>D>		+	10MG	N202834	005	Oct 22, 2012	May CFTG
>A>	AB	+	10MG	N202834	005	Oct 22, 2012	May CFTG
>D>		+!	12MG	N202834	006	Oct 22, 2012	May CFTG
>A>	AB	+!	12MG	N202834	006	Oct 22, 2012	May CFTG

PERAMPANEL

>D>	AB	TEVA PHARMS USA INC	2MG	A209801	001	Jun 08, 2021	May NFTG
>A>	AB		2MG	A209801	001	May 23, 2025	May NFTG
>D>	AB		4MG	A209801	002	Jun 08, 2021	May NFTG
>A>	AB		4MG	A209801	002	May 23, 2025	May NFTG
>D>	AB		6MG	A209801	003	Jun 08, 2021	May NFTG
>A>	AB		6MG	A209801	003	May 23, 2025	May NFTG
>D>	AB		8MG	A209801	004	Jun 08, 2021	May NFTG
>A>	AB		8MG	A209801	004	May 23, 2025	May NFTG
>D>	AB		10MG	A209801	005	Jun 08, 2021	May NFTG
>A>	AB		10MG	A209801	005	May 23, 2025	May NFTG
>D>	AB		12MG	A209801	006	Jun 08, 2021	May NFTG
>A>	AB		12MG	A209801	006	May 23, 2025	May NFTG

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB	JUBILANT GENERICS	2MG	A213694	001	Mar 18, 2025	Mar NEWA
AB		4MG	A213694	002	Mar 18, 2025	Mar NEWA
AB		8MG	A213694	003	Mar 18, 2025	Mar NEWA
AB		16MG	A213694	004	Mar 18, 2025	Mar NEWA

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

PHENDIMETRAZINE TARTRATE

>A>	+	ACERTIS PHARMS	105MG	N018074	001	May CAHN
>D>	+	VIRTUS	105MG	N018074	001	May CAHN

TABLET; ORAL

BONTRIL PDM

AA	+	BAUSCH	35MG	A085272	001	Mar CAHN
		PHENDIMETRAZINE TARTRATE				
>A>	AA	ACERTIS PHARMS	35MG	A085588	001	May CAHN
>A>	@	MPP PHARMA	35MG	A203600	001	Dec 27, 2017 May CAHN
>D>	@	NOSTRUM LABS INC	35MG	A203600	001	Dec 27, 2017 May CAHN
>D>	AA	VIRTUS	35MG	A085588	001	May CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

BIORPHEN

AP	+	DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019 Feb CFTG
		PHENYLEPHRINE HYDROCHLORIDE				
AP		SOMERSET THERAPS LLC	0.5MG/5ML (0.1MG/ML)	A215617	001	Feb 14, 2025 Feb NFTG
		PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE				
>A>	+	SINTETICA SA	20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025 May NEWA

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

@ VISTAPHARM LLC

@

125MG/5ML

125MG/5ML

A040342	001	Jan 31, 2001	Jan CAHN
A040342	002	Aug 18, 2005	Jan CAHN

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

AB1	CAPLIN	10MG/ML	A219212	001	Apr 17, 2025	Apr NEWA
	TABLET; ORAL					
	PHYTONADIONE					
	@	HIKMA	5MG	A212112	001	Dec 19, 2024 Feb DISC

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

AB	AMNEAL	1.25%	A217733	001	Apr 28, 2025	Apr NFTG
	VUITY					
AB	+	ABBVIE	1.25%	N214028	001	Oct 28, 2021 Apr CFTG

PINDOLOL

TABLET; ORAL

PINDOLOL

>A>	AB	MPP PHARMA	5MG	A205415	001	Jan 13, 2016 May CAHN
>A>	AB		10MG	A205415	002	Jan 13, 2016 May CAHN
>D>	AB	NOSTRUM LABS INC	5MG	A205415	001	Jan 13, 2016 May CAHN
>D>	AB		10MG	A205415	002	Jan 13, 2016 May CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

>A>	@	AVIV PHARMA	EQ 15MG BASE	A078472	001	Feb 13, 2013 May CAHN
>A>	@		EQ 30MG BASE	A078472	002	Feb 13, 2013 May CAHN
>A>	@		EQ 45MG BASE	A078472	003	Feb 13, 2013 May CAHN
>D>	@	NOSTRUM LABS INC	EQ 15MG BASE	A078472	001	Feb 13, 2013 May CAHN
>D>	@		EQ 30MG BASE	A078472	002	Feb 13, 2013 May CAHN
>D>	@		EQ 45MG BASE	A078472	003	Feb 13, 2013 May CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

POWDER; INTRAVENOUS

PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

+	!	B BRAUN MEDICAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N206056	001	Apr 03, 2025	Apr NEWA
+	!		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N206056	002	Apr 03, 2025	Apr NEWA
+	!		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N206056	003	Apr 03, 2025	Apr NEWA

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB		SOLIS PHARMS	10MG	A074118	002	Jun 15, 1993	Apr CAHN
AB			20MG	A074118	001	Jun 15, 1993	Apr CAHN

PITOLISANT HYDROCHLORIDE

TABLET; ORAL

WAKIX

+		HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Feb CAHN
+	!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Feb CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

@		SOLIS PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BO T;11.2GM/BOT	A202060	001	Mar 08, 2017	Apr CAHN
---	--	--------------	--	---------	-----	--------------	----------

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

@		APOTEX	1MG	A210164	001	Jun 11, 2024	Jan DISC
@			2MG	A210164	002	Jun 11, 2024	Jan DISC
@			3MG	A210164	003	Jun 11, 2024	Jan DISC
@			4MG	A210164	004	Jun 11, 2024	Jan DISC
@		HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Apr DISC
@			2MG	A210236	002	Sep 26, 2024	Apr DISC
@			3MG	A210236	003	Sep 26, 2024	Apr DISC
@			4MG	A210236	004	Sep 26, 2024	Apr DISC
		POMALYST					
+		BRISTOL	1MG	N204026	001	Feb 08, 2013	Apr CTEC
+			2MG	N204026	002	Feb 08, 2013	Apr CTEC
+			3MG	N204026	003	Feb 08, 2013	Apr CTEC
+	!		4MG	N204026	004	Feb 08, 2013	Apr CTEC

POSACONAZOLE

TABLET, DELAYED RELEASE; ORAL

POSACONAZOLE

AB		MSN	100MG	A218434	001	Feb 24, 2025	Feb NEWA
AB		QILU PHARM HAINAN	100MG	A217720	001	Apr 23, 2025	Apr NEWA

POTASSIUM CHLORIDE

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

AA		AJENAT PHARMS	20MEQ	A212183	001	May 06, 2019	Jan CAHN
AA	+	!	GENUS	20MEQ	N208019	001	Aug 19, 2015
	@	+		40MEQ	N208019	003	Aug 25, 2023

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

AP		NEXUS	2MEQ/ML	A217704	001	Aug 14, 2023	Mar CAHN
----	--	-------	---------	---------	-----	--------------	----------

SOLUTION; ORAL

POTASSIUM CHLORIDE

AA		AJENAT PHARMS	20MEQ/15ML	A216156	001	Mar 07, 2023	Jan CAHN
AA			40MEQ/15ML	A216156	002	Mar 07, 2023	Jan CAHN
AA		ASCENT PHARMS INC	20MEQ/15ML	A211992	001	Apr 09, 2025	Mar NEWA
AA			40MEQ/15ML	A211992	002	Apr 09, 2025	Mar NEWA

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB1		GUANGZHOU NOVAKEN	10MEQ	A214395	001	Jan 28, 2021	Apr CAHN
AB1			20MEQ	A214395	002	Jan 28, 2021	Apr CAHN
>D>	AB2	MYLAN	8MEQ	A204662	001	Aug 21, 2014	May CAHN
>D>	AB2		10MEQ	A204662	002	Aug 21, 2014	May CAHN

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

>A>	AB2	NORVIUM BIOSCIENCE	8MEQ	A204662	001	Aug 21, 2014	May CAHN
>A>	AB2		10MEQ	A204662	002	Aug 21, 2014	May CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D>	AP	ICU MEDICAL INC	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	May CAHN
>A>	AP	OTSUKA ICU MEDCL	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	May CAHN

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

AP	CIPLA	1.18GM/5ML (236MG/ML) ;	A217892	001	Jan 24, 2025	Jan NEWA
		1.12GM/5ML (224MG/ML)				
AP		3.54GM/15ML (236MG/ML) ;	A217892	002	Jan 24, 2025	Jan NEWA
		3.36GM/15ML (224MG/ML)				
AP		11.8GM/50ML (236MG/ML) ;	A217892	003	Jan 24, 2025	Jan NEWA
		11.2GM/50ML (224MG/ML)				
>A>	POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE					
>A>	+! FRESENIUS KABI USA	1.18GM/100ML (11.8MG/ML) ;	N212832	004	May 09, 2025	May NEWA
		1.12GM/100ML (11.2MG/ML)				
>A>	+!	1.18GM/250ML (4.72MG/ML) ;	N212832	005	May 09, 2025	May NEWA
		1.12GM/250ML (4.48MG/ML)				

PRALATREXATE

SOLUTION;INTRAVENOUS

FOLOTYN

AP	+	ACROTECH BIOPHARMA	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Feb CFTG
AP	+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Feb CFTG

PRALATREXATE

AP	DR REDDYS	20MG/ML (20MG/ML)	A206183	001	Mar 10, 2025	Feb NFTG
AP		40MG/2ML (20MG/ML)	A206183	002	Mar 10, 2025	Feb NFTG

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>A>	@	AVIV PHARMA	0.125MG	A091450	001	Oct 08, 2010	May CAHN
>A>	@		0.25MG	A091450	002	Oct 08, 2010	May CAHN
>A>	@		0.5MG	A091450	003	Oct 08, 2010	May CAHN
>A>	@		1MG	A091450	004	Oct 08, 2010	May CAHN
>A>	@		1.5MG	A091450	005	Oct 08, 2010	May CAHN
>D>	@	NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010	May CAHN
>D>	@		0.25MG	A091450	002	Oct 08, 2010	May CAHN
>D>	@		0.5MG	A091450	003	Oct 08, 2010	May CAHN
>D>	@		1MG	A091450	004	Oct 08, 2010	May CAHN
>D>	@		1.5MG	A091450	005	Oct 08, 2010	May CAHN

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

PREDNISOLONE ACETATE

>A>	AB	AMNEAL	1%	A218256	001	Jun 11, 2025	May NEWA
-----	----	--------	----	---------	-----	--------------	----------

PREDNISONE

TABLET;ORAL

PREDNISONE

	@	AIPING PHARM INC	5MG	A080336	002		Jan CAHN
AB	+!	HIKMA	1MG	A080352	002	Apr 22, 1982	Apr CMS1
AB	+!		2.5MG	A080352	003	Apr 22, 1982	Apr CMS1
AB	+!		10MG	A080352	004		Apr CMS1
AB	+!		20MG	A080352	005		Apr CMS1
AB	+!		50MG	A080352	006		Apr CMS1
AB		POINTVIEW HLDINGS	5MG	A212629	001	Dec 05, 2023	Apr CAHN
AB			10MG	A212629	002	Dec 05, 2023	Apr CAHN
AB			20MG	A212629	003	Dec 05, 2023	Apr CAHN

PREGABALIN

CAPSULE;ORAL

PREGABALIN

@	ACTAVIS ELIZABETH	25MG	A091025	001	Jul 09, 2020	Apr DISC
@		50MG	A091025	002	Jul 09, 2020	Apr DISC
@		75MG	A091025	003	Jul 09, 2020	Apr DISC

CAPSULE; ORAL
PREGABALIN

	@		100MG	A091025	004	Jul 09, 2020	Apr	DISC
	@		150MG	A091025	005	Jul 09, 2020	Apr	DISC
	@		200MG	A091025	006	Jul 09, 2020	Apr	DISC
	@		225MG	A091025	007	Jul 09, 2020	Apr	DISC
	@		300MG	A091025	008	Jul 09, 2020	Apr	DISC
	@	APOTEX	25MG	A211685	001	Jul 07, 2021	Apr	DISC
	@		50MG	A211685	002	Jul 07, 2021	Apr	DISC
	@		75MG	A211685	003	Jul 07, 2021	Apr	DISC
	@		100MG	A211685	004	Jul 07, 2021	Apr	DISC
	@		150MG	A211685	005	Jul 07, 2021	Apr	DISC
	@		200MG	A211685	006	Jul 07, 2021	Apr	DISC
	@		225MG	A211685	007	Jul 07, 2021	Apr	DISC
	@		300MG	A211685	008	Jul 07, 2021	Apr	DISC
AB		HLTHCARE	25MG	A091222	001	Feb 21, 2025	Feb	NEWA
AB			50MG	A091222	002	Feb 21, 2025	Feb	NEWA
AB			75MG	A091222	003	Feb 21, 2025	Feb	NEWA
AB			100MG	A091222	004	Feb 21, 2025	Feb	NEWA
AB			150MG	A091222	005	Feb 21, 2025	Feb	NEWA
AB			200MG	A091222	006	Feb 21, 2025	Feb	NEWA
AB			225MG	A091222	007	Feb 21, 2025	Feb	NEWA
AB			300MG	A091222	008	Feb 21, 2025	Feb	NEWA
>A>	AB	JUBILANT GENERICS	25MG	A209530	001	May 20, 2025	May	NEWA
>A>	AB		50MG	A209530	002	May 20, 2025	May	NEWA
>A>	AB		75MG	A209530	003	May 20, 2025	May	NEWA
>A>	AB		100MG	A209530	004	May 20, 2025	May	NEWA
>A>	AB		150MG	A209530	005	May 20, 2025	May	NEWA
>A>	AB		200MG	A209530	006	May 20, 2025	May	NEWA
>A>	AB		225MG	A209530	007	May 20, 2025	May	NEWA
>A>	AB		300MG	A209530	008	May 20, 2025	May	NEWA
AB		TORRENT	25MG	A206942	001	Feb 21, 2025	Feb	NEWA
AB			50MG	A206942	002	Feb 21, 2025	Feb	NEWA
AB			75MG	A206942	003	Feb 21, 2025	Feb	NEWA
AB			100MG	A206942	004	Feb 21, 2025	Feb	NEWA
AB			150MG	A206942	005	Feb 21, 2025	Feb	NEWA
AB			200MG	A206942	006	Feb 21, 2025	Feb	NEWA
AB			225MG	A206942	007	Feb 21, 2025	Feb	NEWA
AB			300MG	A206942	008	Feb 21, 2025	Feb	NEWA
TABLET, EXTENDED RELEASE;ORAL								
PREGABALIN								
	@	ALVOGEN	82.5MG	A211593	001	Apr 13, 2021	Feb	DISC
	@		165MG	A211593	002	Apr 13, 2021	Feb	DISC
	@		330MG	A211593	003	Apr 13, 2021	Feb	DISC
	@	APOTEX	165MG	A213313	001	Apr 13, 2021	Jan	DISC
	@		330MG	A213313	002	Apr 13, 2021	Jan	DISC
AB		HQ PHARMA	330MG	A217857	001	Jan 28, 2025	Jan	NEWA

PRIMIDONE

TABLET; ORAL

PRIMIDONE

@	CHARTWELL RX	50MG	A040862	001	Oct 03, 2008	Apr	CAHN
@		250MG	A040862	002	Oct 03, 2008	Apr	CAHN

PROBENECID; SULOPENEM ETZADROXIL

TABLET; ORAL

ORLYNVAH

@ +	ITERUM THERAP	500MG; 500MG	N213972	001	Oct 25, 2024	Apr	DISC
-----	---------------	--------------	---------	-----	--------------	-----	------

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A218674	001	Feb 04, 2025	Jan	NEWA
AP		500MG/ML	A218674	002	Feb 04, 2025	Jan	NEWA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

@ +	GLAXOSMITHKLINE	2.5MG	N011127	003		Mar	CRLD
@ +		5MG	N011127	001		Mar	CMS1
@ +		5MG	N011127	001		Mar	CRLD
@ +		25MG	N011127	002		Mar	CMS1
@ +		25MG	N011127	002		Mar	CRLD

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

@ NEXUS EQ 5MG BASE/ML A204860 001 Feb 15, 2019 Apr DISC

PROCHLORPERAZINE MALEATE

TABLET;ORAL
PROCHLORPERAZINE MALEATE

>A> AB CEROVENE INC EQ 5MG BASE A217847 001 May 19, 2025 May NEWA
>A> AB EQ 10MG BASE A217847 002 May 19, 2025 May NEWA

PROGESTERONE

CAPSULE;ORAL
PROMETRIUM

>A> AB + ACERTIS PHARMS 100MG N019781 001 May 14, 1998 May CAHN
>A> AB +! 200MG N019781 002 Oct 15, 1999 May CAHN
>A> @ 300MG N019781 003 Oct 15, 1999 May CAHN
>D> AB + VIRTUS 100MG N019781 001 May 14, 1998 May CAHN
>D> AB +! 200MG N019781 002 Oct 15, 1999 May CAHN
>D> @ 300MG N019781 003 Oct 15, 1999 May CAHN

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE

AA STRIDES PHARMA 6.25MG/5ML A040891 001 Mar 13, 2009 Apr CAHN
AA +! XTTRIUM LABS INC 6.25MG/5ML A087953 001 Nov 15, 1982 Feb CAHN

PROPACARCAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
PROPACARCAINE HYDROCHLORIDE

>A> AT MANKIND PHARMA 0.5% A219136 001 May 21, 2025 May NEWA

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL
PROTRIPTYLINE HYDROCHLORIDE

AB ! EPIC PHARMA LLC 10MG A202220 002 Nov 19, 2012 Apr CHRS
@ HIKMA 5MG A078913 001 Sep 16, 2008 Apr DISC
@ 10MG A078913 002 Sep 16, 2008 Apr DISC

PYRIMETHAMINE

TABLET;ORAL
PYRIMETHAMINE

>D> AB ALVOGEN 25MG A211271 001 Jul 27, 2021 May DISC
>A> @ 25MG A211271 001 Jul 27, 2021 May DISC

QUETIAPINE FUMARATE

TABLET;ORAL
QUETIAPINE FUMARATE

AB GRAVITI PHARMS EQ 25MG BASE A077380 001 Mar 27, 2012 Feb CAHN
AB EQ 50MG BASE A077380 002 Mar 27, 2012 Feb CAHN
AB EQ 100MG BASE A077380 003 Mar 27, 2012 Feb CAHN
AB EQ 150MG BASE A077380 004 Mar 27, 2012 Feb CAHN
AB EQ 200MG BASE A077380 005 Mar 27, 2012 Feb CAHN
AB EQ 300MG BASE A077380 006 Mar 27, 2012 Feb CAHN
AB EQ 400MG BASE A077380 007 Mar 27, 2012 Feb CAHN

SEROQUEL

AB +! CHEPLAPHARM EQ 25MG BASE N020639 001 Sep 26, 1997 Mar CAHN
AB + EQ 50MG BASE N020639 007 Oct 04, 2005 Mar CAHN
AB + EQ 100MG BASE N020639 002 Sep 26, 1997 Mar CAHN
@ + EQ 150MG BASE N020639 004 Dec 20, 1998 Mar CAHN
AB + EQ 200MG BASE N020639 003 Sep 26, 1997 Mar CAHN
AB +! EQ 300MG BASE N020639 005 Jul 26, 2000 Mar CAHN
AB + EQ 400MG BASE N020639 006 Oct 04, 2005 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

AB MEDICAP LABS EQ 50MG BASE A202939 001 May 09, 2017 Feb CAHN
AB EQ 150MG BASE A202939 002 May 09, 2017 Feb CAHN
AB EQ 200MG BASE A202939 003 May 09, 2017 Feb CAHN
AB EQ 300MG BASE A202939 004 May 09, 2017 Feb CAHN
AB EQ 400MG BASE A202939 005 May 09, 2017 Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
SEROQUEL XR

AB	+	CHEPLAPHARM	EQ 50MG BASE	N022047	001	May 17, 2007	Mar CAHN
AB	+		EQ 150MG BASE	N022047	005	Aug 11, 2008	Mar CAHN
AB	+	!	EQ 200MG BASE	N022047	002	May 17, 2007	Mar CAHN
AB	+		EQ 300MG BASE	N022047	003	May 17, 2007	Mar CAHN
AB	+		EQ 400MG BASE	N022047	004	May 17, 2007	Mar CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL

	ISENTRESS							
	+!	MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jan	CTEC
	ISENTRESS HD							
AB	+!	MSD SUB MERCK	EQ 600MG BASE	N022145	002	May 26, 2017	Apr	CFTG
	RALTEGRAVIR POTASSIUM							
	@	HETERO LABS LTD III	EQ 400MG BASE	A203540	001	Dec 19, 2024	Jan	DISC
AB		LUPIN LTD	EQ 600MG BASE	A217990	001	May 06, 2025	Apr	NFTG

RAMELTEON

TABLET;ORAL

		RAMELTEON						
AB			APPCO	8MG	A213815	001	Oct 26, 2020	Mar CAHN
BX			AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Mar CTEC
BX			I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar CTEC
BX			XIROMED	8MG	A216209	001	Nov 25, 2022	Mar CTEC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

		RANITIDINE HYDROCHLORIDE						
	@		APOTEX	EQ 150MG BASE	A074680	001	Sep 12, 1997	Mar DISC
	@			EQ 300MG BASE	A074680	002	Sep 12, 1997	Mar DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

		RANOLAZINE						
AB			ARTHUR GRP	500MG	A212781	001	Mar 23, 2020	Jan CAHN
AB				1GM	A212781	002	Mar 23, 2020	Jan CAHN
AB	!		CADILA	1GM	A210188	002	Aug 19, 2019	Mar CHRS
AB			JUBILANT GENERICS	500MG	A211361	001	Apr 15, 2025	Apr NEWA
AB				1GM	A211361	002	Apr 15, 2025	Apr NEWA
	@		SUN PHARM	500MG	A211707	001	May 28, 2019	Mar DISC
	@			1GM	A211707	002	May 28, 2019	Mar DISC
AB			TORRENT	500MG	A210407	001	Feb 04, 2025	Jan NEWA
AB				1GM	A210407	002	Feb 04, 2025	Jan NEWA

RASAGILINE MESYLATE

TABLET;ORAL

		RASAGILINE MESYLATE						
	@		CARNEGIE	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Apr CAHN
	@			EQ 1MG BASE	A201942	002	Nov 18, 2021	Apr CAHN
AB			TORRENT	EQ 0.5MG BASE	A210150	001	May 05, 2025	Apr NEWA
AB				EQ 1MG BASE	A210150	002	May 05, 2025	Apr NEWA

REGORAFENIB

TABLET;ORAL

		REGORAFENIB						
AB			ACTAVIS LABS FL	40MG	A209728	001	Jan 13, 2025	Jan NFTG
			STIVARGA					
AB	+	!	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012	Jan CFTG

REPAGLINIDE

TABLET;ORAL

		REPAGLINIDE						
	@		SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Feb DISC
	@			2MG	A077571	003	Jul 11, 2013	Feb DISC

RIFAMPIN

CAPSULE;ORAL

		RIFADIN						
	@	+	SANOFI AVENTIS US	150MG	N050420	002		Apr CMS1

RILPIVIRINE HYDROCHLORIDE

TABLET, FOR SUSPENSION;ORAL
EDURANT PED

>D>	@ +	JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	May CMFD
>A>	+!		EQ 2.5MG BASE	N219016	001	Mar 15, 2024	May CMFD

RILUZOLE

TABLET;ORAL
RILUZOLE

AB		NORVIUM BIOSCIENCE	50MG	A203042	001	Jul 01, 2013	Feb CAHN
----	--	--------------------	------	---------	-----	--------------	----------

RISDIPLAM

TABLET;ORAL
EVRYSDI

	+!	GENENTECH INC	5MG	N219285	001	Feb 11, 2025	Feb NEWA
--	----	---------------	-----	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL
RISEDRONATE SODIUM

@		SUN PHARM	35MG	A203925	001	Jul 09, 2019	Apr DISC
---	--	-----------	------	---------	-----	--------------	----------

RISPERIDONE

SOLUTION;ORAL
RISPERIDONE

@		APOZEAL PHARMS	1MG/ML	A078909	001	Jul 29, 2009	Apr CAHN
@		LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	Feb DISC

TABLET;ORAL

RISPERIDONE

@		APOTEX INC	0.25MG	A077953	001	Sep 15, 2008	Mar DISC
@			0.5MG	A077953	002	Sep 15, 2008	Mar DISC
@			1MG	A077953	003	Sep 15, 2008	Mar DISC
@			2MG	A077953	004	Sep 15, 2008	Mar DISC
@			3MG	A077953	005	Sep 15, 2008	Mar DISC
@			4MG	A077953	006	Sep 15, 2008	Mar DISC

RIVAROXABAN

TABLET;ORAL
RIVAROXABAN

>A>	AB		ALEMBIC	2.5MG	A210301	001	May 14, 2025	May NEWA
>A>	AB			10MG	A210301	002	May 14, 2025	May NFTG
>A>	AB			15MG	A210301	003	May 14, 2025	May NFTG
>A>	AB			20MG	A210301	004	May 14, 2025	May NFTG
	AB		APOTEX	2.5MG	A217810	001	May 02, 2025	Apr NEWA
>A>	AB		ASCENT PHARMS INC	2.5MG	A219332	001	May 14, 2025	May NEWA
>A>	AB			10MG	A219332	002	May 14, 2025	May NFTG
>A>	AB			15MG	A219332	003	May 14, 2025	May NFTG
>A>	AB			20MG	A219332	004	May 14, 2025	May NFTG
	AB		AUROBINDO PHARMA LTD	2.5MG	A208544	001	Apr 10, 2025	Apr NEWA
>A>	AB			10MG	A208544	002	May 15, 2025	May NEWA
>A>	AB			15MG	A208544	003	May 15, 2025	May NEWA
>A>	AB			20MG	A208544	004	May 15, 2025	May NEWA
>A>	AB		BIOCON PHARMA	2.5MG	A218107	001	May 14, 2025	May NEWA
>A>	AB			10MG	A218107	002	May 14, 2025	May NFTG
>A>	AB			15MG	A218107	003	May 14, 2025	May NFTG
>A>	AB			20MG	A218107	004	May 14, 2025	May NFTG
>A>	AB		BRECKENRIDGE	10MG	A208220	001	May 15, 2025	May NEWA
>A>	AB			15MG	A208220	002	May 15, 2025	May NEWA
>A>	AB			20MG	A208220	003	May 15, 2025	May NEWA
>A>	AB		CHANGZHOU PHARM	10MG	A216995	001	May 14, 2025	May NFTG
>A>	AB			15MG	A216995	002	May 14, 2025	May NFTG
>A>	AB			20MG	A216995	003	May 14, 2025	May NFTG
>A>	AB		DR REDDYS	2.5MG	A208534	001	May 14, 2025	May NEWA
>A>	AB			10MG	A208534	002	May 14, 2025	May NFTG
>A>	AB			15MG	A208534	003	May 14, 2025	May NFTG
>A>	AB			20MG	A208534	004	May 14, 2025	May NFTG
>A>	AB		INVAGEN PHARMS	10MG	A208543	001	May 14, 2025	May NFTG
>A>	AB			15MG	A208543	002	May 14, 2025	May NFTG
>A>	AB			20MG	A208543	003	May 14, 2025	May NFTG
	AB		LUPIN LTD	2.5MG	A208555	001	Mar 03, 2025	Feb NFTG
>A>	AB			10MG	A208555	002	May 14, 2025	May NFTG
>A>	AB			15MG	A208555	003	May 14, 2025	May NFTG
>A>	AB			20MG	A208555	004	May 14, 2025	May NFTG

TABLET;ORAL

RIVAROXABAN

>A>	AB	MACLEODS PHARMS LTD	2.5MG	A213114	001	May 14, 2025	May NEWA
>A>	AB		10MG	A213114	002	May 14, 2025	May NFTG
>A>	AB		15MG	A213114	003	May 14, 2025	May NFTG
>A>	AB		20MG	A213114	004	May 14, 2025	May NFTG
>A>	AB	SUNSHINE	10MG	A213348	001	May 14, 2025	May NFTG
>A>	AB		15MG	A213348	002	May 14, 2025	May NFTG
>A>	AB		20MG	A213348	003	May 14, 2025	May NFTG
	AB	TARO	2.5MG	A208557	001	Mar 03, 2025	Feb NFTG

XARELTO

	AB	+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018	Feb CFTG
>D>		+		10MG	N022406	001	Jul 01, 2011	May CFTG
>A>	AB	+		10MG	N022406	001	Jul 01, 2011	May CFTG
>D>		+		15MG	N022406	002	Nov 04, 2011	May CFTG
>A>	AB	+		15MG	N022406	002	Nov 04, 2011	May CFTG
>D>		+!		20MG	N022406	003	Nov 04, 2011	May CFTG
>A>	AB	+!		20MG	N022406	003	Nov 04, 2011	May CFTG

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

@	ALVOGEN	4.6MG/24HR	A204403	001	Sep 03, 2015	Mar DISC
@		9.5MG/24HR	A204403	002	Sep 03, 2015	Mar DISC
@		13.3MG/24HR	A204403	003	Aug 31, 2015	Mar DISC

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB	NORVIUM BIOSCIENCE	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb CAHN
AB		EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb CAHN

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

>A>	AP	MANKIND PHARMA	50MG/5ML (10MG/ML)	A219674	001	May 29, 2025	May NEWA
>A>	AP		100MG/10ML (10MG/ML)	A219674	002	May 29, 2025	May NEWA

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB	AUROBINDO PHARMA LTD	250MCG	A213298	002	Jan 31, 2025	Jan NEWA
@	SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Feb CAHN
@		500MCG	A208236	001	Oct 03, 2018	Feb CAHN

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	ANTHEA PHARMA	40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Mar NEWA
AP		150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Mar NEWA
AP		200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Mar NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB	+	ASTRAZENECA	EQ 5MG BASE	N021366	002	Aug 12, 2003	Jan CAHN
AB	+		EQ 10MG BASE	N021366	003	Aug 12, 2003	Jan CAHN
AB	+		EQ 20MG BASE	N021366	004	Aug 12, 2003	Jan CAHN
AB	+		EQ 40MG BASE	N021366	005	Aug 12, 2003	Jan CAHN

ROSUVASTATIN CALCIUM

>A>	AB	MANKIND PHARMA	EQ 5MG BASE	A206603	001	May 16, 2025	May NEWA
>A>	AB		EQ 10MG BASE	A206603	002	May 16, 2025	May NEWA
>A>	AB		EQ 20MG BASE	A206603	003	May 16, 2025	May NEWA
>A>	AB		EQ 40MG BASE	A206603	004	May 16, 2025	May NEWA
>D>	@	ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	May CMFD
>A>	AB		EQ 5MG BASE	A206513	001	Mar 01, 2019	May CMFD
>D>	@		EQ 10MG BASE	A206513	002	Mar 01, 2019	May CMFD
>A>	AB		EQ 10MG BASE	A206513	002	Mar 01, 2019	May CMFD
>D>	@		EQ 20MG BASE	A206513	003	Mar 01, 2019	May CMFD
>A>	AB		EQ 20MG BASE	A206513	003	Mar 01, 2019	May CMFD
>D>	@		EQ 40MG BASE	A206513	004	Mar 01, 2019	May CMFD
>A>	AB		EQ 40MG BASE	A206513	004	Mar 01, 2019	May CMFD

RUFINAMIDESUSPENSION;ORAL
RUFINAMIDE

AB	MSN	40MG/ML	A214817	001	Apr 15, 2025	Apr	NEWA
----	-----	---------	---------	-----	--------------	-----	------

SACUBITRIL; VALSARTANTABLET;ORAL
SACUBITRIL AND VALSARTAN

AB	DR REDDYS	24MG;26MG	A213627	001	Jan 13, 2025	Jan	NEWA
AB		49MG;51MG	A213627	002	Jan 13, 2025	Jan	NEWA
AB		97MG;103MG	A213627	003	Jan 13, 2025	Jan	NEWA
AB	LUPIN	24MG;26MG	A213808	001	Jan 08, 2025	Jan	NEWA
AB		49MG;51MG	A213808	002	Jan 08, 2025	Jan	NEWA
AB		97MG;103MG	A213808	003	Jan 08, 2025	Jan	NEWA

SAPROPTERIN DIHYDROCHLORIDEPOWDER;ORAL
ZELVYSIA

AB	SHANGHAI AUCYUN	100MG/PACKET	A218645	001	Apr 29, 2025	Apr	NEWA
AB		500MG/PACKET	A218645	002	Apr 29, 2025	Apr	NEWA

TABLET;ORAL
SAPROPTERIN DIHYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA	100MG	A216797	001	Jun 09, 2025	May	NEWA
>A>	AB	ZENARA	100MG	A218797	001	Jun 11, 2025	May	NEWA

SCOPOLAMINESYSTEM;TRANSDERMAL
SCOPOLAMINE

>A>	AB	AMNEALS PHARMS	1MG/72HR	A218384	001	Jun 09, 2025	May	NEWA
AB	!	RICONPHARMA LLC	1MG/72HR	A212342	001	Nov 24, 2020	Apr	CHRS
TRANSDERM SCOP								
AB	+	BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Apr	CHRS

SELENIOS ACIDSOLUTION;INTRAVENOUS
SELENIOS ACID

>D>	+	AM REGENT	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021	May	CFTG
>A>	AP	+	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021	May	CFTG
		+	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Feb	CTEC
AP		+	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Jan	CFTG
AP		+	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019	Feb	CFTG
>A>	AP	ASPIRO	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A219633	001	Jun 11, 2025	May	NFTG
>A>	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219633	002	Jun 11, 2025	May	NEWA
AP		FRESENIUS KABI USA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jan	NFTG
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Feb	CMS1
AP		SUN PHARM	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219547	001	Feb 20, 2025	Feb	NEWA

SELINEXORTABLET;ORAL
XPOVIO

+	KARYOPHARM THERAPS	10MG	N212306	005	Mar 10, 2025	Mar	NEWA
---	--------------------	------	---------	-----	--------------	-----	------

SELPERCATINIBCAPSULE;ORAL
RETEVMO

+	ELI LILLY AND CO	40MG	N213246	001	May 08, 2020	Jan	CAHN
+	!	80MG	N213246	002	May 08, 2020	Jan	CAHN

TABLET;ORAL
RETEVMO

+	ELI LILLY AND CO	40MG	N218160	001	Apr 10, 2024	Jan	CAHN
+		80MG	N218160	002	Apr 10, 2024	Jan	CAHN
+		120MG	N218160	003	Apr 10, 2024	Jan	CAHN
+	!	160MG	N218160	004	Apr 10, 2024	Jan	CAHN

SEVELAMER CARBONATEFOR SUSPENSION; ORAL
SEVELAMER CARBONATE

	@	INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jan DISC
	@		2.4GM/PACKET	A206234	002	Jul 12, 2024	Jan DISC
AB		TORRENT	800MG/PACKET	A215909	001	Feb 27, 2025	Feb NEWA
AB			2.4GM/PACKET	A215909	002	Feb 27, 2025	Feb NEWA

SEVELAMER HYDROCHLORIDETABLET; ORAL
SEVELAMER HYDROCHLORIDE

BX		AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023	Mar CTEC
BX			800MG	A212599	002	Jul 11, 2023	Mar CTEC
AB		NAVINTA LLC	800MG	A218966	001	Feb 03, 2025	Jan NEWA

SILDENAFIL CITRATEFOR SUSPENSION; ORAL
SILDENAFIL CITRATE

AB		APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN
AB		CHARTWELL RX	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN

TABLET; ORAL
SILDENAFIL CITRATE

AB		JUBILANT GENERICS	EQ 20MG BASE	A202954	001	Mar 06, 2025	Feb NEWA
----	--	-------------------	--------------	---------	-----	--------------	----------

SILODOSINCAPSULE; ORAL
SILODOSIN

AB		TORRENT	4MG	A210396	001	Feb 10, 2025	Jan NEWA
AB			8MG	A210396	002	Feb 10, 2025	Jan NEWA

SIMVASTATINTABLET; ORAL
SIMVASTATIN

AB		GRAVITI PHARMS	5MG	A077752	005	Jan 23, 2008	Feb CAHN
AB			10MG	A077752	001	Dec 20, 2006	Feb CAHN
AB			20MG	A077752	002	Dec 20, 2006	Feb CAHN
AB			40MG	A077752	003	Dec 20, 2006	Feb CAHN
AB			80MG	A077752	004	Dec 20, 2006	Feb CAHN

SIPONIMODTABLET; ORAL
MAYZENT

>D>	AB	+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	May CTEC
>A>		+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	May CTEC
	AB	+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CFTG
>D>	AB	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	May CTEC
>A>		+		EQ 1MG BASE	N209884	003	Aug 24, 2021	May CTEC
	AB	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Apr CFTG
>D>	AB	+	!	EQ 2MG BASE	N209884	002	Mar 26, 2019	May CTEC
>A>		+	!	EQ 2MG BASE	N209884	002	Mar 26, 2019	May CTEC
	AB	+	!	EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr CFTG

SIPONIMOD

>D>	AB		RICONPHARMA LLC	EQ 0.25MG BASE	A218444	001	Apr 22, 2025	May DISC
>A>		@		EQ 0.25MG BASE	A218444	001	Apr 22, 2025	May DISC
	AB			EQ 0.25MG BASE	A218444	001	Apr 22, 2025	Apr NFTG
>D>	AB			EQ 1MG BASE	A218444	002	Apr 22, 2025	May DISC
>A>		@		EQ 1MG BASE	A218444	002	Apr 22, 2025	May DISC
	AB			EQ 1MG BASE	A218444	002	Apr 22, 2025	Apr NFTG
>D>	AB			EQ 2MG BASE	A218444	003	Apr 22, 2025	May DISC
>A>		@		EQ 2MG BASE	A218444	003	Apr 22, 2025	May DISC
	AB			EQ 2MG BASE	A218444	003	Apr 22, 2025	Apr NFTG

SIROLIMUSPOWDER; INTRAVENOUS
FYARRO

	+	AADI SUB	100MG/VIAL	N213312	001	Nov 22, 2021	Mar CAHN
--	---	----------	------------	---------	-----	--------------	----------

SITAGLIPTIN HYDROCHLORIDESOLUTION;ORAL
BRYNOVIN

+! AZURITY EQ 25MG BASE/ML N219122 001 Jan 16, 2025 Jan NEWA

SODIUM CHLORIDEINJECTABLE;INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER>D> AP +! ICU MEDICAL INC 900MG/100ML N016366 001 May CAHN
>A> AP +! OTSUKA ICU MEDCL 900MG/100ML N016366 001 May CAHNSOLUTION;INJECTION
SODIUM CHLORIDE 0.9%AP NEXUS 90MG/10ML (9MG/ML) A217535 001 Aug 23, 2023 Mar CAHN
AP 180MG/20ML (9MG/ML) A217535 002 Aug 23, 2023 Mar CAHNSODIUM NITROPRUSSIDEINJECTABLE;INJECTION
SODIUM NITROPRUSSIDE
@ XIROMED

25MG/ML A211277 001 Oct 29, 2020 Jan DISC

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

AA AJENAT PHARMS 454GM/BOT A205727 001 Feb 23, 2016 Jan CAHN

SUSPENSION;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

>A> AA LYNE 15GM/60ML A214912 001 Jun 10, 2025 May NEWA

SOLIFENACIN SUCCINATETABLET;ORAL
SOLIFENACIN SUCCINATEAB TORRENT 5MG A209424 001 Mar 04, 2025 Feb NEWA
AB 10MG A209424 002 Mar 04, 2025 Feb NEWASORAFENIB TOSYLATETABLET;ORAL
SORAFENIB TOSYLATEAB @ APOTEX EQ 200MG BASE A212228 001 Jan 27, 2025 Mar DISC
EQ 200MG BASE A212228 001 Jan 27, 2025 Jan NEWASPIRONOLACTONESUSPENSION;ORAL
SPIRONOLACTONE

AB HETERO LABS LTD III 25MG/5ML A218085 001 Feb 21, 2025 Feb NEWA

TABLET;ORAL
SPIRONOLACTONEAB GRAVITI PHARMS 25MG A219494 001 Jan 23, 2025 Jan NEWA
AB 50MG A219494 002 Jan 23, 2025 Jan NEWA
AB 100MG A219494 003 Jan 23, 2025 Jan NEWASTREPTOZOCININJECTABLE;INJECTION
ZANOSAR

@ + TEVA PHARMS USA 1GM/VIAL N050577 001 May 07, 1982 Feb DISC

SUCCINYLCHOLINE CHLORIDEINJECTABLE;INJECTION
SUCCINYLCHOLINE CHLORIDE

AP FRESENIUS KABI USA 20MG/ML A217885 001 Feb 21, 2025 Feb NEWA

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
SUCCINYLCHOLINE CHLORIDE

AP FRESENIUS KABI USA 100MG/5ML (20MG/ML) A217884 001 Feb 11, 2025 Jan NEWA

SUCRALFATESUSPENSION;ORAL
SUCRALFATE

AB PADAGIS US 1GM/10ML A211780 001 Apr 14, 2025 Apr NEWA

TABLET;ORAL
SUCRALFATE

AB CHARTWELL RX 1GM A074415 001 Jun 08, 1998 Apr CAHN

SULINDACTABLET;ORAL
SULINDAC

AB	EPIC PHARMA	150MG	A072711	002	Mar 25, 1991	Mar CMS1
----	-------------	-------	---------	-----	--------------	----------

SUNITINIB MALATECAPSULE;ORAL
SUNITINIB MALATE

AB	FOSUN WANBANG	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Jan CAHN
AB		EQ 25MG BASE	A218012	002	Aug 21, 2023	Jan CAHN
AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Jan CAHN
AB		EQ 50MG BASE	A218012	004	Aug 21, 2023	Jan CAHN
AB	MSN	EQ 12.5MG BASE	A214824	001	Feb 14, 2025	Feb NEWA
AB		EQ 25MG BASE	A214824	002	Feb 14, 2025	Feb NEWA
AB		EQ 37.5MG BASE	A214824	003	Feb 14, 2025	Feb NEWA
AB		EQ 50MG BASE	A214824	004	Feb 14, 2025	Feb NEWA

SUZETRIGINETABLET;ORAL
JOURNAVX

+	!	VERTEX PHARMS INC	50MG	N219209	001	Jan 30, 2025	Jan NEWA
---	---	-------------------	------	---------	-----	--------------	----------

TACROLIMUSCAPSULE;ORAL
TACROLIMUS

AB	AJENAT PHARMS	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Jan CAHN
AB		EQ 1MG BASE	A206651	002	Nov 30, 2017	Jan CAHN
AB		EQ 5MG BASE	A206651	003	Nov 30, 2017	Jan CAHN

INJECTABLE;INJECTION
PROGRAF

AP	+	!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Jan CTEC
----	---	---	----------	----------------	---------	-----	--------------	----------

AP			NEXUS	EQ 5MG BASE/ML	A217108	001	Feb 12, 2025	Jan NEWA
----	--	--	-------	----------------	---------	-----	--------------	----------

OINTMENT;TOPICAL
TACROLIMUS

BX			ENCUBE	0.1%	A212387	001	Oct 10, 2023	Mar CTEC
----	--	--	--------	------	---------	-----	--------------	----------

TALAZOPARIB TOSYLATECAPSULE;ORAL
TALZENNA

@	+		PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Feb DISC
@	+			EQ 0.25MG BASE	N211651	001	Oct 16, 2018	Feb DISC
@	+			EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Feb DISC
@	+			EQ 0.5MG BASE	N211651	003	Sep 20, 2021	Feb DISC
@	+			EQ 0.75MG BASE	N211651	004	Sep 20, 2021	Feb DISC
@	+			EQ 1MG BASE	N211651	002	Oct 16, 2018	Feb DISC

TAMOXIFEN CITRATETABLET;ORAL
TAMOXIFEN CITRATE

@			APOTEX	EQ 10MG BASE	A090878	001	Sep 23, 2011	Mar DISC
@				EQ 20MG BASE	A090878	002	Sep 23, 2011	Mar DISC

TAMSULOSIN HYDROCHLORIDECAPSULE;ORAL
FLOMAX

@	+		SANOFI	0.4MG	N020579	001	Apr 15, 1997	Feb DISC
---	---	--	--------	-------	---------	-----	--------------	----------

AB			ASCENT PHARMS INC	0.4MG	A214730	001	May 04, 2022	Feb CMFD
AB			GRAVITI PHARMS	0.4MG	A219767	001	May 01, 2025	Apr NEWA
AB	!		ZYDUS PHARMS USA INC	0.4MG	A078225	001	Apr 27, 2010	Feb CHRS

TAPINAROFCREAM;TOPICAL
VTAMA

>D>	+	!	DERMAVANT SCI	1%	N215272	001	May 23, 2022	May CAHN
>A>	+	!	ORGANON LLC	1%	N215272	001	May 23, 2022	May CAHN

TAZAROTENECREAM; TOPICAL
TAZAROTENE

AB	COSETTE	0.05%	A208662	002	Mar 10, 2025	Feb NEWA
----	---------	-------	---------	-----	--------------	----------

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE; INJECTION
OSTEOLITE

@	SUN PHARM INDS INC	N/A	N017972	001		Feb CAHN
---	--------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M PENTETATE KITINJECTABLE; INJECTION
DRAXIMAGE DTPA

AP	+! JUBILANT	N/A	N018511	001	Dec 29, 1989	Mar CFTG
----	-------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M PENTETATE KIT

AP	CURIUM	N/A	A215146	001	Mar 26, 2025	Mar NFTG
----	--------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M SESTAMIBI

>D> AP	SUN PHARM INDS INC	10-30mCi	A079157	001	Jul 10, 2009	May DISC
--------	--------------------	----------	---------	-----	--------------	----------

>A>	@	10-30mCi	A079157	001	Jul 10, 2009	May DISC
-----	---	----------	---------	-----	--------------	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

>D>	@	PHARMALUCENCE	12mCi/ML	N017321	001	May CAHN
-----	---	---------------	----------	---------	-----	----------

>D>	@		24mCi/ML	N017321	002	May CAHN
-----	---	--	----------	---------	-----	----------

>D>	@		48mCi/ML	N017321	003	May CAHN
-----	---	--	----------	---------	-----	----------

>A>	@	SUN PHARM INDS INC	12mCi/ML	N017321	001	May CAHN
-----	---	--------------------	----------	---------	-----	----------

>A>	@		24mCi/ML	N017321	002	May CAHN
-----	---	--	----------	---------	-----	----------

>A>	@		48mCi/ML	N017321	003	May CAHN
-----	---	--	----------	---------	-----	----------

TELMISARTAN

TABLET; ORAL

MICARDIS

AB	+ BOEHRINGER INGELHEIM	80MG	N020850	002	Nov 10, 1998	Feb CHRS
----	------------------------	------	---------	-----	--------------	----------

TELMISARTAN

AB	! INVENTIA	80MG	A205150	003	Oct 30, 2015	Feb CHRS
----	------------	------	---------	-----	--------------	----------

AB	MACLEODS PHARMS LTD	20MG	A203986	001	Jan 15, 2025	Jan NEWA
----	---------------------	------	---------	-----	--------------	----------

AB		40MG	A203986	002	Jan 15, 2025	Jan NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A203986	003	Jan 15, 2025	Jan NEWA
----	--	------	---------	-----	--------------	----------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

@	SUN PHARM INDUSTRIES	7.5MG	A078581	001	Sep 08, 2009	Mar DISC
---	----------------------	-------	---------	-----	--------------	----------

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

@	NEXTSOURCE	5MG	A203898	001	Feb 10, 2016	Mar CAHN
---	------------	-----	---------	-----	--------------	----------

@		20MG	A203898	002	Feb 10, 2016	Mar CAHN
---	--	------	---------	-----	--------------	----------

@		100MG	A203898	003	Feb 10, 2016	Mar CAHN
---	--	-------	---------	-----	--------------	----------

AB		100MG	A203898	003	Feb 10, 2016	Mar CMFD
----	--	-------	---------	-----	--------------	----------

@		140MG	A203898	004	Feb 10, 2016	Mar CAHN
---	--	-------	---------	-----	--------------	----------

AB		140MG	A203898	004	Feb 10, 2016	Mar CMFD
----	--	-------	---------	-----	--------------	----------

@		180MG	A203898	005	Feb 10, 2016	Mar CAHN
---	--	-------	---------	-----	--------------	----------

AB		180MG	A203898	005	Feb 10, 2016	Mar CMFD
----	--	-------	---------	-----	--------------	----------

@		250MG	A203898	006	Feb 10, 2016	Mar CAHN
---	--	-------	---------	-----	--------------	----------

AB		250MG	A203898	006	Feb 10, 2016	Mar CMFD
----	--	-------	---------	-----	--------------	----------

@	TRI-SOURCE PHARMA	5MG	A203898	001	Feb 10, 2016	Apr CAHN
---	-------------------	-----	---------	-----	--------------	----------

@		20MG	A203898	002	Feb 10, 2016	Apr CAHN
---	--	------	---------	-----	--------------	----------

AB		100MG	A203898	003	Feb 10, 2016	Apr CAHN
----	--	-------	---------	-----	--------------	----------

AB		140MG	A203898	004	Feb 10, 2016	Apr CAHN
----	--	-------	---------	-----	--------------	----------

AB		180MG	A203898	005	Feb 10, 2016	Apr CAHN
----	--	-------	---------	-----	--------------	----------

AB		250MG	A203898	006	Feb 10, 2016	Apr CAHN
----	--	-------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

>A>	AB	AJANTA PHARMA LTD	EQ 1MG BASE	A219482	001	May 12, 2025	May NEWA
>A>	AB		EQ 2MG BASE	A219482	002	May 12, 2025	May NEWA
>A>	AB		EQ 5MG BASE	A219482	003	May 12, 2025	May NEWA
>A>	AB		EQ 10MG BASE	A219482	004	May 12, 2025	May NEWA

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

@	BRECKENRIDGE PHARM	EQ 250MG BASE	A077714	001	Jun 04, 2010	Mar DISC
---	--------------------	---------------	---------	-----	--------------	----------

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

@	APOTEX	7MG	A209601	001	Nov 02, 2018	Feb DISC
@		14MG	A209601	002	Nov 02, 2018	Feb DISC
AB	CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Mar NEWA
AB		14MG	A218663	002	Apr 07, 2025	Mar NEWA

TERIPARATIDESOLUTION;SUBCUTANEOUS
BONSITY

	ALVOGEN	0.56MG/2.24ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Feb CPOT
AP	FORTEO +! LILLY	0.56MG/2.24ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Feb CPOT
AP	TERIPARATIDE +! ALMAJECT	0.56MG/2.24ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Feb CPOT
AP	+!	0.6MG/2.4ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Feb CTEC
AP	APOTEX	0.56MG/2.24ML (0.25MG/ML)	A211097	001	Nov 16, 2023	Feb CPOT
AP	TEVA PHARMS USA	0.56MG/2.24ML (0.25MG/ML)	A208569	001	Nov 16, 2023	Feb CPOT

TESTOSTERONESOLUTION, METERED;TRANSDERMAL
TESTOSTERONE

@	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan DISC
---	--------	----------------------	---------	-----	--------------	----------

THEOPHYLLINESOLUTION, ELIXIR;ORAL
ELIXOPHYLLIN

AA	+! SOLIS PHARMS	80MG/15ML	A085186	001		Apr CAHN
AB	THEOPHYLLINE AJANTA PHARMA LTD	300MG	A218401	002	Mar 26, 2025	Mar NEWA
AB		450MG	A218401	001	Jan 13, 2025	Jan NEWA
	@ RHODES PHARMS	300MG	A214113	001	May 11, 2023	Jan DISC

THIAMINE HYDROCHLORIDEINJECTABLE;INJECTION
THIAMINE HYDROCHLORIDE

AP	GLAND	100MG/ML	A217800	001	Feb 24, 2025	Feb NEWA
----	-------	----------	---------	-----	--------------	----------

THIOTEPAPOWDER;INTRAVENOUS
TEPADINA AND SODIUM CHLORIDE

>A>	+! ADIENNE SA	200MG	N208264	003	Apr 10, 2025	May NEWA
	SOLUTION;INTRAVENOUS TEPYLUTE					
	+! SHORLA	100MG/10ML (10MG/ML)	N216984	002	Feb 26, 2025	Mar NEWA

TICAGRELORTABLET;ORAL
BRILINTA

AB	+ ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Mar CTEC
	TICAGRELOR					
AB	ALEMBIC	90MG	A208576	001	May 01, 2025	Apr NEWA
AB	APOTEX	90MG	A208584	001	May 01, 2025	Apr NEWA
AB	INVAGEN PHARMS	90MG	A208537	001	May 05, 2025	Apr NEWA
AB	MSN	90MG	A208596	001	Apr 07, 2020	Mar CMFD
	@	90MG	A208596	001	Apr 07, 2020	Feb CAHN

TABLET;ORAL									
TICAGRELOR									
AB		SUNSHINE	90MG	A208508	001	Apr 06, 2020	Mar	CMFD	
AB		WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Mar	CMFD	
AB			90MG	A208390	002	Sep 04, 2018	Mar	CMFD	
<u>TICLOPIDINE HYDROCHLORIDE</u>									
TABLET;ORAL									
TICLOPIDINE HYDROCHLORIDE									
	@	APOTEX	250MG	A075089	001	Jul 01, 1999	Mar	DISC	
<u>TIMOLOL MALEATE</u>									
SOLUTION/DROPS;OPHTHALMIC									
TIMOLOL MALEATE									
>D>	AT2	APOTEX	EQ 0.5% BASE	A204936	001	Apr 17, 2015	May	DISC	
>A>		@	EQ 0.5% BASE	A204936	001	Apr 17, 2015	May	DISC	
<u>TOBRAMYCIN</u>									
POWDER;INHALATION									
TOBI PODHALER									
		+! VIATRIS	28MG	N201688	001	Mar 22, 2013	Feb	CAHN	
SOLUTION;INHALATION									
TOBI									
AN		+! VIATRIS	300MG/5ML	N050753	001	Dec 22, 1997	Feb	CAHN	
<u>TOFACITINIB CITRATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
TOFACITINIB CITRATE									
	@	DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024	Apr	DISC	
		XELJANZ XR							
	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Apr	CTEC	
<u>TOLTERODINE TARTRATE</u>									
TABLET;ORAL									
TOLTERODINE TARTRATE									
AB		PTS CONSULTING	1MG	A204721	001	Jan 24, 2020	Mar	CAHN	
AB			2MG	A204721	002	Jan 24, 2020	Mar	CAHN	
<u>TOLVAPTAN</u>									
TABLET;ORAL									
JYNARQUE									
AB2	+	OTSUKA	15MG	N204441	001	Apr 23, 2018	Apr	CFTG	
AB2	+		30MG	N204441	002	Apr 23, 2018	Apr	CFTG	
AB	+!		45MG	N204441	003	Apr 23, 2018	Apr	CFTG	
AB2	+		60MG	N204441	004	Apr 23, 2018	Apr	CFTG	
AB	+		90MG	N204441	005	Apr 23, 2018	Apr	CFTG	
SAMSCA									
AB1	+	OTSUKA	15MG	N022275	001	May 19, 2009	Apr	CTEC	
AB1	+!		30MG	N022275	002	May 19, 2009	Apr	CTEC	
TOLVAPTAN									
AB1		ALKEM LABS LTD	15MG	A211891	003	Sep 06, 2022	Apr	CTEC	
AB1			30MG	A211891	001	May 19, 2020	Apr	CTEC	
AB1		APOTEX	15MG	A207605	002	Sep 06, 2022	Apr	CTEC	
AB1			30MG	A207605	001	May 19, 2020	Apr	CTEC	
AB1		ENDO OPERATIONS	15MG	A206119	001	Feb 15, 2022	Apr	CTEC	
AB1			30MG	A206119	002	Feb 15, 2022	Apr	CTEC	
AB1		HETERO LABS LTD V	15MG	A205646	002	Sep 06, 2022	Apr	CTEC	
AB1			30MG	A205646	001	Jul 16, 2021	Apr	CTEC	
AB2		LUPIN LTD	15MG	A216063	001	Apr 23, 2025	Apr	NFTG	
AB2			30MG	A216063	002	Apr 23, 2025	Apr	NFTG	
AB			45MG	A216063	003	Apr 23, 2025	Apr	NFTG	
AB2			60MG	A216063	004	Apr 23, 2025	Apr	NFTG	
AB			90MG	A216063	005	Apr 23, 2025	Apr	NFTG	
AB1		MSN	15MG	A216949	001	Jun 21, 2023	Apr	CTEC	
AB1			30MG	A216949	002	Jun 21, 2023	Apr	CTEC	
<u>TOPIRAMATE</u>									
CAPSULE;ORAL									
TOPIRAMATE									
>A>	AB	RUBICON	15MG	A216683	001	May 27, 2025	May	NEWA	
>A>	AB		25MG	A216683	002	May 27, 2025	May	NEWA	
>A>	AB		50MG	A216683	003	May 27, 2025	May	NEWA	

CAPSULE;ORAL
TOPIRAMATE

>D>		ZYDUS PHARMS USA INC	50MG	A 078877	003	Oct 23, 2024	May CTEC
>A>	AB		50MG	A 078877	003	Oct 23, 2024	May CTEC

TABLET;ORAL
TOPIRAMATE

>A>	@	SENORES PHARMS	25MG	A 090353	001	Sep 01, 2010	May CAHN
>A>	@		50MG	A 090353	002	Sep 01, 2010	May CAHN
>A>	@		100MG	A 090353	003	Sep 01, 2010	May CAHN
>A>	@		200MG	A 090353	004	Sep 01, 2010	May CAHN
>D>	AB	SUN PHARM	200MG	A 090278	004	Mar 27, 2009	May DISC
>A>	@		200MG	A 090278	004	Mar 27, 2009	May DISC
>D>	@	WOCKHARDT	25MG	A 090353	001	Sep 01, 2010	May CAHN
>D>	@		50MG	A 090353	002	Sep 01, 2010	May CAHN
>D>	@		100MG	A 090353	003	Sep 01, 2010	May CAHN
>D>	@		200MG	A 090353	004	Sep 01, 2010	May CAHN

TORSEMIDETABLET;ORAL
TORSEMIDE

AB		COREPHARMA	5MG	A 076894	001	May 31, 2005	Apr CAHN
AB			10MG	A 076894	002	May 31, 2005	Apr CAHN
AB			20MG	A 076894	003	May 31, 2005	Apr CAHN
AB			100MG	A 076894	004	May 31, 2005	Apr CAHN

TRAMADOL HYDROCHLORIDETABLET;ORAL
TRAMADOL HYDROCHLORIDE

AB		APDM PHARMS	50MG	A 090404	001	Jan 31, 2011	Feb CAHN
	@	APOTEX	50MG	A 075981	001	Jul 10, 2002	Mar DISC
	@	MERRO PHARM USA	50MG	A 206706	001	Jul 02, 2019	Feb DISC

TABLET, EXTENDED RELEASE;ORAL
TRAMADOL HYDROCHLORIDE

AB1	!	LUPIN LTD	100MG	A 200503	001	Aug 29, 2011	Jan CTEC
AB1			200MG	A 200503	002	Aug 29, 2011	Jan CTEC
AB1			300MG	A 200503	003	Aug 29, 2011	Jan CTEC
AB1		MACLEODS PHARMS LTD	100MG	A 209404	001	Jan 31, 2025	Jan NEWA
AB1			200MG	A 209404	002	Jan 31, 2025	Jan NEWA
AB1			300MG	A 209404	003	Jan 31, 2025	Jan NEWA

TRAMETINIB DIMETHYL SULFOXIDETABLET;ORAL
TRAMETINIB DIMETHYL SULFOXIDE

@	HIKMA	EQ 0.5MG	A 219002	001	Aug 06, 2024	Feb CAHN
@		EQ 2MG	A 219002	002	Aug 06, 2024	Feb CAHN

TRANEXAMIC ACIDINJECTABLE;INJECTION
TRANEXAMIC ACID

@	FRESENIUS KABI USA	100MG/ML	A 091596	001	Mar 02, 2012	Jan DISC
---	--------------------	----------	----------	-----	--------------	----------

SOLUTION;INTRAVENOUS
TRANEXAMIC ACID

>A>	AP	RTU PHARMA SA	1GM/100ML (10MG/ML)	A 218896	001	Jun 02, 2025	May NEWA
-----	----	---------------	---------------------	----------	-----	--------------	----------

TABLET;ORAL
TRANEXAMIC ACID

>A>	AB	APPCO	650MG	A 218729	001	Jun 11, 2025	May NEWA
-----	----	-------	-------	----------	-----	--------------	----------

TRAVOPROSTSOLUTION/DROPS;OPHTHALMIC
TRAVATAN Z

AT2	+	SANDOZ	0.004%	N 021994	001	Sep 21, 2006	Feb CTEC
	@	ALEMBIC	0.004%	A 210458	001	Dec 20, 2019	Feb DISC
AT2		APOTEX	0.004%	A 203431	001	Jul 10, 2015	Feb CTEC
	!	CHARTWELL RX	0.004%	A 091340	001	Mar 01, 2013	Feb CTEC
AT2		GLAND	0.004%	A 218159	001	Jul 12, 2024	Feb CTEC
AT2		MICRO LABS	0.004%	A 203767	001	Mar 19, 2021	Feb CTEC
AT2		MYLAN	0.004%	A 205050	001	Jul 07, 2017	Feb CTEC
AT2		SOMERSET THERAPS LLC	0.004%	A 217228	001	Sep 23, 2024	Feb CTEC

TREOSULFANPOWDER; INTRAVENOUS
GRAFAPEX

+	!	MEDEXUS	1GM/VIAL	N214759	001	Jan 21, 2025	Jan CAHN
+	!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan CAHN
+	!	MGFKSMB	1GM/VIAL	N214759	001	Jan 21, 2025	Jan NEWA
+	!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan NEWA

TREPROSTINILPOWDER; INHALATION
TYVASO DPI

+	!	UNITED THERAP	0.032MG/INH	N214324	002	May 23, 2022	Jan CHRS
+	!		0.048MG/INH	N214324	003	May 23, 2022	Jan CHRS
+	!		0.08MG/INH	N214324	005	Oct 24, 2024	Jan CHRS

TREPROSTINIL SODIUMPOWDER; INHALATION
YUTREPIA

>A>		+	!	LIQUIDIA TECH	EQ 0.0265MG BASE/INH	N213005	001	May 23, 2025	May NEWA
>A>		+	!		EQ 0.053MG BASE/INH	N213005	002	May 23, 2025	May NEWA
>A>		+	!		EQ 0.0795MG BASE/INH	N213005	003	May 23, 2025	May NEWA
>A>		+	!		EQ 0.106MG BASE/INH	N213005	004	May 23, 2025	May NEWA

TRETINOINCAPSULE; ORAL
TRETINOIN

AB	@	BARR LABS INC	10MG	A077684	001	Jun 22, 2007	Feb DISC
	!	ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Feb CHRS

GEL; TOPICAL
RETIN-A

AB		+	!	BAUSCH	0.01%	N017955	001		Jan CAHN
AB				AUROBINDO PHARMA LTD	0.01%	A218246	001	Jan 13, 2025	Jan NEWA
AB					0.025%	A218245	001	Feb 27, 2025	Feb NEWA
AB				ENCUBE	0.01%	A217588	001	Mar 03, 2025	Feb NEWA
AB					0.025%	A217587	001	Mar 03, 2025	Feb NEWA

TRIAMCINOLONE ACETONIDEGEL; TOPICAL
ARISTOGEL

@	+	ASTELLAS	0.1%	A083380	001		Feb CRLD
---	---	----------	------	---------	-----	--	----------

INJECTABLE; INJECTION
KENALOG-10

AB		+		APOTHECON	10MG/ML	N012041	001		Feb CTEC
AB				TRIAMCINOLONE ACETONIDE					
AB				DR REDDYS	10MG/ML	A218773	001	Mar 12, 2025	Feb NEWA
AB					40MG/ML	A218421	001	Apr 11, 2025	Apr NEWA

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	@			BEACH PRODS	0.025%	A204608	001	Jul 07, 2016	May CAHN
>D>	@			PAI HOLDINGS PHARM	0.025%	A204608	001	Jul 07, 2016	May CAHN
AT		!		XTTRIUM LABS INC	0.025%	A088450	001	Apr 01, 1985	Feb CAHN
AT		!			0.1%	A088451	001	Apr 03, 1985	Feb CAHN

TRIAMCINOLONE HEXACETONIDEINJECTABLE; INJECTION
ARISTOSPAN

>D>	@	+		ANIKA THERAPS INC	5MG/ML	N016466	001		May CAHN
>D>	@	+			20MG/ML	N016466	002		May CAHN
>A>	@	+		ETHYPHARM INC	5MG/ML	N016466	001		May CAHN
>A>	@	+			20MG/ML	N016466	002		May CAHN

TROSPIMUM CHLORIDE

TABLET; ORAL

TROSPIMUM CHLORIDE

AB				ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb CAHN
----	--	--	--	---------------	------	---------	-----	--------------	----------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

@	APOTEX	EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar DISC
---	--------	---------------	---------	-----	--------------	----------

VALBENAZINE TOSYLATE

CAPSULE; ORAL

INGREZZA

+ NEUROCRINE

VALBENAZINE TOSYLATE

@	ZYDUS LIFESCIENCES	EQ 40MG BASE	A216137	001	Aug 07, 2024	Feb DISC
---	--------------------	--------------	---------	-----	--------------	----------

@		EQ 60MG BASE	A216137	002	Aug 07, 2024	Feb DISC
---	--	--------------	---------	-----	--------------	----------

@		EQ 80MG BASE	A216137	003	Aug 07, 2024	Feb DISC
---	--	--------------	---------	-----	--------------	----------

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	SPH ZHONGXI PHARM	EQ 450MG BASE	A218027	001	Apr 16, 2025	Apr NEWA
----	-------------------	---------------	---------	-----	--------------	----------

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

@	PAI HOLDINGS	250MG/5ML	A077105	001	Jul 29, 2005	Apr CAHN
---	--------------	-----------	---------	-----	--------------	----------

VALSARTAN

SOLUTION; ORAL

PREXXARTAN

>A>	@ +	CARMEL BIOSCIENCES	4MG/ML	N209139	001	Dec 19, 2017	May CPOT
-----	-----	--------------------	--------	---------	-----	--------------	----------

>D>	@ +		20MG/5ML	N209139	001	Dec 19, 2017	May CPOT
-----	-----	--	----------	---------	-----	--------------	----------

VALSARTAN

>A>	!	NOVITIUM PHARMA	4MG/ML	A214102	001	Nov 02, 2021	May CPOT
-----	---	-----------------	--------	---------	-----	--------------	----------

>A>	AB	!	4MG/ML	A214102	001	Nov 02, 2021	May CTEC
-----	----	---	--------	---------	-----	--------------	----------

>D>	!		20MG/5ML	A214102	001	Nov 02, 2021	May CPOT
-----	---	--	----------	---------	-----	--------------	----------

>A>	AB	RUBICON	4MG/ML	A216460	001	Jun 05, 2025	May NEWA
-----	----	---------	--------	---------	-----	--------------	----------

TABLET; ORAL

VALSARTAN

@ RENATA

AB		40MG	A218169	001	Aug 05, 2024	Feb DISC
----	--	------	---------	-----	--------------	----------

		40MG	A218169	001	Aug 05, 2024	Jan CAHN
--	--	------	---------	-----	--------------	----------

	@	80MG	A218169	002	Aug 05, 2024	Feb DISC
--	---	------	---------	-----	--------------	----------

AB		80MG	A218169	002	Aug 05, 2024	Jan CAHN
----	--	------	---------	-----	--------------	----------

	@	160MG	A218169	003	Aug 05, 2024	Feb DISC
--	---	-------	---------	-----	--------------	----------

AB		160MG	A218169	003	Aug 05, 2024	Jan CAHN
----	--	-------	---------	-----	--------------	----------

	@	320MG	A218169	004	Aug 05, 2024	Feb DISC
--	---	-------	---------	-----	--------------	----------

AB		320MG	A218169	004	Aug 05, 2024	Jan CAHN
----	--	-------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

@	STERISCIENCE	EQ 500MG BASE/VIAL	A060180	001		Apr CAHN
---	--------------	--------------------	---------	-----	--	----------

@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Apr CAHN
---	--	--------------------	---------	-----	--------------	----------

@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Apr CAHN
---	--	--------------------	---------	-----	--------------	----------

@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Apr CAHN
---	--	--------------------	---------	-----	--------------	----------

@		EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Apr CAHN
---	--	------------------	---------	-----	--------------	----------

@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Apr CAHN
---	--	------------------	---------	-----	--------------	----------

@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Apr CAHN
---	--	------------------	---------	-----	--------------	----------

@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Apr CAHN
---	--	------------------	---------	-----	--------------	----------

@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Apr CAHN
---	--	-------------------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

AP	MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan CMFD
----	--------------------	--------------------	---------	-----	--------------	----------

AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan CMFD
----	--	------------------	---------	-----	--------------	----------

@	PLANO PHARMS	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010	Mar CAHN
---	--------------	--------------------	---------	-----	--------------	----------

@		EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010	Mar CAHN
---	--	------------------	---------	-----	--------------	----------

@		EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Mar CAHN
---	--	------------------	---------	-----	--------------	----------

@		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Mar CAHN
---	--	-------------------	---------	-----	--------------	----------

POWDER; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

AP	GLAND	EQ 750MG BASE/VIAL	A218140	001	Mar 21, 2025	Mar NEWA
----	-------	--------------------	---------	-----	--------------	----------

AP		EQ 1.25GM BASE/VIAL	A218140	002	Mar 21, 2025	Mar NEWA
----	--	---------------------	---------	-----	--------------	----------

AP		EQ 1.5GM BASE/VIAL	A218140	003	Mar 21, 2025	Mar NEWA
----	--	--------------------	---------	-----	--------------	----------

AP	+!	MYLAN LABS LTD	N209481	002	Jul 10, 2018	Mar CFTG
----	----	----------------	---------	-----	--------------	----------

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

AB	AUROBINDO PHARMA	EQ 0.5MG BASE	A214595	001	May 02, 2025	Apr	NEWA
AB		EQ 1MG BASE	A214595	002	May 02, 2025	Apr	NEWA
>A>	HANDA PHARMS LLC	EQ 0.5MG BASE	A213268	001	May 21, 2025	May	NEWA
>A>		EQ 1MG BASE	A213268	002	May 21, 2025	May	NEWA
>D>	MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May	CAHN
>D>		EQ 1MG BASE	A202019	002	Feb 28, 2024	May	CAHN
>A>	NORVIUM BIOSCIENCE	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May	CAHN
>A>		EQ 1MG BASE	A202019	002	Feb 28, 2024	May	CAHN
@	PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Feb	DISC
@		EQ 1MG BASE	A217115	002	Jul 23, 2024	Feb	DISC
AB	SHILPA	EQ 0.5MG BASE	A216615	001	Apr 08, 2025	Mar	NEWA
AB		EQ 1MG BASE	A216615	002	Apr 08, 2025	Mar	NEWA
AB	VIWIT PHARM	EQ 0.5MG BASE	A212879	001	May 06, 2025	Apr	NEWA
AB		EQ 1MG BASE	A212879	002	May 06, 2025	Apr	NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN IN SODIUM CHLORIDE 0.9%

>D>	+!	LONG GROVE PHARMS	50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	May	DISC
>A>	@ +		50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	May	DISC

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Feb	CAHN
AB		EQ 75MG BASE	A201272	002	Nov 23, 2018	Feb	CAHN
AB		EQ 150MG BASE	A201272	003	Nov 23, 2018	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ABON PHARMS LLC	EQ 150MG BASE	A217841	001	Feb 07, 2025	Jan	NEWA
AB		EQ 225MG BASE	A217841	002	Feb 07, 2025	Jan	NEWA
>A>	MPP PHARMA	EQ 150MG BASE	A205468	002	Mar 24, 2017	May	CAHN
>A>		EQ 225MG BASE	A205468	003	Mar 24, 2017	May	CAHN
>D>	NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017	May	CAHN
>D>		EQ 225MG BASE	A205468	003	Mar 24, 2017	May	CAHN
AB	TORRENT	EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jan	NEWA
AB		EQ 75MG BASE	A218180	002	Jan 28, 2025	Jan	NEWA
AB		EQ 150MG BASE	A218180	003	Jan 28, 2025	Jan	NEWA
AB		EQ 225MG BASE	A218180	004	Jan 28, 2025	Jan	NEWA

VIGABATRIN

TABLET; ORAL

VIGABATRIN

	@	AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Feb	DISC
>A>	@	CARNEGIE	500MG	A215519	001	Apr 28, 2023	May	CAHN
>D>	@	RYAN LABS	500MG	A215519	001	Apr 28, 2023	May	CAHN
	@		500MG	A215519	001	Apr 28, 2023	Jan	DISC

VIMSELTINIB

CAPSULE; ORAL

ROMVIMZA

+	DECIPHERA PHARMS	14MG	N219304	001	Feb 14, 2025	Feb	NEWA
+		20MG	N219304	002	Feb 14, 2025	Feb	NEWA
+!		30MG	N219304	003	Feb 14, 2025	Feb	NEWA

VORICONAZOLE

FOR SUSPENSION; ORAL

VORICONAZOLE

AB	ZHEJIANG POLY PHARM	200MG/5ML	A216805	001	Jan 02, 2024	Mar	CAHN
----	---------------------	-----------	---------	-----	--------------	-----	------

ZANUBRUTINIB

CAPSULE; ORAL

BRUKINSA

+	BEONE MEDICINES USA	80MG	N213217	001	Nov 14, 2019	Apr	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

ZINC ACETATECAPSULE;ORAL
GALZIN+ ETON
+!EQ 25MG ZINC
EQ 50MG ZINCN020458 001 Jan 28, 1997 Jan CAHN
N020458 002 Jan 28, 1997 Jan CAHNZINC CHLORIDEINJECTABLE;INJECTION
ZINC CHLORIDE

>A>	AP	RK PHARMA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	May CAHN
>D>	AP	STIRA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	May CAHN
	AP		EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr NEWA

ZINC SULFATESOLUTION;INTRAVENOUS
ZINC SULFATE

	AP	ASPIRO	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A219585	001	May 01, 2025	Apr NEWA
	AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A219585	002	May 01, 2025	Apr NEWA
	AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A219585	003	May 01, 2025	Apr NEWA
>A>	AP	STIRA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	May NEWA
>A>	AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	May NEWA
>A>	AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217624	003	Jun 10, 2025	May NEWA

ZOLEDRONIC ACIDINJECTABLE;INTRAVENOUS
ZOLEDRONIC ACID

@ APOTEX

EQ 5MG BASE/100ML

A204367 001 Dec 24, 2015 Mar DISC

ZOLMITRIPTANSPRAY;NASAL
ZOLMITRIPTAN

AB		PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Apr CHRS
AB		ZOMIG					
	AB	+! AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Apr CHRS

ZOLPIDEM TARTRATETABLET;ORAL
AMBIEN

AB		+ COSETTE	5MG	N019908	001	Dec 16, 1992	Jan CAHN
AB		+!	10MG	N019908	002	Dec 16, 1992	Jan CAHN

ZOLPIDEM TARTRATE

@ APOTEX INC
@5MG
10MGA077884 001 Apr 23, 2007 Mar DISC
A077884 002 Apr 23, 2007 Mar DISCTABLET;SUBLINGUAL
EDLUAR

AB		+ VIATRIS	5MG	N021997	001	Mar 13, 2009	Feb CAHN
AB		+!	10MG	N021997	002	Mar 13, 2009	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
AMBIEN CR

AB		+ COSETTE	6.25MG	N021774	002	Sep 02, 2005	Jan CAHN
AB		+!	12.5MG	N021774	001	Sep 02, 2005	Jan CAHN

ZOLPIDEM TARTRATE

@ APOTEX
@6.25MG
12.5MGA200266 001 Sep 10, 2013 Mar DISC
A200266 002 Sep 10, 2013 Mar DISCZONISAMIDECAPSULE;ORAL
ZONISAMIDE@ APOTEX
@
@25MG
50MG
100MGA077642 001 Dec 22, 2005 Mar DISC
A077642 002 Dec 22, 2005 Mar DISC
A077642 003 Dec 22, 2005 Mar DISC

>A>	AB	MACLEODS PHARMS LTD	25MG	A219507	001	May 12, 2025	May NEWA
>A>	AB		50MG	A219507	002	May 12, 2025	May NEWA
>A>	AB		100MG	A219507	003	May 12, 2025	May NEWA

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

ACETAMINOPHEN AND IBUPROFEN

STRIDES PHARMA

250MG; 125MG

A217241 001 Jan 17, 2025 Jan NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA

0.2055MG/SPRAY

A216561 001 Jan 27, 2025 Jan NEWA

CETIRIZINE HYDROCHLORIDE

TABLET; ORAL

ZYRTEC ALLERGY

+ KENVUE BRANDS

5MG

N019835 003 Nov 16, 2007 Apr CMFD

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ APOTEX

100MG

A074948 001 Jun 19, 1998 Mar DISC

@

200MG

A074948 002 Jul 26, 2002 Mar DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

>D>

ANDA REPOSITORY

EQ 20MG BASE

A216149 001 Mar 15, 2023 May CAHN

>A>

GUARDIAN DRUG

EQ 20MG BASE

A216149 001 Mar 15, 2023 May CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

CONTRACT PHARMACAL

60MG

A219032 001 Feb 28, 2025 Feb NEWA

180MG

A219032 002 Feb 28, 2025 Feb NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 180MG; 240MG

A215232 001 Apr 17, 2025 Apr NEWA

IBUPROFEN

SUSPENSION/DROPS; ORAL

IBUPROFEN

>D>

@ AUROBINDO PHARMA LTD

40MG/ML

A213506 001 Apr 08, 2024 May CMFD

>A>

40MG/ML

A213506 001 Apr 08, 2024 May CMFD

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

STRIDES PHARMA

200MG; 30MG

A077628 001 Aug 14, 2006 Apr CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ APOTEX

5MG

A211443 001 Apr 21, 2021 Jan DISC

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM A-D

@ + KENVUE BRANDS

1MG/5ML

N019487 001 Mar 01, 1988 Apr DISC

LOPERAMIDE HYDROCHLORIDE

@ PAI HOLDINGS

1MG/5ML

A074352 001 Nov 17, 1995 Feb CAHN

@ WOCKHARDT BIO AG

1MG/5ML

A074730 001 Aug 28, 1997 Apr DISC

LORATADINE

CAPSULE; ORAL

LORATADINE

CATALENT PHARMA

10MG

A215127 001 Feb 28, 2025 Feb NEWA

TABLET, CHEWABLE; ORAL

LORATADINE

SUN PHARM

10MG

A210088 002 Apr 25, 2025 Apr NEWA

MOMETASONE FUROATE

	SPRAY, METERED;NASAL						
>D>	MOMETASONE FUROATE						
>D>	AUROBINDO PHARMA	0.05MG/SPRAY		A217498	001	Nov 22, 2024	May DISC
>A>	@	0.05MG/SPRAY		A217498	001	Nov 22, 2024	May DISC

NAPROXEN SODIUM

	TABLET;ORAL						
	NAPROXEN SODIUM						
	@ NOVELGENIX THERAPS	220MG		A207612	001	Nov 16, 2018	Apr DISC

OLOPATADINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	OLOPATADINE HYDROCHLORIDE						
>D>	@ BAUSCH AND LOMB INC	EQ 0.1% BASE		A206046	001	Jul 26, 2017	May CMFD
>A>		EQ 0.1% BASE		A206046	001	Jul 26, 2017	May CMFD
		EQ 0.2% BASE		A206087	001	Dec 05, 2017	Feb CMFD
	GLENMARK PHARMS INC	EQ 0.2% BASE		A219557	001	Feb 28, 2025	Feb NEWA
>D>	@ RISING	EQ 0.1% BASE		A204392	001	Mar 21, 2018	May CMFD
>A>		EQ 0.1% BASE		A204392	001	Mar 21, 2018	May CMFD
		EQ 0.2% BASE		A204620	001	Jun 16, 2020	Apr CMFD

OMEPRAZOLE

	TABLET, DELAYED RELEASE;ORAL						
	OMEPRAZOLE						
	@ APOTEX	20MG		A210070	001	Feb 11, 2019	Jan DISC

POTASSIUM IODIDE

	TABLET;ORAL						
	THYROSAFE						
	BTG INTL	130MG		A076350	002	Apr 02, 2025	Mar NFTG

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2025

NO MAY 2025 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2025 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		I-960	Jan 16, 2028
	10167291	Jul 01, 2036	DP U-2519			
	10167291	Jul 01, 2036	DP U-2666			
	10167291	Jul 01, 2036	DP U-2667			
	10167291	Jul 01, 2036	DP U-2668			
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10167291	Jul 01, 2036	DP U-2682			
	10167291	Jul 01, 2036	DP U-2683			
	10167291	Jul 01, 2036	DP U-2684			
	10167291	Jul 01, 2036	DP U-2685			
	10167291	Jul 01, 2036	DP U-2686			
	10167291	Jul 01, 2036	DP U-2687			
	10167291	Jul 01, 2036	DP U-4109			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
	9796721	Jul 01, 2036	DS DP U-4108			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	10272083	Jan 21, 2035	U-2519		I-960	Jan 16, 2028
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	11059829	Jul 01, 2036	DS DP U-4108			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8748413	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8748413	Jul 01, 2030	DS DP			
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	9913826	May 05, 2031	U-4046		ODE-506	Nov 22, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	>A> 12281113	Sep 10, 2041	DS DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899 001				>A> NPP		May 09, 2028
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	7396341	Oct 10, 2026	DP	Y		
	7837235	Mar 13, 2028	DP	Y		
	8733341	Oct 16, 2030	DP	Y		
	9027967	Mar 31, 2027	DP	Y		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	12233033	Aug 23, 2038	U-2106			
	12233033	Aug 23, 2038	U-2224			
	12233033	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	12233033	Aug 23, 2038	U-2106			
	12233033	Aug 23, 2038	U-2224			
	12233033	Aug 23, 2038	U-3180			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12168021	May 15, 2035	U-2414			
	12168022	May 15, 2035	U-2414			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	>A> 11179574	Oct 13, 2036	U-804			
	>A> 11446512	Jan 17, 2037	U-804			
	>A> 11697028	Oct 13, 2036	U-804			
	>A> 12290700	Oct 13, 2036	U-804			
	>A> 12296011	Jan 12, 2038	U-3163			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	>A> 12280146	Dec 08, 2043	DP			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
	12005141	Feb 24, 2041	DP U-3311			
	12226528	Feb 24, 2041	DP U-3309			
	12226528	Feb 24, 2041	DP U-3310			
	12226528	Feb 24, 2041	DP U-3311			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	>A> 6967208	Nov 21, 2026	DS DP U-1167	>A> NPP		Apr 17, 2028
	>A> 6967208	Nov 21, 2026	DS DP U-1200	>A> PED		Oct 17, 2028
	>A> 6967208	Nov 21, 2026	DS DP U-1301			
	>A> 6967208	Nov 21, 2026	DS DP U-1302			
	>A> 6967208	Nov 21, 2026	DS DP U-1323			
	>A> 6967208	Nov 21, 2026	DS DP U-1501			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	>A> 6967208	Nov 21, 2026	DS DP U-1502			
	>A> 6967208	Nov 21, 2026	DS DP U-1729			
	>A> 6967208	Nov 21, 2026	DS DP U-1730			
	>A> 6967208	Nov 21, 2026	DS DP U-4178			
	>A> 6967208*PED	May 21, 2027				
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	>A> 6967208	Nov 21, 2026	DS DP U-1200		>A> NPP	Apr 17, 2028
	>A> 6967208	Nov 21, 2026	DS DP U-1301		>A> PED	Oct 17, 2028
	>A> 6967208	Nov 21, 2026	DS DP U-1302			
	>A> 6967208	Nov 21, 2026	DS DP U-1323			
	>A> 6967208	Nov 21, 2026	DS DP U-4178			
	>A> 6967208*PED	May 21, 2027				
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				
<u>APIXABAN - ELIQUIS</u>						
N 202155 003	>A> 6967208	Nov 21, 2026	DS DP U-4179		>A> NS	Apr 17, 2028
	>A> 6967208*PED	May 21, 2027			>A> PED	Oct 17, 2028
	>A> 9326945	Feb 24, 2031	DP			
	>A> 9326945*PED	Aug 24, 2031				
<u>APIXABAN - ELIQUIS SPRINKLE</u>						
N 220073 001	>A> 11896586	Nov 22, 2040	DP U-4180		>A> NP	Apr 17, 2028
	>A> 11896586*PED	May 22, 2041			>A> PED	Oct 17, 2028
	>A> 6967208	Nov 21, 2026	DS DP U-4180			
	>A> 6967208*PED	May 21, 2027				
<u>APOMORPHINE HYDROCHLORIDE - ONAPGO</u>						
N 214056 001					NP	Feb 03, 2028
<u>APREPITANT - CINVANTI</u>						
N 209296 001	>A> 12290520	Sep 18, 2035	DP			
<u>APREPITANT - APONVIE</u>						
N 216457 001	>A> 12290520	Sep 18, 2035	DP			
<u>ARIPIRAZOLE - MEZOFY</u>						
N 211448 001	>A> 9694008	Aug 07, 2033	DP			
<u>ARIPIRAZOLE - MEZOFY</u>						
N 211448 002	>A> 9694008	Aug 07, 2033	DP			
<u>ARIPIRAZOLE - MEZOFY</u>						
N 211448 003	>A> 9694008	Aug 07, 2033	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	12251381	Apr 09, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	12251381	Apr 09, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	12251381	Apr 09, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	12251381	Apr 06, 2039	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	12251381	Apr 06, 2039	U-543			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ATRASANTAN HYDROCHLORIDE - VANRAFIA</u>						
N 219208 001	10016393	Jul 07, 2034	DP		NCE	Apr 02, 2030
	11491137	Dec 16, 2040	U-3980			
	11874283	Feb 18, 2032	U-3980			
	11998526	Dec 16, 2040	U-3980			
	12121509	Dec 16, 2040	U-3980			
	8623819	Aug 22, 2028	U-3980			
	9364458	Jul 07, 2034	DP U-3980			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2026	DS			
	9617546	Feb 14, 2026	DS U-3673			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	12252494	Apr 10, 2040	U-3506			
<u>AVIBACTAM SODIUM; AZTREONAM - EMBLAVEO</u>						
N 217906 001	7112592	Jan 07, 2026	DS DP U-4147		NP	Feb 07, 2028
	7612087	Nov 12, 2026	DP		GAIN	Feb 07, 2033
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS DP			
<u>AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)</u>						
N 219616 001					>A> NCE	May 08, 2030
<u>BACLOFEN - BACLOFEN</u>						
A 214445 001					PC	Jul 14, 2025
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					M-187	Dec 19, 2027
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	9463289	May 18, 2031	DP	Y		
	9808587	May 18, 2031	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	9463289	May 18, 2031	DP	Y		
	9808587	May 18, 2031	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP	Y		
	11395889	May 18, 2031	DP	Y		
>A>	12296089	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	10561808	Jan 01, 2032	DP	Y		
	11395889	May 18, 2031	DP	Y		
>A>	12296089	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP	Y		
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					ODE*	Aug 09, 2026
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	>A> 9908845	Sep 05, 2034	DS DP U-3201			
	>A> 9908845	Sep 05, 2034	DS DP U-3780			
	>A> 9908845	Sep 05, 2034	DS DP U-4176			
	>A> RE49948	Sep 05, 2034	DS DP U-3201			
	>A> RE49948	Sep 05, 2034	DS DP U-3780			
	>A> RE49948	Sep 05, 2034	DS DP U-4176			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	12138248	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	12138248	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA</u>						
N 212209 001	12208086	Jul 29, 2042	DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	12208167	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	12208167	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	12208167	Feb 26, 2044	DP U-713			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	12257348	May 23, 2041	DP U-3947			
>A>	12295935	Dec 27, 2040	U-3356			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	12257348	May 23, 2041	DP U-3987			
>A>	12295935	Dec 27, 2040	U-3987			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2026	DS DP			
<u>BIRCH TRITERPENES - FILSUEVZ</u>						
N 215064 001	12268695	Jan 04, 2039	U-3811			
	8828444	Jun 21, 2026	DP			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	12171882	Jan 23, 2043	U-4085			
	12171882	Jan 23, 2043	U-4086			
	12171883	Jan 23, 2043	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
>A>	12296047	Jan 22, 2041	DP U-4184			
>A>	12318483	Jul 02, 2044	U-4152			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
>A>	12296047	Jan 22, 2041	DP U-4184			
>A>	12318483	Jul 02, 2044	U-4152			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					M-314	Feb 21, 2028
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					M-314	Feb 21, 2028
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 001	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 002	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 004	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 005	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 006	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 007	12161640	Jul 26, 2032	DP U-4100			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	>A> 12310961	Jan 20, 2043	U-3419			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	11389448	Apr 13, 2032	DP			
	12178815	Jul 18, 2038	U-3348			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	11389448	Apr 13, 2032	DP			
	12178815	Jul 18, 2038	U-3348			
<u>CABOZANTINIB S-MALATE - CABOMETIX</u>						
N 208692 001	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CABOZANTINIB S-MALATE - CABOMETIX</u>						
N 208692 002	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CABOZANTINIB S-MALATE - CABOMETIX</u>						
N 208692 003	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					NPP	Dec 18, 2027
					PED	Jun 18, 2028
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					NPP	Dec 18, 2027
					PED	Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					NPP	Dec 18, 2027
					PED	Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					NPP	Dec 18, 2027
					PED	Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					NPP	Dec 18, 2027
					PED	Jun 18, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	001				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	002				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	003				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	004				NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANTHARIDIN - YCANTH</u>						
N 212905	001	12233042	Aug 22, 2038	DP U-3663		
	>A>	12290651	Feb 19, 2041	DP		
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197	001	12252495	Oct 10, 2028	U-3762		
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197	002	12252495	Oct 10, 2028	U-3762		
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591	001	10596178	Jul 22, 2035	DP		
		12208101	Jul 22, 2035	DP		
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591	002	10596178	Jul 22, 2035	DP		
		12208101	Jul 22, 2035	DP		
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186	001	12194150	Dec 21, 2041	U-219		
		12201596	Dec 21, 2041	U-1649		
		12201596	Dec 21, 2041	U-4004		
		12201596	Dec 21, 2041	U-4005		
		12263148	Dec 21, 2041	U-1649		
		12263148	Dec 21, 2041	U-219		
		12263148	Dec 21, 2041	U-4004		
		12263148	Dec 21, 2041	U-4005		
		12263149	Dec 21, 2041	U-1649		
		12263149	Dec 21, 2041	U-219		
		12263149	Dec 21, 2041	U-4004		
		12263149	Dec 21, 2041	U-4005		
		12274793	Oct 07, 2034	DP		
	>A>	12295931	Dec 21, 2041	U-1649		
	>A>	12295931	Dec 21, 2041	U-219		
	>A>	12295931	Dec 21, 2041	U-4004		
	>A>	12295931	Dec 21, 2041	U-4005		
	>A>	12303482	Dec 21, 2041	U-1649		
	>A>	12303482	Dec 21, 2041	U-219		
	>A>	12303482	Dec 21, 2041	U-4004		
	>A>	12303482	Dec 21, 2041	U-4005		
	>A>	12303605	Oct 07, 2034	DP		
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186	002	12194150	Dec 21, 2041	U-219		
		12201596	Dec 21, 2041	U-1649		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	>A> 12295931	Dec 21, 2041	U-1649			
	>A> 12295931	Dec 21, 2041	U-219			
	>A> 12295931	Dec 21, 2041	U-4004			
	>A> 12295931	Dec 21, 2041	U-4005			
	>A> 12303482	Dec 21, 2041	U-1649			
	>A> 12303482	Dec 21, 2041	U-219			
	>A> 12303482	Dec 21, 2041	U-4004			
	>A> 12303482	Dec 21, 2041	U-4005			
	>A> 12303605	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	>A> 12295931	Dec 21, 2041	U-1649			
	>A> 12295931	Dec 21, 2041	U-219			
	>A> 12295931	Dec 21, 2041	U-4004			
	>A> 12295931	Dec 21, 2041	U-4005			
	>A> 12303482	Dec 21, 2041	U-1649			
	>A> 12303482	Dec 21, 2041	U-219			
	>A> 12303482	Dec 21, 2041	U-4004			
	>A> 12303482	Dec 21, 2041	U-4005			
	>A> 12303605	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	>A> 12295931	Dec 21, 2041	U-1649			
	>A> 12295931	Dec 21, 2041	U-219			
	>A> 12295931	Dec 21, 2041	U-4004			
	>A> 12295931	Dec 21, 2041	U-4005			
	>A> 12303482	Dec 21, 2041	U-1649			
	>A> 12303482	Dec 21, 2041	U-219			
	>A> 12303482	Dec 21, 2041	U-4004			
	>A> 12303482	Dec 21, 2041	U-4005			
	>A> 12303605	Oct 07, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
>A>	12295931	Dec 21, 2041	U-1649			
>A>	12295931	Dec 21, 2041	U-219			
>A>	12295931	Dec 21, 2041	U-4004			
>A>	12295931	Dec 21, 2041	U-4005			
>A>	12303482	Dec 21, 2041	U-1649			
>A>	12303482	Dec 21, 2041	U-219			
>A>	12303482	Dec 21, 2041	U-4004			
>A>	12303482	Dec 21, 2041	U-4005			
>A>	12303605	Oct 07, 2034	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	>A> 7417042	Jul 20, 2026	DS DP			
	>A> 7417042*PED	Jan 20, 2027				
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	>A> 9493582	Feb 27, 2033	DP			
	>A> 9493582*PED	Aug 27, 2033				
	>A> RE47954	Oct 21, 2029	U-3449			
	>A> RE47954*PED	Apr 21, 2030				
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	>A> 7417042	Jul 20, 2026	DS DP			
	>A> 7417042*PED	Jan 20, 2027				
	>A> 7737112	Dec 07, 2027	DP			
	>A> 7737112*PED	Jun 07, 2028				
	>A> 9493582	Feb 27, 2033	DP			
	>A> 9493582*PED	Aug 27, 2033				
	>A> RE47954	Oct 21, 2029	U-3449			
	>A> RE47954*PED	Apr 21, 2030				
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	>A> 7417042	Jul 20, 2026	DS DP			
	>A> 7417042*PED	Jan 20, 2027				
	>A> 7737112	Dec 07, 2027	DP			
	>A> 7737112*PED	Jun 07, 2028				
	>A> 9493582	Feb 27, 2033	DP			
	>A> 9493582*PED	Aug 27, 2033				
	>A> RE47954	Oct 21, 2029	U-3449			
	>A> RE47954*PED	Apr 21, 2030				
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	>A> RE48960	Feb 16, 2029	DS DP	U-3087		
	>A> RE48960	Feb 16, 2029	DS DP	U-3088		
<u>CEDAZURIDINE; DECITABINE - INOOVI</u>						
N 212576 001	12195496	Oct 07, 2040	DP			
	12239653	Feb 24, 2041	U-2865			
	12239653	Feb 24, 2041	U-2866			
<u>CHENODIOL - CTEXLI</u>						
N 219488 001				NP		Feb 21, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001	11969403	May 14, 2039	DP			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	8148374	Sep 03, 2029	DS DP U-1279			
	8148374	Sep 03, 2029	DS DP U-2939			
	8148374	Sep 03, 2029	DS DP U-4162			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 002	10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-4162			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	12274751	Nov 22, 2036	U-2814			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	12233035	Nov 01, 2033	U-4132			
	12280025	Nov 01, 2033	U-4168			
<u>COPPER - MIUDELLA</u>						
N 218201 001	10022264	Mar 22, 2034	DP		NP	Feb 24, 2028
	10159596	Aug 14, 2032	DP			
	10166141	Jun 13, 2034	DP			
	10188546	Aug 14, 2032	DP			
	10398588	Feb 24, 2034	DP U-4155			
	10918516	Jan 23, 2037	DP			
	11207209	Aug 16, 2034	DP			
	11850181	Aug 14, 2032	DP			
	12138199	Oct 18, 2033	DP			
	9089418	Apr 09, 2033	DP			
	9265652	Apr 28, 2034	U-4155			
	9427351	Aug 14, 2032	DP			
	9610191	Feb 24, 2034	U-4155			
<u>COPPER CU-64 DOTATATE - DETECTNET</u>						
N 213227 001	10383961	Jul 02, 2033	U-2951			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL</u>						
N 008372 008	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	12233105	Oct 27, 2043	U-3904			
	12233105	Oct 27, 2043	U-3905			
	12233105	Oct 27, 2043	U-3906			
	12233105	Oct 27, 2043	U-3907			
	12233105	Oct 27, 2043	U-3908			
	12233105	Oct 27, 2043	U-3909			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	12233105	Oct 27, 2043	U-3910			
	12233105	Oct 27, 2043	U-3911			
	12233105	Oct 27, 2043	U-3912			
	12233105	Oct 27, 2043	U-3913			
	12233105	Oct 27, 2043	U-3914			
	12233105	Oct 27, 2043	U-3915			
	12233105	Oct 27, 2043	U-3916			
	12233105	Oct 27, 2043	U-3917			
	12233105	Oct 27, 2043	U-3918			
	12233105	Oct 27, 2043	U-3919			
	12233105	Oct 27, 2043	U-3920			
	12233105	Oct 27, 2043	U-3921			
	12233105	Oct 27, 2043	U-3922			
	12233105	Oct 27, 2043	U-3923			
	12233105	Oct 27, 2043	U-3924			
	12233105	Oct 27, 2043	U-3925			
	12233105	Oct 27, 2043	U-3926			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 002	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 003	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218820 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP	Y		
	8561859	Apr 16, 2032	DP	Y		
	9669974	May 11, 2034	DP	Y		
	9676525	Feb 07, 2034	DP	Y		
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	7772243	May 05, 2028	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	7772243	May 05, 2028	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	7772243	May 05, 2028	DS DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	12213988	Apr 01, 2041	U-4140			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 001					M-200	Sep 30, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 002					M-200	Sep 30, 2027
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	12161653	Feb 17, 2032	U-1940			
<u>DEURUXOLITINIB PHOSPHATE - LEQSEIVI</u>						
N 217900 001	12247034	May 10, 2044	DS DP			
	>A> 12285432	Aug 11, 2042	U-3976			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10081621	Mar 25, 2031	DP U-4087			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10058546	Jul 15, 2033	U-4093			
	10081621	Mar 25, 2031	DP U-4087			
	10206877	Apr 14, 2035	DP U-4092			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	11951212	Apr 14, 2035	DP U-4089			
	12186306	Jan 10, 2043	U-4088			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	9012496	Jul 15, 2033	U-4097			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001					>A> NPP	Apr 07, 2028
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	>A> 8927497	Jul 21, 2025	DP U-4173			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	>A> 8927497	Jul 21, 2025	DP U-4173			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	>A> 8927497	Jul 21, 2025	DP U-4173			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 001	12178823	Nov 12, 2035	U-4167		>A> NP	Mar 26, 2028
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 002	12178823	Nov 12, 2035	U-4167		>A> NP	Mar 26, 2028
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 003	12178823	Nov 12, 2035	U-4167		>A> NP	Mar 26, 2028
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
<u>DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)</u>						
N 215400 001	>A> 10532049	Feb 26, 2039	DP			
	>A> 11304942	Feb 26, 2039	DP			
	>A> 11819501	Feb 26, 2039	U-4188			
	>A> 11819501	Feb 26, 2039	U-848			
<u>DIHYDROERGOTAMINE MESYLATE - ATZUMI</u>						
N 217901 001	>A> 10758532	Dec 11, 2039	DP			
	>A> 10792253	Aug 04, 2037	DP			
	>A> 11744967	Oct 12, 2041	DP			
	>A> 11872314	Aug 04, 2037	DP			
	>A> 12102754	Oct 12, 2041	DP			
	>A> 12263162	Dec 11, 2039	DP			
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855 001	8669281	Oct 29, 2033	DS DP			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ADLARTY</u>						
N 212304 002	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 001					PC	Jul 15, 2025
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 002					PC	Jul 15, 2025
<u>DROSPIRENONE - SLYND</u>						
N 211367 001 >A>	12280151	Jun 28, 2031	DP			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	12233074	Feb 09, 2043	DP U-3152			
	7732430	Jan 15, 2028	DP U-3152			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	12171742	Apr 13, 2037	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	12213983	Apr 26, 2035	U-2412			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	12213983	Apr 26, 2035	U-2412			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	12194025	Nov 12, 2041	U-4111			
	12285409	Nov 01, 2039	DP			
<u>ELAFIBRANOR - IQIRVO</u>						
N 218860 001	12233038	Mar 30, 2037	U-1854			
	>A> 12295927	Mar 30, 2037	U-1854			
	>A> 12295928	Mar 30, 2037	U-1854			
	>A> 12310935	Mar 30, 2037	U-1854			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-3157		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4075			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4075		ODE*	Oct 21, 2026
	10239867	Apr 09, 2027	DS DP U-3158		ODE*	Dec 21, 2027
	10239867	Apr 09, 2027	DS DP U-4056		ODE-512	Dec 20, 2031
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4065		ODE-512	Dec 20, 2031
	10239867	Apr 09, 2027	DS DP U-3590			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	10081621	Mar 25, 2031	DP U-3600		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4065			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 001					>A> PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 002					>A> PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 003					>A> PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 004					>A> PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 216620 001					>A> PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 216620 002					>A> PC	Nov 09, 2025
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	12263153	Apr 03, 2034	U-4171			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	12263153	Apr 03, 2034	U-4171			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	12178819	May 04, 2027	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	12178819	May 04, 2027	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 208452 001					>A> PC	Nov 23, 2025
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-957	Dec 20, 2027
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-957	Dec 20, 2027
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10005761	Aug 27, 2030	U-3738			
	10005761	Aug 27, 2030	U-4051			
	10258622	Nov 21, 2032	U-2802			
	10258622	Nov 21, 2032	U-4051			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8541575	Feb 26, 2030	DS DP U-4051			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9314464	Jul 04, 2031	U-4051			
	9474754	Aug 05, 2033	U-2802			
	9474754	Aug 05, 2033	U-4051			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	9850230	Aug 27, 2030	U-4051			
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 001	10899744	Jun 01, 2037	DS	U-4099	NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS	U-4099		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 001	10899744	Jun 01, 2037	DS	U-4099	NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS	U-4099		
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 002	10899744	Jun 01, 2037	DS	U-4099	NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS	U-4099		
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	12251384	Jun 25, 2044	DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 218550 001					ODE*	Aug 15, 2026
					ODE*	Aug 15, 2026
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	12161628	Feb 23, 2037		U-4101		
	12161628	Feb 23, 2037		U-4102		
	12161628	Feb 23, 2037		U-4103		
	12161628	Feb 23, 2037		U-4104		
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 001	12161628	Feb 23, 2037		U-4101		
	12161628	Feb 23, 2037		U-4102		
	12161628	Feb 23, 2037		U-4103		
	12161628	Feb 23, 2037		U-4104		
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 002	12161628	Feb 23, 2037		U-4101		
	12161628	Feb 23, 2037		U-4102		
	12161628	Feb 23, 2037		U-4103		
	12161628	Feb 23, 2037		U-4104		
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 213708 001					PC	Jun 03, 2025
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 219239 001					CGT	Sep 03, 2025
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	12280024	Mar 13, 2035	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	12280024	Mar 13, 2035	DP			
<u>EPINEPHRINE - NEFFY</u>						
N 214697 002	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039		U-3979		
	11173209	Feb 06, 2038		U-3979		
	11191838	Feb 06, 2039	DP	U-3979		
	11717571	Feb 06, 2039		U-3979		
	11744895	Feb 06, 2039		U-3979		
	11918655	Feb 06, 2039		U-3979		
<u>EPLONTENSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	8101743	Apr 01, 2026	DS DP			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035		U-3034	I-959	Jan 17, 2028
	10869844	Sep 10, 2035		U-3035		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3036			
	10869844	Sep 10, 2035	U-4113			
	10869844	Sep 10, 2035	U-4114			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11173134	Sep 10, 2035	U-4115			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11311500	Sep 10, 2035	U-4116			
	11311500	Sep 10, 2035	U-4117			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	11446260	Mar 14, 2034	U-4118			
	11446260	Mar 14, 2034	U-4119			
	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
	11883526	Feb 18, 2040	U-4120			
	8785500	Mar 05, 2033	U-2502			
	8785500	Mar 05, 2033	U-4112			
	9592207	Mar 20, 2027	U-2502			
	9592207	Mar 20, 2027	U-4112			
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 001				>A> PC		Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 002				>A> PC		Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 003				>A> PC		Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 004				>A> PC		Nov 02, 2025
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV</u>						
N 218718 001	12178824	Jun 24, 2041	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2026	DS DP			
<u>FITUSIRAN SODIUM - QFITLIA</u>						
N 219019 001	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
<u>FITUSIRAN SODIUM - QFITLIA</u>						
N 219019 002	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923 001	9849027	Nov 07, 2028	DP U-4157			
	9849027	Nov 07, 2028	DP U-708			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
<u>FOSCARBIDOPA; FOSLEVODOPA - VYALEV</u>						
N 216962 001	>A> 12251365	Jun 10, 2040	U-4030		NP	Oct 16, 2027
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	12208109	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	12208109	Jun 02, 2037	DP			
<u>GALLIUM GA-68 GOZETOTIDE - GOZELLIX</u>						
N 219592 001	11027031	Jul 28, 2035	U-3317			
<u>GEPOTIDACIN MESYLATE - BLUJEPa</u>						
N 218230 001	8389524	Feb 12, 2029	DS DP U-4166		NCE GAIN	Mar 25, 2030 Mar 25, 2035
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001	>A> 7696182	May 16, 2026	DS DP U-3774			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002	>A> 7696182	May 16, 2026	DS DP U-3774			
<u>HYDROCHLOROTHIAZIDE - INZIROO</u>						
N 219141 001	11878022	Jan 23, 2044	DP U-4138			
	11878022	Jan 23, 2044	DP U-4139			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	12201690	Jun 14, 2039	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	12171738	Feb 09, 2030	U-4105			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	12171738	Feb 09, 2030	U-4105			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	12171778	Jun 16, 2039	U-3956			
	9388415	Sep 09, 2025	U-3956			
	9388416	Sep 09, 2025	U-3956			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	12171778	Jun 16, 2039	U-3956			
	9388415	Sep 09, 2025	U-3956			
	9388416	Sep 09, 2025	U-3956			
<u>IOMEPROL - IOMERVU</u>						
N 216016 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 004					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 005					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 006					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 007					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 008					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 009					NCE	Nov 27, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IOMEPROL - IOMERVU</u> N 216016 010					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 011					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 012					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 013					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 004					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 005					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 006					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 007					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 008					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 009					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 010					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 011					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 012					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 013					NCE	Nov 27, 2029
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u> N 021527 001	8474447	Jan 17, 2030	DP	Y		
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u> N 218276 001	10093663	Jul 14, 2034	U-3980		I-963	Mar 20, 2028
	10093663	Jul 14, 2034	U-4161			
>A>	12285422	Aug 30, 2038	U-4181			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	001				PC	Jan 11, 2025
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	002				PC	Jan 11, 2025
<u>IVACAFTOR - KALYDECO</u>						
N 203188	001	10646481	Aug 13, 2029	DP		
		10646481*PED	Feb 13, 2030			
		11564916	Aug 13, 2029	U-3530		
		11564916*PED	Feb 13, 2030			
		8410274	Dec 28, 2026	DP		
		8410274*PED	Jun 28, 2027			
		8754224	Dec 28, 2026	DS DP		
		8754224*PED	Jun 28, 2027			
		9670163	Dec 28, 2026	DP U-1311		
		9670163*PED	Jun 28, 2027			
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001	10646481	Aug 13, 2029	DP		
		10646481*PED	Feb 13, 2030			
		11564916	Aug 13, 2029	U-3528		
		11564916*PED	Feb 13, 2030			
		12214083	Feb 27, 2033	DP U-4126		
		7495103	May 20, 2027	DS DP		
		7495103*PED	Nov 20, 2027			
		8324242	Aug 05, 2027	U-1311		
		8324242	Aug 05, 2027	U-1906		
		8324242	Aug 05, 2027	U-2527		
		8324242*PED	Feb 05, 2028			
		8410274	Dec 28, 2026	DP		
		8410274*PED	Jun 28, 2027			
		8754224	Dec 28, 2026	DS DP		
		8754224*PED	Jun 28, 2027			
		9670163	Dec 28, 2026	DP U-1311		
		9670163	Dec 28, 2026	DP U-2530		
		9670163*PED	Jun 28, 2027			
<u>IVACAFTOR - KALYDECO</u>						
N 207925	002	10646481	Aug 13, 2029	DP		
		10646481*PED	Feb 13, 2030			
		11564916	Aug 13, 2029	U-3528		
		11564916*PED	Feb 13, 2030			
		12214083	Feb 27, 2033	DP U-4126		
		7495103	May 20, 2027	DS DP		
		7495103*PED	Nov 20, 2027			
		8324242	Aug 05, 2027	U-1311		
		8324242	Aug 05, 2027	U-1906		
		8324242	Aug 05, 2027	U-2527		
		8324242*PED	Feb 05, 2028			
		8410274	Dec 28, 2026	DP		
		8410274*PED	Jun 28, 2027			
		8754224	Dec 28, 2026	DS DP		
		8754224*PED	Jun 28, 2027			
		9670163	Dec 28, 2026	DP U-1311		
		9670163	Dec 28, 2026	DP U-2530		
		9670163*PED	Jun 28, 2027			
<u>IVACAFTOR - KALYDECO</u>						
N 207925	003	10646481	Aug 13, 2029	DP		
		10646481*PED	Feb 13, 2030			
		11564916	Aug 13, 2029	U-3528		
		11564916*PED	Feb 13, 2030			
		12214083	Feb 27, 2033	DP U-4126		
		7495103	May 20, 2027	DS DP		
		7495103*PED	Nov 20, 2027			
		8324242	Aug 05, 2027	U-1311		
		8324242	Aug 05, 2027	U-1906		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	8324242	Aug 05, 2027	U-2963			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2966			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	12214083	Feb 27, 2033	DP U-4127			
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	12214083	Feb 27, 2033	DP U-4127			
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10076513	Dec 04, 2028	DP U-2411			
	10076513*PED	Jun 04, 2029				
	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACFTOR - ORKAMBI</u>						
N 206038 001	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DS DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 002	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-3424			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-3424			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-3426			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-3424			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-3427			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-3427			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-3428			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-3429			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-3429			
	9931334*PED	Jun 28, 2027				
<u>IVERMECTIN - IVERMECTIN</u>						
A 215922 002					CGT	Oct 01, 2025
<u>LACTULOSE - LACTULOSE</u>						
A 217914 001					CGT	Sep 13, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACTULOSE - LACTULOSE</u>						
A 217914 002					CGT	Sep 13, 2025
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	12257246	Jul 07, 2030	U-2718			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	12257246	Jul 07, 2030	U-2718			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	12257246	Jul 07, 2030	U-2718			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 001	12138351	Apr 13, 2041	DP			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 002	12138351	Apr 13, 2041	DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001 >A>	12121582	Jun 14, 2036	DP			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	12083112*PED	Sep 03, 2036				
	12226409	May 15, 2038	U-4146			
	12226409*PED	Nov 15, 2038				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	12083112*PED	Sep 03, 2036				
	12226409	May 15, 2038	U-4146			
	12226409*PED	Nov 15, 2038				
<u>LEVACETYLLAUCINE - AQNEURSA</u>						
N 219132 001	11400067	Aug 11, 2037	U-4170			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001					NCE*	Dec 30, 2026
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	12178819	May 04, 2027	DP			
<u>LISINOPRIL - QBRELIS</u>						
N 208401 001	12186360	Nov 06, 2035	DP			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001 >A>	7838531	Jul 26, 2029	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002 >A>	7838531	Jul 26, 2029	U-3070			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOSARTAN POTASSIUM - ARBLI</u>						
N 218772 001	11890273	Oct 07, 2041	DP			
	12156869	Oct 07, 2041	DP U-4158			
	12156869	Oct 07, 2041	DP U-4159			
	12156869	Oct 07, 2041	DP U-4160			
<u>LOTILANER - XDEMVY</u>						
N 217603 001	12171750	Dec 14, 2038		U-3674		
	12213964	Dec 14, 2038	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	RE48825	Mar 12, 2029	DS			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	RE48825	Mar 12, 2029	DS			
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAKETAN - PLUVICTO</u>						
N 215833 001	10406240	Aug 15, 2028	DS DP U-4169		I-965	Mar 28, 2028
	11318121	Aug 15, 2028	DS DP U-4169			
	11951190	Nov 12, 2035	U-4169			
	12208102	Sep 18, 2041	U-4169			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001					M-187	Feb 28, 2028
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001	12239659	Jun 14, 2044	U-4143			
	>A> 12290529	Aug 02, 2044	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 001	>A> 12296050	Oct 05, 2043	DP U-4186		>A> I-938	Mar 13, 2027
	>A> 12296050	Oct 05, 2043	DP U-4187		>A> NCE	Sep 29, 2026
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 002	>A> 12296050	Oct 05, 2043	DP U-4186		>A> I-938	Mar 13, 2027
	>A> 12296050	Oct 05, 2043	DP U-4187		>A> NCE	Sep 29, 2026
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 003	>A> 12296050	Oct 05, 2043	DP U-4186		>A> I-938	Mar 13, 2027
	>A> 12296050	Oct 05, 2043	DP U-4187		>A> NCE	Sep 29, 2026
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 004	>A> 12296050	Oct 05, 2043	DP U-4186		>A> I-938	Mar 13, 2027
	>A> 12296050	Oct 05, 2043	DP U-4187		>A> NCE	Sep 29, 2026
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	12213989	Nov 18, 2042	U-4137			
	>A> 12295940	Oct 11, 2043	DS DP			
<u>MELOXICAM - QAMZOVA</u>						
N 217593 001	12059423	Jul 19, 2040	DS DP			
<u>MELOXICAM - XIFYRM</u>						
N 218395 001	>A> 12263176	Jul 31, 2041	DP			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10029010	Apr 11, 2036	U-4133		NP	Jan 30, 2028
	10058614	Apr 11, 2036	DP			
	10137131	Apr 11, 2036	DP U-1719			
	10195278	Apr 11, 2036	U-1719			
	10265324	Apr 11, 2036	U-1719			
	10363312	Apr 11, 2036	U-1719			
	10369224	Apr 11, 2036	U-4134			
	10426839	Apr 11, 2036	U-4135			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10463736	Apr 11, 2036	DP			
	10471014	Apr 11, 2036	U-1719			
	10471069	Apr 11, 2036	U-1719			
	10512692	Apr 11, 2036	U-1719			
	10512693	Apr 11, 2036	U-1719			
	10517950	Apr 11, 2036	U-1719			
	10532101	Apr 11, 2036	U-1719			
	10537642	Apr 11, 2036	U-1719			
	10561664	Apr 11, 2036	U-1719			
	10583144	Apr 11, 2036	U-1719			
	10653777	Apr 11, 2036	U-1719			
	10688102	Apr 11, 2036	U-1719			
	10688185	Apr 11, 2036	U-1719			
	10695429	Apr 11, 2036	U-1719			
	10695430	Apr 11, 2036	U-1719			
	10702535	Apr 11, 2036	U-4136			
	10702602	Apr 11, 2036	U-1719			
	10722583	Apr 11, 2036	U-1719			
	10729696	Apr 11, 2036	U-1719			
	10729697	Apr 11, 2036	U-1719			
	10729773	Apr 11, 2036	U-1719			
	10758617	Apr 11, 2036	U-1719			
	10758618	Apr 11, 2036	U-1719			
	10780165	Apr 11, 2036	U-1719			
	10780166	Apr 11, 2036	U-1719			
	10799588	Apr 11, 2036	U-1719			
	10821181	Apr 11, 2036	U-1719			
	10821182	Apr 11, 2036	U-1719			
	10894053	Apr 11, 2036	U-1719			
	10905693	Apr 11, 2036	U-1719			
	10918722	Apr 11, 2036	U-1719			
	10933136	Apr 11, 2036	U-1719			
	10933137	Apr 11, 2036	U-1719			
	10940153	Apr 11, 2036	U-1719			
	10987358	Apr 11, 2036	U-1719			
	11013805	Apr 11, 2036	U-1719			
	11013806	Apr 11, 2036	U-1719			
	11020483	Apr 11, 2036	U-1719			
	11045549	Apr 11, 2036	U-1719			
	11135295	Apr 11, 2036	U-1719			
	11207328	Apr 11, 2036	U-1719			
	11219626	Apr 11, 2036	U-1719			
	11285213	Apr 11, 2036	U-1719			
	11331323	Apr 11, 2036	U-1719			
	11369684	Apr 11, 2036	U-1719			
	11426414	Apr 11, 2036	U-1719			
	11471464	Apr 11, 2036	U-1719			
	11471465	Apr 11, 2036	U-1719			
	11504429	Apr 11, 2036	U-1719			
	11510927	Apr 11, 2036	U-1719			
	11571428	Apr 11, 2036	U-1719			
	11602563	Apr 11, 2036	U-1719			
	11607456	Apr 11, 2036	U-1719			
	11617755	Apr 11, 2036	U-1719			
	11617756	Apr 11, 2036	U-1719			
	11617791	Apr 11, 2036	U-1719			
	11628173	Apr 11, 2036	U-1719			
	11712441	Apr 11, 2036	U-1719			
	11738085	Apr 11, 2036	U-1719			
	11759522	Apr 11, 2036	U-1719			
	11801250	Apr 11, 2036	U-1719			
	11806354	Apr 11, 2036	U-1719			
	11826370	Apr 11, 2036	U-1719			
	11865117	Apr 11, 2036	U-1719			
	12128052	May 28, 2040	U-1719			
	9821075	Apr 11, 2036	DP U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MERCAPTOPURINE - MERCAPTOPURINE</u>						
A 216418 001					CGT	Aug 25, 2025
<u>MESNA - MESNA</u>						
A 218871 001					CGT	Jul 13, 2025
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	12194008	Dec 22, 2029	U-2843			
	12194009	Dec 22, 2029	U-2843			
<u>METRONIDAZOLE - LIKMEZ</u>						
N 216755 001	12257236	Jan 16, 2039	DP U-3169			
	12257236	Jan 16, 2039	DP U-4163			
	12257236	Jan 16, 2039	DP U-4164			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	12280042	May 30, 2038	DS U-2371			
<u>MIGLUSTAT - OPFOLDA</u>						
N 215211 001	12246062	Sep 16, 2038	U-3726			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	>A> 12059409	Sep 28, 2029	DP			
	>A> 12059409*PED	Mar 28, 2030				
	>A> 12097189	Sep 28, 2029	U-2996			
	>A> 12097189	Sep 28, 2029	U-3670			
	>A> 12097189*PED	Mar 28, 2030				
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	>A> 12059409	Sep 28, 2029	DP			
	>A> 12059409*PED	Mar 28, 2030				
	>A> 12097189	Sep 28, 2029	U-2996			
	>A> 12097189	Sep 28, 2029	U-3670			
	>A> 12097189*PED	Mar 28, 2030				
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11571402	Feb 17, 2041	DP			
	11806321	Feb 17, 2041	U-4130			
	11806322	Mar 16, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12011424	Feb 17, 2041	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12090128	Feb 17, 2041	DP U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	>A> 12295925	Feb 17, 2041	U-4130			
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11806321	Feb 17, 2041	U-4130			
	11806322	Mar 16, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12011424	Feb 17, 2041	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 001	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12275688	Feb 17, 2041	DP U-4130			
>A>	12295925	Feb 17, 2041	U-4130			
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 002	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11806321	Feb 17, 2041	U-4130			
	11806322	Mar 16, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12275688	Feb 17, 2041	DP U-4130			
>A>	12295925	Feb 17, 2041	U-4130			
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	12268745	Jan 20, 2031	U-4172			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Feb 27, 2035	DP U-1384			
	10918616	Feb 27, 2035	U-1384			
	10918617	Feb 27, 2035	DP			
	10945985	Feb 27, 2035	DP			
	11590095	Feb 27, 2035	U-1384			
<u>MOTIXAFORTIDE ACETATE - APHEXDA</u>						
N 217159 001	12257285	Dec 29, 2041	DP			
	12268725	Dec 29, 2041	DP			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					NPP	Feb 07, 2028
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	12194143	Aug 16, 2039	DP U-1752			
	12226526	Aug 16, 2039	DP U-1752			
<u>NALMEFENE HYDROCHLORIDE - OPVEE</u>						
N 217470 001	>A> 12290596	Aug 04, 2042	U-4182			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 001					>A> NPP	Mar 27, 2028
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 002					>A> NPP	Mar 27, 2028
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 003					>A> NPP	Mar 27, 2028
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 001					>A> PC	Nov 19, 2025
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 002					>A> PC	Nov 19, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 003					>A> PC	Nov 19, 2025
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	12186308	Apr 16, 2038	DP U-2804			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 001	11730725	Jan 25, 2039	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 002	11730725	Jan 25, 2039	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 003	11730725	Jan 25, 2039	DP			
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 001					D-195	Jan 31, 2028
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
>A>	12297177	Aug 09, 2039	DP			
	7951958	Mar 11, 2026	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
>A>	12297177	Aug 09, 2039	DP			
	7951958	Mar 11, 2026	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
>A>	12297177	Aug 09, 2039	DP			
	7951958	Mar 11, 2026	DS			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 001	>A> 12290494	Mar 08, 2041	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 002	>A> 12290494	Mar 08, 2041	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 001	RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 002	RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 003	10251848	Feb 26, 2035	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	12246054	Feb 03, 2036	U-2857			
	12251418	Feb 03, 2036	U-2857			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	>A> 10011633	Nov 08, 2031	U-3186			
	>A> 10011633	Nov 08, 2031	U-3648			
	>A> 10093697	Nov 08, 2031	U-3186			
	>A> 10093697	Nov 08, 2031	U-3648			
	>A> 10487111	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3648			
	>A> 11365182	Jun 20, 2039	U-3186			
	>A> 11365182	Jun 20, 2039	U-3648			
	>A> 11732006	Nov 08, 2031	U-3186			
	>A> 11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	>A> 9694018	Nov 08, 2031	U-3186			
	>A> 9694018	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	>A> 10011633	Nov 08, 2031	U-3186			
	>A> 10011633	Nov 08, 2031	U-3648			
	>A> 10093697	Nov 08, 2031	U-3186			
	>A> 10093697	Nov 08, 2031	U-3648			
	>A> 10487111	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3648			
	>A> 11365182	Jun 20, 2039	U-3186			
	>A> 11365182	Jun 20, 2039	U-3648			
	>A> 11732006	Nov 08, 2031	U-3186			
	>A> 11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	>A> 9694018	Nov 08, 2031	U-3186			
	>A> 9694018	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	>A> 10011633	Nov 08, 2031	U-3186			
	>A> 10011633	Nov 08, 2031	U-3648			
	>A> 10093697	Nov 08, 2031	U-3186			
	>A> 10093697	Nov 08, 2031	U-3648			
	>A> 10487111	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3648			
	>A> 11365182	Jun 20, 2039	U-3186			
	>A> 11365182	Jun 20, 2039	U-3648			
	>A> 11732006	Nov 08, 2031	U-3186			
	>A> 11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	>A> 9694018	Nov 08, 2031	U-3186			
	>A> 9694018	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	>A> 10011633	Nov 08, 2031	U-3186			
	>A> 10011633	Nov 08, 2031	U-3648			
	>A> 10093697	Nov 08, 2031	U-3186			
	>A> 10093697	Nov 08, 2031	U-3648			
	>A> 10487111	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3648			
	>A> 11365182	Jun 20, 2039	U-3186			
	>A> 11365182	Jun 20, 2039	U-3648			
	>A> 11732006	Nov 08, 2031	U-3186			
	>A> 11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	>A> 9694018	Nov 08, 2031	U-3186			
	>A> 9694018	Nov 08, 2031	U-3648			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	12194035	Aug 23, 2031	U-3141			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	12178816	Oct 07, 2029	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	12178816	Oct 07, 2029	DP			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	9127276	May 01, 2034	DS			
	9157082	Apr 27, 2032			U-4050	
	9163239	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
	9593333	Feb 14, 2034			U-4050	
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	7396341	Oct 10, 2026	DP		Y	
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP		Y	
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP		Y	
	9027967	Mar 31, 2027	DP		Y	
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	12275715	Sep 18, 2035	DS DP		U-3684	
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	9265740	Oct 24, 2030	DP		U-1569	
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	>A> 9265740	Mar 05, 2029	DP			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001					M-270	Dec 20, 2027
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	>A> 10709691	Oct 12, 2035			U-2770	
	>A> 10709691	Oct 12, 2035			U-4177	
	>A> 8609862	Jan 13, 2031			U-2770	
	>A> 8609862	Jan 13, 2031			U-4177	
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	>A> 10709691	Oct 12, 2035			U-2770	
	>A> 10709691	Oct 12, 2035			U-4177	
	>A> 8609862	Jan 13, 2031			U-2770	
	>A> 8609862	Jan 13, 2031			U-4177	
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	12246094	Aug 24, 2027	DP			
	>A> 12280152	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	12246094	Aug 24, 2027	DP			
	>A> 12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	12246094	Aug 24, 2027	DP			
	>A> 12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	12246094	Aug 24, 2027	DP			
	>A> 12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	12246094	Aug 24, 2027	DP			
	>A> 12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	12246094	Aug 24, 2027	DP			
	>A> 12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	12246094	Aug 24, 2027	DP			
	>A> 12280152	Aug 24, 2027	DP			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573	Mar 24, 2033	DS DP U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573	Mar 24, 2033	DS DP U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573	Mar 24, 2033	DS DP U-2774			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 001	>A> 12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002	>A> 12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003	>A> 12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12201614	Jun 08, 2037	U-4031			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12201614	Jun 08, 2037	U-4031			
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001	8168775	Aug 10, 2032	DS DP U-2378			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	12290566	Dec 14, 2038	DP U-4174			
	12290566	Dec 14, 2038	DP U-4175			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	11592396	Sep 01, 2030	DS			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	12201615	Dec 25, 2039	U-3804			
	12201616	Oct 25, 2039	U-3804			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 004	12257342	Sep 26, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 005	12257342	Sep 26, 2036	DP			
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214966 001					CGT	Sep 06, 2025
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	12268666	Jul 29, 2039	DP			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	12268666	Jul 29, 2039	DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 001	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	RE43728	Nov 16, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 009	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	RE43728	Nov 16, 2029	DS DP			
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE</u>						
N 212832 004	>A> 11813291	Oct 12, 2041	DP U-4185			
	>A> 11925661	Oct 12, 2041	DP U-4185			
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE</u>						
N 212832 005	>A> 11813291	Oct 12, 2041	DP U-4185			
	>A> 11925661	Oct 12, 2041	DP U-4185			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
N 217604 001	12233166	Jun 18, 2038	DP			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	12285417	Aug 29, 2039	U-2440			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	8309569	Jul 18, 2029	U-1707	Y		
	8309569	Jul 18, 2029	U-1708	Y		
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	12213967	Dec 30, 2040	DP			
	12213968	Dec 30, 2040	DP			
	12226406	Dec 30, 2040	DP			
	>A> 12295944	Aug 12, 2040	U-4183			
	>A> 12318373	Aug 12, 2040	U-4191			
	>A> 12318374	Dec 30, 2040	DP			
<u>RISDIPLAM - EVRYSDI</u>						
N 219285 001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
	11827646	Jan 25, 2036	U-1943		NCE	Aug 07, 2025
	12122789	Apr 15, 2041	DS DP			
	9586955	Feb 08, 2033	DS DP			
	9969754	May 11, 2035	DS DP U-1943			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	12226419	May 20, 2031	DP			
	12233067	Jul 28, 2040	U-4151			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001 >A>	12280037	Dec 11, 2041	U-3302			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001 >A>	12291508	Jul 26, 2032	U-2584			
	>A> 12291508	Jul 26, 2032	U-2855			
	>A> 12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002 >A>	12291508	Jul 26, 2032	U-2584			
	>A> 12291508	Jul 26, 2032	U-2855			
	>A> 12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003 >A>	12291508	Jul 26, 2032	U-2584			
	>A> 12291508	Jul 26, 2032	U-2855			
	>A> 12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 004 >A>	12291508	Jul 26, 2032	U-2584			
	>A> 12291508	Jul 26, 2032	U-2855			
	>A> 12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 005	10519139	Aug 14, 2035	DS DP U-2584		>A> ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		>A> ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		>A> ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS			
	>A> 12291508	Jul 26, 2032	U-2584			
	>A> 12291508	Jul 26, 2032	U-2855			
	>A> 12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001					M-311	Sep 27, 2027
					M-312	Sep 27, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 213246	002				M-311 M-312	Sep 27, 2027 Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 218160	001				M-311 M-312	Sep 27, 2027 Sep 27, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	Sep 21, 2029
					>A> ODE*	Sep 21, 2029
					>A> ODE*	May 29, 2031
					>A> ODE*	May 29, 2031
					>A> ODE*	May 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160	002				M-311 M-312	Sep 27, 2027 Sep 27, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	Sep 21, 2029
					>A> ODE*	Sep 21, 2029
					>A> ODE*	May 29, 2031
					>A> ODE*	May 29, 2031
					>A> ODE*	May 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160	003				M-311 M-312	Sep 27, 2027 Sep 27, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	Sep 21, 2029
					>A> ODE*	Sep 21, 2029
					>A> ODE*	May 29, 2031
					>A> ODE*	May 29, 2031
					>A> ODE*	May 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160	004				M-311 M-312	Sep 27, 2027 Sep 27, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	May 08, 2027
					>A> ODE*	Sep 21, 2029
					>A> ODE*	Sep 21, 2029
					>A> ODE*	May 29, 2031
					>A> ODE*	May 29, 2031
					>A> ODE*	May 29, 2031
<u>SELU METINIB SULFATE - KOSELUGO</u>						
N 213756	001	12220403	Mar 26, 2029	DP		
		7425637	Mar 13, 2026	DS		
		8178693	Mar 13, 2026	DS DP		
<u>SELU METINIB SULFATE - KOSELUGO</u>						
N 213756	002	12220403	Mar 26, 2029	DP		
		7425637	Mar 13, 2026	DS		
		8178693	Mar 13, 2026	DS DP		
<u>SEMA GLUTIDE - OZEMPIC</u>						
N 209637	001	10220155	Jul 17, 2026	DP	Y	I-961
		10357616	Jan 20, 2026	DP	Y	
		10376652	Jan 20, 2026	DP	Y	
		11097063	Jul 17, 2026	DP	Y	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 27, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
>A>	12295988	Oct 10, 2038	U-2628			
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 004	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 005	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 006	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DS DP U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12214017	Aug 24, 2038	DP U-3162			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001	8039435	Aug 21, 2032	DS DP		NPP ODE-508 ODE-509	Dec 20, 2027 Dec 20, 2031 Dec 20, 2031
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12186321	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Apr 23, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Apr 23, 2036	U-3889			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Apr 23, 2036	U-3889			
<u>SITAGLIPTIN HYDROCHLORIDE - BRYNOVIN</u>						
N 219122 001	11944621	Oct 23, 2040	DP			
	>A> 12295953	Oct 23, 2040	DP			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	>A> 12304813	Feb 10, 2030	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	12226377	Jul 21, 2037	DP			
	>A> 12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	12226377	Jul 21, 2037	DP			
	>A> 12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	12226377	Jul 21, 2037	DP			
	>A> 12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	12226377	Jul 21, 2037	DP			
	>A> 12303478	Jul 21, 2037	U-4189			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	>A> 12304813	Feb 10, 2030	DP			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002					ODE*	Mar 19, 2027
<u>SOFPIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001	>A> 12156865	May 22, 2034	DP U-2398			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
	12263145	Dec 30, 2042	U-3693			
	>A> 12318362	Mar 19, 2040	U-3765			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	>A> 12290495	Apr 01, 2034	U-2096			
	>A> 12290495	Apr 01, 2034	U-2494			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	>A> 12280056	Nov 18, 2039	U-4107			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	11827635	May 20, 2040	DS DP U-4107			
>A>	12280056	Nov 18, 2039	U-4107			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
>A>	12280056	Nov 18, 2039	U-4107			
<u>SUCCINYLCHOLINE CHLORIDE - SUCCINYLCHOLINE CHLORIDE</u>						
N 215143 001	>A> 12295932	Nov 02, 2041	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					NPP	Dec 12, 2027
					PED	Jun 12, 2028
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					NPP	Dec 12, 2027
					PED	Jun 12, 2028
<u>SUZETRIGINE - JOURNAVX</u>						
N 219209 001	11834441	Dec 04, 2040	DS DP U-4125		NCE	Jan 30, 2030
<u>TADALAFIL - TADLIO</u>						
N 214522 001	12186322	Dec 24, 2038	DP U-3397			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10426743	May 19, 2036	U-2625		I-956	Dec 12, 2027
	10426743	May 19, 2036	U-4048			
	11497718	Nov 13, 2039	U-4048			
	11612573	May 19, 2036	U-2625			
	11612573	May 19, 2036	U-4048			
	11938099	Nov 13, 2039	U-4048			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	12201604	Jan 25, 2033	U-3003			
	12201604	Jan 25, 2033	U-3865			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	12201604	Jan 25, 2033	U-3003			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	12161645	Sep 12, 2031	U-2853			
	12162865	May 21, 2034	U-2736			
	12168014	May 03, 2038	U-2736			
	12168014	May 03, 2038	U-2852			
	12168014	May 03, 2038	U-2853			
	12168015	Sep 12, 2031	DS DP			
	12168016	Sep 12, 2031	U-2736			
	12168016	Sep 12, 2031	U-2853			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001					NPP	Apr 04, 2028
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001					NPP	Apr 04, 2028
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	>A> 12310978	Feb 21, 2039	U-4194			
<u>TETRACAINE HYDROCHLORIDE - TETRACAINE HYDROCHLORIDE</u>						
A 217227 001					CGT	Jun 25, 2025
<u>THIOTEPA - TEPADINA AND SODIUM CHLORIDE</u>						
N 208264 003	>A> 9931458	May 31, 2037	DP			
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 002	11975013	Aug 16, 2041	DP			
<u>TICAGRELOR - TICAGRELOR</u>						
A 208390 001					>A> PC	Oct 28, 2025
<u>TICAGRELOR - TICAGRELOR</u>						
A 208531 001					>A> PC	Oct 28, 2025
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	7396341	Oct 10, 2026	DP	Y		
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP	Y		
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP	Y		
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP	Y		
	9027967*PED	Sep 30, 2027				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	7396341	Oct 10, 2026	DP	Y		
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP	Y		
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP	Y		
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP	Y		
	9027967*PED	Sep 30, 2027				
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 001	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 002	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 004	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 005	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011					I-958	Dec 20, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012					I-958	Dec 20, 2027
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	7166722	Nov 16, 2028	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	7166722	Nov 16, 2028	DS DP			
<u>TIZANIDINE HYDROCHLORIDE - ONTRALFY</u>						
N 216190 001	12263158	May 07, 2042	DP U-2779			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	11253523	Mar 14, 2034		U-3326		
	11253523	Mar 14, 2034		U-3327		
	11253523	Mar 14, 2034		U-3328		
	11253523	Mar 14, 2034		U-3329		
	11253523*PED	Sep 14, 2034				
	9937181	Mar 14, 2034	DP			
	9937181*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	10639309*PED	Sep 14, 2034				
	11253523	Mar 14, 2034		U-3326		
	11253523	Mar 14, 2034		U-3327		
	11253523	Mar 14, 2034		U-3328		
	11253523	Mar 14, 2034		U-3329		
	11253523*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 213082 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 001					>A> PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 002					>A> PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 003					>A> PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 004					>A> PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 005					>A> PC	Nov 08, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	>A> 12290503	Aug 21, 2040	DP U-3413			
	>A> 12290503	Aug 21, 2040	DP U-3414			
	>A> 12290503	Aug 21, 2040	DP U-3415			
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001	12201555	Feb 14, 2031	DS DP			
	12201557	Jun 18, 2030	DS DP U-4129			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 001	7199162	Mar 21, 2026	U-4142		NCE	Jan 21, 2030
					>A> ODE-513	Jan 21, 2032
					>A> ODE-514	Jan 21, 2032
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 002	7199162	Mar 21, 2026	U-4142		NCE	Jan 21, 2030
					>A> ODE-513	Jan 21, 2032
					>A> ODE-514	Jan 21, 2032
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 005	11357782	May 14, 2027	U-1849			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12168666	Nov 13, 2040	DS DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	7452895	Nov 16, 2025	DS DP U-2788			
	7452895	Nov 16, 2025	DS DP U-4153			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	7452895	Nov 16, 2025	DS DP U-2788			
	7452895	Nov 16, 2025	DS DP U-4153			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	12168004	Jan 30, 2035	DP			
	12194030	Dec 22, 2041	U-4121			
	12194030	Dec 22, 2041	U-4122			
	12220408	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	12168004	Jan 30, 2035	DP			
	12220408	Jan 30, 2035	DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001					>A> I-966	Apr 28, 2028
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	12201639	Mar 17, 2040	DS DP U-3747			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	12161690	Nov 06, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	12186362	Jan 30, 2035	DP			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	12180219	Mar 12, 2034	DS DP		I-955	Dec 18, 2027
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	>A> 12290499	Oct 17, 2042	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9662338	Apr 02, 2035	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001					>A> NCE	May 03, 2027
					>A> GAIN	May 03, 2032

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 002					>A> NCE >A> GAIN	May 03, 2027 May 03, 2032
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	12233106	Jul 11, 2042	U-3927			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					I-964	Mar 20, 2028
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Aug 23, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 45TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm